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1. Introduction 
1.1. Normal functions of the kidney 
 
The kidneys are two intra-abdominal organs found in all mammals.  In 
humans, they are relatively small measuring 9-13 centimetres in length. 
Despite their small size they receive 25% of cardiac output, and have the 
highest perfusion rate per-unit mass of all organs. Their principal function is 
excretion of excess fluid and electrolytes. In addition the kidneys also provide 
acid-base homeostasis, regulation of blood pressure, and production of 
hormones involved in red blood cell production and vitamin D metabolism. 
Therefore, kidney disease has wide ranging consequences and 
complications. 
 
1.2. Definition of chronic kidney disease 
 
The definition of chronic kidney disease is currently based on impairment of 
renal excretory function and chronicity, being diagnosed if there is evidence 
of kidney damage for more than 3 months. Measurement of renal excretory 
function involves blood testing for measurement of serum creatinine which is 
corrected in a formula that includes terms for age, gender and ethnicity to 
derive an estimation of the glomerular filtration rate (GFR). In health, the 
GFR approximates 100-120 ml/min/1.73m2.  CKD is divided into five stages 
depending on the GFR (Table 1-1)..When the GFR declines to less than 15 
the term End Stage Renal Disease (ESRD) is used. This is synonymous with 
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the terms End Stage Renal Failure (ESRD) and Established Renal Failure 
(ERF). 
Table 1-1 National Institute of Clinical Excellence Classification of CKD (2008) [1] 
 
 
 
 
 
 
 
1.3. Epidemiology of Chronic Kidney Disease 
Chronic Kidney Disease (CKD) is an increasingly recognised global public 
health problem. As it is asymptomatic, estimates of prevalence rely on 
community screening studies. As methodology and populations vary there is 
wide variation (Table 1-2). 
  
Stage GFR Description 
1 90 Normalkidneyfunctionbuturine
findingsorstructuralabnormalitiesor
genetictraitpointtokidneydisease 
2 60 ?89 Mildlyreducedkidneyfunction,and
otherfindings(asforstage1)pointto
kidneydisease 
3A 
3B 
45 ?59 
30 ?44 
Moderatelyreducedkidneyfunction 
4 15 ?29 Severelyreducedkidneyfunction 
5 <15 Verysevere,orendstagekidneydisease
(sometimescallestablishedrenalfailure) 
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Table 1-2 CKD prevalence in a range of populations [2] 
Country Study 
Number 
of 
subjects 
Age of 
subjects
Definition of 
CKD 
Prevalence 
of CKD 
Australia AUSDIAB 11247 25 CKD 1-5 16% 
D.R of Congo Sumaili et al. 503 20 CKD 1-5 12.40% 
Netherlands PREVEND 8459 28-75 CKD 1-5 12% 
Norway HUNT 2 65604 20 CKD 3-5 4.70% 
South China Chen et al. 6311 >20 CKD 1-5 12.10% 
Spain EPIRCE 2746 20 CKD 3-5 6.80% 
Thailand THAI SEEK 3459 8 CKD 1-4 17.50% 
Tibet Chen et al. 1289 18 CKD 1-5 19.10% 
UK CKD-QI 930997 Any CKD 3-5 5.41% 
UK NEOERICA 38262 18 CKD 3-5 8.50% 
USA NHANES IV 13233 20 CKD 1-4 13.10% 
 
In the UK, prevalence of CKD stage 3-5 is estimated at 5-8.5% and 
prevalence increases with age [3, 4].  The majority of these people have 
stage 3 CKD and are followed up in primary care. The prevalence of CKD in 
the UK is predicted to rise sharply due to the combined effects of an ageing 
population, and epidemics of obesity, diabetes and cardiovascular disease 
[5, 6].  Currently, diabetes and cardiovascular disease are the two biggest 
causes of ESRD in the UK [7]. It is notable that most people with CKD will not 
reach ESRD and are far more likely to die from cardiovascular disease [8].  
Preliminary data suggest that cardiovascular disease may also be a risk 
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factor for CKD progression. Thus kidney and cardiovascular disease may 
exacerbate each other, leading to a vicious circle of progressive 
cardiovascular and renal decline [9]. 
 
1.4. Renal replacement therapy 
CKD stage 5 or ESRD is treated by renal replacement therapy or actively 
managed with conservative non-dialytic care in a pathway that includes 
palliative care. Renal replacement therapy (RRT) aims to replace the 
functions of the kidney. The gold standard is renal transplantation as if 
successful this will replace all the functions of the kidney and patients are not 
tied to a regime of regular dialysis. However there is a limited pool of donors 
and the majority of incident patients have a choice between haemodialysis 
and peritoneal dialysis. Haemodialysis (HD) is a process which involves 
removal of blood into a machine where the blood is purified by filtration 
across a semi-permeable membrane and then returned to the patient (Figure 
1-1).  
Figure 1-1- Haemodialysis 
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HD requires access to a large vein and this is usually in the form of an 
arteriovenous fistula. It is a resource intensive treatment typically using 120 
litres of highly purified water per patient-treatment session, which is further 
heated to between 35 and 37°C to prevent excessive blood heat loss. It also 
requires a dialysis monitor and technical expertise. It only replaces the 
excretory function of the kidney.  HD is usually in hospital and typically 
occurs 3 times per week for 4 hours per session. A minority of patients and 
their carers have been trained to deliver the treatment at home.  Peritoneal 
dialysis (PD) involves insertion of a synthetic tube into the peritoneal space 
which lies within the abdomen surrounding the bowel and intra-abdominal 
organs. It uses the peritoneum as the semi-permeable membrane across 
which waste products diffuse (Figure 1-2). Fluid is drained into the abdomen 
and after a few hours, fluid and the waste products are drained out. It is 
primarily a self-delivered treatment and so can be performed at home. 
Figure 1-2- Principle of peritoneal dialysis 
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Currently there are 51,000 patients in the UK receiving RRT (Figure 1-3). 
Renal transplantation is the most prevalent form of RRT accounting for 49%, 
in-centre HD accounts for 43% and 8% have PD [10]. 
Figure 1-3 Treatment modality in prevalent RRT patients in the UK on 31/12/2010 [10] 
 
The projected 5-7% annual increase in RRT patients will predominantly be in 
the in-centre HD population and this is reflected in Figure 1-4 [10].  
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Figure 1-4  Growth in prevalent RRT patients by treatment modality in the UK 1997-
2010 [10] 
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2. Background 
2.1. Risk factors for cardiovascular disease in dialysis patients  
The aim of this section is to describe the background to the development of 
my study hypothesis. This requires an appreciation that cardiovascular risk in 
HD patients cannot be fully explained by traditional risk factors. I will describe 
the influence of non-traditional risk factors, reverse causality and the 
possibility that HD may itself promulgate some of the excessive rates of 
cardiovascular morbidity and mortality. Thus, modifications to the process of 
HD may be the key to improving outcomes. It is well recognised that dialysis 
patients suffer excess cardiac morbidity and mortality [11, 12]. Figure 2-1 
shows US derived data for the cardiovascular mortality rates by age and 
ethnicity for dialysis patients and healthy controls. The y-axis is a logarithmic 
scale, emphasising the excess of cardiovascular death.  It is also appreciated 
that the causes of mortality have a distinctly different pattern to the general 
population [13].  Increased mortality is driven by a combination of sudden 
cardiac death and heart failure as can be seen in Figure 2-2 from 2011 US 
Renal Data System Report [14].  
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Figure 2-1 : Graph showing the cardiovascular mortality rates by age and ethnicity for 
dialysis patients and healthy controls from US registry data [11]. 
 
 
Figure 2-2- Causes of death in prevalent US dialysis patients from 2011 US Renal Data 
System annual report; AMI, acute myocardial infarction; CHF, congestive heart failure; 
CVA, cerebrovascular accident[14]. 
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Since the widespread use of weight independent formulae to estimate GFR, 
there is accumulating data that this excess cardiovascular risk occurs in 
earlier stages of CKD and has a graded and linear association of GFR [15].  
Increased mortality in CKD cannot solely be explained by accumulation of 
traditional risk factors for atherosclerosis and cardiovascular disease (Table 
2-1, Table 2-2). Indeed many traditional risk factors display ‘reverse causality’ 
a termed coined to describe their paradoxical behaviour compared to the 
general population. 
Table 2-1 Predicted 5 year cardiovascular risk and the observed 5 year cardiovascular 
risk using the New Zealand Cardiovascular Risk Calculator (n = 274)[16] 
No. of patients Predicted 5 years CVD risk Observed 5 years CVD 
6 >30% 66.6% 
7 25–30% 71.4% 
13 20–25% 61.5% 
14 15–20% 50%
52 10–15% 36.5% 
92 5–10% 27.1% 
39 2.5–5% 10.2% 
51 <2.5% 3.9%
 
Table 2-2- Cardiovascular risk factors in CKD patients 
Traditional risk factors Non-traditional risk factors 
Hypertension Albuminuria 
Diabetes Abnormal calcium/phosphate metabolism 
Smoking Hypervolaemia/Over-hydration 
Hypercholesterolaemia Oxidative stress 
Male sex Malnutrition 
Age Inflammation 
Family history Anaemia 
Obesity Vascular calcification 
Hyperglycaemia Arterial stiffness 
Left ventricular hypertrophy 
Advanced-Glycation End Product 
deposition 
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2.1.1. Hypertension 
There is a strong and linear risk association of BP to cardiovascular morbidity 
and mortality in the general population. A recent- meta-analysis including one 
million adults confirmed this risk is reduced by anti-hypertensive drug therapy 
with no evidence of a threshold at which risk reduction stops down to at least 
115/75 mm Hg [17]. Hypertension is an independent risk factor for left 
ventricular hypertrophy, ischaemic heart disease, cardiac failure, stroke, and 
cardiovascular mortality [18]. Cardiovascular mortality is increased three-fold 
in patients starting dialysis therapy with uncontrolled hypertension [19]. 
However, the relationship of risk to hypertension is fundamentally more 
complicated in ESRD.  Large observational studies of HD patients 
consistently show a J or U-shaped association, with a paradoxical survival 
advantage in hypertensive patients and the highest mortality in hypotensive 
patients after multivariable adjustment depicted in Figure 2-3 [20, 21]. Based 
on this some have cautioned against using drug therapy to lower blood 
pressure in hypertensive dialysis patients. Meta-analyses have suggested 
benefit of using drugs [22]. However the meta-analyses themselves were 
criticised for the wide heterogeneity of studies included and whether lowering 
blood pressure in HD patients reduces mortality is far from clear [23]. The 
cause of the J-curve has been widely debated and its existence has been 
questioned. However it has been clearly demonstrated in other high-risk 
populations such as coronary artery disease, and the most commonly cited 
explanations include a confounding effect of co-morbidity such as heart 
failure, malnutrition or cancer and decreased coronary flow reserve due to 
arterial stiffness [24]. 
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Figure 2-3 - J shaped association of systolic BP to 15 month cardiovascular mortality 
in 40,933 HD patients [20]. 
 
2.1.2. Hypervolaemia 
The mechanisms underlying hypertension in HD patients are complex and 
include overactivity of the renin-angiotensin-aldosterone system, abnormal 
endothelial function and iatrogenic factors such as use of erythropoiesis 
stimulating agents. However in ESRD the principal reason for hypertension is 
the loss of renal regulation of salt and water excretion [25]. This leads to 
extra-cellular volume overload (synonymous with hypervolaemia or 
overhydration) with consequent adverse cardiac remodelling and higher inter-
dialytic weight gain [18, 26].  As such, the principle approach is to use a 
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combination of ultrafiltration by dialysis to dry-weight and antihypertensive 
therapy to control BP.  
 
2.1.2.1. Methods to determine and optimise volume status  
Whilst achieving euvolaemia or dry weight is an uncontroversial target, the 
best way to determine this is unclear. Dry weight is currently based on 
imprecise empirical observations in most centres and commonly defined as 
the lowest body weight a patient can tolerate without developing intra-dialytic 
or inter-dialytic hypotension. The frequent risk of dialysis related hypo-
perfusion is due to imprecision in the assessment of dry weight. If dry weight 
could be accurately, reliably and practicably determined then we would not 
have to resort to ‘probing’ for this by trial and error with the risks outlined. 
Two developments in the assessment of dry weight are worthy of mention. 
Intradialytic relative blood volume (RBV) monitoring uses a photo-optical 
technique to noninvasively measure real-time absolute hematocrit through 
equipment attached at the arterial end of the dialyser. Graphs of RBV against 
time have been proven to predict interdialytic reductions in blood pressure 
[27]. RBV changes are closely related to ultrafiltration and plasma-refill rate. 
However plasma refilling is impaired in autonomic dysfunction, which is 
common in HD patients. This reduces the specificity of RBV change to direct 
HD prescription and there is no data that its use can improve outcomes [28]. 
One of the most promising methods is bioelectrical impedance analysis 
(BIA). It measures resistance which is proportional to tissue water and 
reactance which is proportional to cell mass providing an index of volume 
status which can be longitudinally monitored. The difficulty arises in 
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converting this measure of relative hydration into absolute volumes of fluid as 
they require algorithms using assumptions from studies of healthy volunteers 
that perform poorly when applied to populations with disordered hydration. 
We conducted a study showing the added value of combining the relative 
hydration data from bioimpedance with absolute hydration data from a novel 
deuterium breath-test by portable mass spectrometer [29]. This highlighted 
that higher co-morbidity scores led to increasing underestimation of 
extracellular volume by bioimpedance [29]. Recently two novel approaches to 
quantify excess hydration by bioimpedance have been proposed. 
Assessment of continuous intra-dialytic calf bioimpedance ratios does not 
rely on geometric assumptions or comparison to population averages typical 
of whole-body methods [24].  Chamney et al proposed a three compartment 
physiological tissue model allowing quantification of excess fluid compared to 
normal controls [30]. Whilst requiring a population reference standard, the 
unique separation of extracellular volume into that due to excess and normal 
hydration is an important conceptual advance and has been shown to be of 
prognostic value in predicting mortality in a HD population [31].  Machek et al 
have used this new approach to perform bioimpedance guided prescription of 
dry weight in 52 HD patients. They showed that not only did this assist in 
dealing with hypertension in the overhydrated but it enabled a 73% reduction 
in intradialytic adverse events by increasing the target weight in the under-
hydrated group [32]. These preliminary data are promising but whether this 
will be of a discernible long-term value requires studies randomising 
clinicians to be blinded or have access to bioimpedance data and such 
studies have commenced (ISRCTN 95439739). 
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2.1.2.2. Complex relationship of hypertension to 
hypervolaemia 
The existence of overhydration in hypertensive dialysis patients is far from 
universal. Wabel and co-workers measured pre-dialysis systolic BP and fluid 
status in 500 HD patients by bioimpedance monitoring (compared to a 
matched healthy population). Only 15% of patients fitted the stereotype of 
overhydration with hypertension. 13% of patients had hypertension despite 
under-hydration and 10% had overhydration despite normal or low BP [33]. 
Similar findings were seen in a another study using the same methodology in 
639 patients using peritoneal dialysis (PD) Figure 2-4 [34].  These studies 
highlight that although physicians often estimate hydration status by blood 
pressure, the two factors are often dissociated in the setting of the 
physiological derangements characteristic of ESRD.  A wide variety of 
pathophysiological mechanisms may contribute to this dissociation. 
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Figure 2-4- Scatter plot of the relation between absolute delta tissue hydration (litres) 
in the X-axis and systolic BP (mmHg) in the Y-axis in patients of the EuroBCM study 
cohort of 639 dialysis patients. Different zones of patients can be seen in the plot. 
Zone A patients (27%) are both normohydrated and normotensive. Zone B (26%) are 
both fluid overloaded and hypertensive. Zone C (13%), are hypertensive despite being 
normal or underhydrated Zone D, (28%) are normo- and hypotensive despite being 
fluid overloaded. Zone E (7%) are hypotensive and normohydrated or normotensive 
and underhydrated [34]. 
 
2.1.2.3. Over-activity of the renin-angiotensin system 
Volume-independent factors contribute to hypertension in ESRD. Despite 
loss of renal excretory function, dialysis patients have inappropriately high 
renin levels relative to their salt and volume status [35]. A subgroup of 
patients with volume independent hypertension do not respond to salt or 
volume removal but are sensitive to ACE-inhibitors [35]. This subgroup can 
have hypertension despite low volume. (Zone C in Figure 2-4). 
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2.1.2.4. Increased arterial stiffness  
Arterial stiffness measured by pulse wave velocity is independently 
associated with increased risk of cardiovascular disease in HD patients, 
(Figure 2-5). Sigrist et al assessed the relationship of vascular calcification to 
arterial stiffness and its progression with time in 134 patients (60 on HD, 28  
Figure 2-5- Probabilities of overall survival in 241 HD patients according to tertiles of 
Pulse Wave Velocity (PWV) [36]. 
  
on PD, 46 stage 4 CKD) assessed at baseline and 2 years by femoral artery 
computed tomography and pulse wave velocity (PWV) [37]. Increased PWV 
correlated with vascular calcification and increased with progressive stage of 
CKD. Vascular calcification was strongly predictive of death, being present in 
20 of the 21 patients who died [37]. This was highly correlated with 
decreasing diastolic BP and increasing pulse pressure [37]. In this setting the 
principal driver of hypertension is not hypervolaemia but increased arterial 
stiffness. This allows hypertension to occur despite normal or under-
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hydration. Arterial stiffness will also further aggravate hypertension in those 
with overhydration.  
 
2.1.2.5. Advanced glycation end-product tissue deposition  
A relatively novel risk factor in increasing arterial stiffness is the formation 
and tissue deposition of advanced glycation end-products (AGEs). These 
heterogeneous compounds were classically described as end-products of a 
complex non-enzymatic reaction between glucose and proteins with a long 
half-life such as collagen. It is now known that AGEs accumulate by a variety 
of non-glucose mediated methods including ingested processed food, 
hyperlipidaemia, oxidative stress, carbonyl stress and reduced renal 
clearance. AGE formation has therefore been proposed to be a direct result 
of cumulative metabolic stress [38]. AGE accumulation causes cross-linking 
of collagen fibres directly increasing arterial stiffness. AGE levels are 
markedly increased in dialysis patients and predictive of mortality [38]. This 
may be as a result of increased arterial stiffness and increased endothelial 
dysfunction. 
2.1.2.6. The lag phenomenon and buffering of water-free 
sodium 
The Tassin group coined the term ‘lag phenomenon’ to explain a well 
described time delay between normalization of extracellular volume in HD 
patients by ultrafiltration and a sustained further reduction in blood pressure. 
This lag lasted several months, highlighting a dissociation between 
hypertension and hydration state [39]. The explanation for this may be linked 
to Jens Titze’s work showing that large amounts of sodium can be buffered in 
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the interstitial space without commensurate water retention [40]. 
Accumulation within resistance vessels may also contribute to increased 
tonic vasoconstriction, further favouring the development of hypertension. 
This extension to the traditional model of fluid homeostasis is supported by 
data showing that sodium is pro-inflammatory and is capable of direct 
adverse cardiovascular consequences independent of its effect on BP [40, 
41].  
Figure 2-6 The lag phenomenon. A delayed reduction in mean arterial pressure 
occurred several months after the exchangeable sodium and body weight had 
stabilized [42] 
 
2.1.2.7. The role of hyperglycaemia in hypervolaemia 
Hyperglycaemia may be another factor in the dissociation of BP and 
hydration status. Patients with diabetes ingest water as a result of glucose 
driven hypertonicity. Ramdeen et al performed a one year balance study in 9 
diabetic and 7 non-diabetic HD patients. This demonstrated sodium intake 
with commensurate water retention accounted for the entire inter-dialytic fluid 
gains in non-diabetic patients but only half the fluid gains in diabetic patients. 
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The other half was pure water intake presumably driven by hyperglycaemia 
[43]. In this setting free water ingestion is not being driven by the 
conventional salt and water paradigm and overhydration may even occur 
without hypertension. Acute hyperglycaemia and hyperinsulinemia can 
directly cause hypertension via vasopressor effects [44]. We have previously 
demonstrated that PD exchanges with hypertonic glucose based dialysate 
causes sustained hyperglycaemia and hyperinsulinaemia with resultant 
hypertension in both the fed and starved state [45]. In this setting 
hypertension can occur despite the dehydrating effect of peritoneal 
ultrafiltration and is abrogated by the use of glucose-sparing dialysate. 
 
2.1.2.8. Potential risks of probing for dry weight 
Probing for dry weight may also be at the risk of under-perfusing other 
vascular beds including those of the kidney, gut and brain. Although it might 
seem counter-intuitive to be concerned about renal perfusion in a dialysis 
patient it is well recognised that maintenance of residual renal function 
confers a survival advantage and improves volume control. Gunal and co-
workers targeted normal BP as a surrogate for normal volume status in 78 
PD patients by increasing ultrafiltration volumes with 3.86% glucose 
dialysate, and salt-restriction. They showed an impressive reduction in BP to 
a normotensive range at the expense of a 28% decrease in urine volume in 
the 19 patients with significant residual renal function [46]. The gut is also an 
important vascular bed, extracting 25% of resting cardiac output to maintain 
nutrition. 70% of gut bacteria possess pro-inflammatory endotoxin. In health, 
protection from endotoxin is afforded by energy-dependent tight-junctions in 
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the gut wall. In disease states with aberrant perfusion such as advanced 
heart failure and septic shock, endotoxin translocation across leaking tight- 
junctions is well described [47]. We hypothesised that dialysis might also lead 
to aberrant gut perfusion and endotoxaemia and performed a study in 249 
subjects without heart failure across the spectrum of CKD. Serum endotoxin 
levels were 1000 times greater in HD patients compared to non-CKD 
patients, with a four-fold increase between pre-dialysis CKD stage 5 and 
commencing HD or PD [48]. These elevated levels correlated with 
intradialytic hypotension, systemic inflammation, and troponin T levels. 
Whether dialysis-associated endotoxaemia is a culprit or bystander in the 
pathophysiology of inflammation, malnutrition and adverse cardiovascular 
outcomes in this setting is subject to current studies.  We have further 
proposed and are investigating the hypothesis that the cerebral 
microcirculation is also sensitive to dialysis-induced circulatory stress 
potentially explaining specific patterns of brain injury highly prevalent in the 
dialysis setting [49].  
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2.1.3.  Left ventricular hypertrophy 
LVH is a well-recognised risk factor for cardiovascular morbidity and mortality 
in the haemodialysis population, and the risk of complications can be 
stratified according to the differential patterns of left ventricular geometry 
(Figure 2-7). 
 
Figure 2-7 Time in months after starting dialysis to the first episode of heart failure, in 
245 patients stratified by left ventricular geometry on echocardiography [50]   
 
  
The link to LV hypertrophy (determined by LV mass) is well established in HD 
patients. LVH is thought to be an adaptive response that allows for normal 
LVEF despite abnormal pressure or volume load. Multiple risk factors are 
thought to be contributory including aortic stiffness, volume and pressure 
overload, hyperphosphatemia and neurohormonal activation [51]. Recent 
work has extended this picture with the implication of endogenous digitalis 
glycosides and fibroblast growth factor 23, both known to have higher 
concentrations in ESRD [52, 53]. In particular, sodium has been shown to 
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induce adrenal gland secretion of endogenous digitalis glycosides and in vitro 
studies have shown they directly induce myocyte hypertrophy thus providing 
a novel mechanism linking high dietary salt intake and impaired sodium 
excretion to hypertension and LVH in HD patients [54]. 
 
2.1.4. Dyslipideamia 
In the general population, meta-analyses of over 50,000 patients have 
confirmed there is a linear association between total and low-density 
lipoprotein-cholesterol (LDL-C) levels and cardiovascular morbidity and 
mortality [55]. Their reduction by drug therapy causes large reductions in 
cardiovascular risk of at least 20%. This relative risk reduction is independent 
of blood pressure and is complex in nature, with a greater impact on coronary 
event rates than stroke [55]. Recent meta-analyses have suggested the 
benefits of reducing total cholesterol and LDL-C using HMG-CoA reductase 
inhibitors (statins) are extended to those with low baseline risk [56]. In the 
absence of nephrotic syndrome, CKD is characterized by a distinctly different 
pattern of dyslipidaemia than the general population. Total cholesterol and 
LDL-C, the principle targets of statins, tend to be normal or low. High-density 
lipoprotein cholesterol (HDL-C) concentrations tend to be low and 
triglycerides tend to be increased [57]. The pattern is further complicated by 
variations in lipoprotein abnormalities depending on the stage of CKD, the 
modality of dialysis and the primary renal disease. As such epidemiological 
studies in HD have often shown paradoxical patterns of reverse causality 
with low cholesterol being associated with high mortality. Liu et al 
demonstrated in a study of 823 HD patients that this inverse relationship 
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reverted to a conventional relationship if the patients had low levels of C-
reactive protein (CRP)[58]. This suggested that the inverse relationship might 
be explained by comorbidity associated with inflammation (Figure 2-8).  
Figure 2-8- Association Between Cholesterol Level and Mortality in Dialysis Patients: 
Role of Inflammation and Malnutrition [58] 
 
 
Recent large randomised trials of statins in CKD and HD have shown the 
beneficial effects of reducing total and HDL cholesterol seen in the general 
population are either diminished or absent. The Die Deutsche Diabetes 
Dialyse (4D) study achieved a 40% reduction in LDL-C in 1225 HD patients 
with type 2 diabetes [59]. Despite this there was no reduction in the 
composite endpoint of cardiovascular and all-cause mortality [59]. Further 
analyses confirmed the distinctly different causes of mortality in HD patients 
with adjudicated deaths from coronary artery disease accounting for only 9%, 
whilst 33% died of sudden death or heart failure (Figure 2-9). Other 
explanations for the negative finding include the study probably being 
underpowered for the primary endpoint. 
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Figure 2-9 Causes of death in the 4D (Die Deutsche Diabetes Dialyse) study [57].+- 
 
 
The AURORA trial randomized 2776 patients to rosuvastatin or placebo 
achieving a 43% reduction in LDL cholesterol. Despite this there was no 
effect on the primary composite endpoint of cardiovascular mortality and 
cardiovascular events [60]. The SHARP (Study of Heart And Renal 
Protection) trial in 9270 CKD patients including 3023 on dialysis, showed 
LDL-C reduction caused a significant decrease in major atherosclerotic 
events, but no reduction in cardiovascular or all-cause mortality [61]. 
Therefore, in dialysis patients, particularly without ischemic heart disease, the 
benefits of lowering cholesterol remain uncertain.  
 
2.1.5.  Smoking 
Cigarette smoking is associated with increased cardiovascular morbidity and 
mortality in the general population. In CKD smoking is associated with more 
rapid progression of renal disease, but the effect of smoking in the dialysis 
population is less well studied [62]. Registry data typically underestimate true 
smoking prevalence [63]. A recent meta-analysis of studies including over 
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6000 dialysis patients, showed active smoking is associated with a significant 
increase in all-cause mortality (hazard ratio 1.65, 95% CI 1.26-2.14; p<0.001) 
although there was no corresponding increased risk of incident 
cardiovascular events [64]. The data were limited by heterogeneity and few 
studies assessed smoking as the primary endpoint. 
 
2.1.6. Glycaemic control in diabetic HD patients 
Diabetes is a potent cardiovascular risk factor in the general population as 
well as the the most common cause of CKD requiring HD in the Western 
world [65].  Indeed there are increasing data demonstrating that even in non-
diabetic subjects hyperglycaemia per se is an independent cardiovascular 
risk factor [66-68].  Compared with non-diabetic HD patients, diabetic HD 
patients are characterised by having approximately double the mortality rate 
but the reasons for this are poorly defined [69, 70]. Certainly those with 
diabetes have a clustering of traditional and non-traditional risk factors but as 
with other risk factors in ESRD there is incredible complexity relating 
hyperglycaemia to stage of CKD, drug effects, co-morbidity and treatment-
related factors. These combine to ensure findings and guidelines developed 
in the general population cannot simply be extrapolated. Nevertheless, 
current UK Renal Association guidelines suggest a target of HbA1C of 6.5-
7.5% irrespective of stage of CKD. This is based on non-CKD trials and 
observational data. Observational studies consistently show a J or U-shaped 
association of HbA1C to mortality in CKD or ESRD, contrasting with the 
linear association seen in the general population (Figure 2-10).  
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Figure 2-10 Hazard Ratios of all-cause mortality against HbA1C in 54,757 HD patients 
using time-averaged Cox proportional hazards regression [71].  
 
 
 
The Diabetes Control and Complications Trial (DCCT) of 1441 patients with 
type 1 diabetes and no other co-morbidities showed that intensified 
glycaemic control delayed the onset of microvascular complications [72]. The 
UK Prospective Diabetes Study in newly diagnosed type 2 diabetes showed 
strict glycaemic control delayed the onset of proteinuria and microvascular 
complications [73]. However, insulin and glucose homeostasis is markedly 
dysregulated in CKD (Figure 2-11). Assessment of glycaemic control is 
further complicated as erythrocyte survival is altered by use of erythropoeisis-
stimulating agents and glycated albumin may be a more appropriate marker 
[74].  
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Figure 2-11 Dysregulation of glycaemic control in advanced CKD [75] 
 
 
HbA1C reflects averaged glucose whereas in those having intermittent 
dialysis, marked short-term glycaemic variability that cannot be captured by 
HbA1c has been well demonstrated in studies using continuous glucose 
monitoring [76, 77]. Furthermore, glucose variability is a potent inducer of 
oxidative stress [78]. Though intensive glycaemic control can delay the onset 
of microvascular complications in newly diagnosed diabetes no trial has 
shown it can reduce cardiovascular end points or mortality. More recent 
larger randomised trials in the non-CKD population (ACCORD, ADVANCE, 
VADT) show that intensified glycaemic control in patients with pre-existing 
type 2 diabetes and cardiovascular co-morbidity led to either no benefit or 
significantly increased mortality [79-81]. Recent observational data shows 
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sustained extremes of glycaemia are variably and weakly associated with 
decreased survival in ESRD [82].  
 
In summary, glycaemic control is markedly dysregulated in CKD and 
extrapolation of trial data from the non-CKD population cannot be assumed. 
There is reverse causality with U-shaped associations of HbA1C to mortality. 
HbA1C is in itself an imperfect marker of glycaemic control in CKD and 
ESRD. In the absence of randomised trials, aggressive glycaemic control 
cannot be routinely recommended for all diabetic HD patients, as there are 
no proven mortality benefits and the risks of such a strategy are likely 
increased. Individualized targets and consideration of risks-benefit ratios 
should be used.  
 
2.1.7. Coronary artery disease 
Coronary artery disease (CAD) is both a consequence of cardiovascular 
disease as well as a risk factor for future cardiovascular events. Clustering of 
risk factors in ESRD means it is perhaps unsurprising to find clinically silent 
CAD but there have been few studies to determine the true prevalence in 
CKD or ESRD. Ohtake et al used coronary angiography to demonstrate 
>50% coronary artery stenosis in 16 of 30 asymptomatic stage 5 CKD 
patients, with no history of angina or MI at the initiation of RRT [83]. Hayashi 
et al used angiography or multi-slice computed tomography to demonstrate 
significant stenosis in 35 of 60 asymptomatic patients [84]. It should be noted 
that in the Hayashi study the study population was enriched by a screening 
step which excluded 20 lower risk patients, so they are likely to have 
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overestimated true prevalence in an asymptomatic population [84]. 
Nevertheless, it was notable that scintigraphy had a low sensitivity and 
specificity in both the latter studies. This is in keeping with the abundance of 
data demonstrating poor sensitivity and specificity of conventional screening 
tests such as stress ECG, scintigraphy and echocardiography [85, 86]. In the 
era prior to the emergence of nephrogenic systemic fibrosis and subsequent 
contraindication of gadolinium in CKD, Mark et al used gadolinium contrast-
enhanced cardiac magnetic resonance imaging in 134 ESRD patients as part 
of screening for renal transplantation [87]. In 19 patients, they found a pattern 
of contrast enhancement discrete to a coronary artery territory, consistent 
with prior and unrecognized MI. Of those 19, 9 had no antecedent history of 
ischemic heart disease demonstrating a low prevalence (7%) of silent CAD 
[87]. However as this latter population were candidates for renal 
transplantation, they might have less co-morbidity with consequently different 
CAD prevalence than an unselected ESRD population. Andrade et al also 
conducted a contrast enhanced magnetic resonance study in 72 high-risk but 
asymptomatic ESRD patients. High-risk was defined similarly to criteria used 
for CAD screening for renal transplantation; namely type 1 or 2 diabetes, age 
greater than 50 years and suspected or stable ischemic heart disease. 
Unrecognized MI was found in 18 patients (25%) [88]. An intriguing recent 
study examined the heart at autopsy in 120 patients who had been treated by 
HD for greater than a year [89]. They found a 39% prevalence of significant 
stenosis (Table 2-3).  
 32 
 
Table 2-3- cardiac features at autopsy in 120 prevalent HD patients[89] 
Feature Count 
n=120 
% 
Any cardiac calcification 74 62 
Coronary artery calcification 74 62 
Mitral annular calcification 52 42 
Aortic valve calcification 42 35 
>75% coronary stenosis 47 39 
 
The initiation of dialysis may play a role in the pattern of acute coronary 
syndromes. Prior studies have demonstrated that in a cohort of ESRD 
patients who experience an acute MI, 29% occur in the first year and 52% 
occur within 2 years [90].  
 
2.1.7.1. Outcomes of coronary interventions in CKD 
It is known that patients with ESRD and CKD are routinely excluded from 
intervention trials in CAD. A recent systematic review estimated 75% and 
80% of trials excluded those with CKD or ESRD respectively [91]. Baseline 
renal function was reported in only 7% of trials [91]. As such there is reliance 
on either assuming benefits and harms are the same as in the general 
population or using post-hoc subgroup analyses of those trials. Despite such 
limitations, data from such post-hoc analyse and large registries consistently 
demonstrate worse outcomes in CKD from acute coronary syndromes, PCI 
and CABG.  Shroff et al, have recently compared national audit data for 
acute MI hospitalisations in 31,709 patients with advanced CKD or ESRD to 
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274, 777 non-CKD patients between 1998 and 2000 [92]. They found that 
those with CKD were less likely to present with chest pain, less likely to have 
ST elevation, less likely to receive evidence-based drugs and more likely to 
be complicated by heart failure or major bleeding [92]. Logistic regression 
analysis gave adjusted odds ratios denoting 45-55% increase of in-hospital 
mortality (Table 2-4). 
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Table 2-4 Adjusted Odds Ratio and 95% CIs of in-hospital clinical events after Acute 
MI (AMI) from a large registry [92] 
  Number Death 
Recurrent 
AMI Stroke 
Major 
bleeding 
Dialysis 2390 
1.55 (1.39-
1.74) 
1.14 (0.82-
1.57) 
0.94 (0.66-
1.34) 
1.41 (1.16-
1.73) 
Advanced 
CKD 29319 
1.44 (1.39-
1.49) 
1.30 (1.19-
1.42) 
0.94 (0.85-
1.05) 
1.62 (1.53-
1.73) 
Non-CKD 274777 Reference Reference Reference Reference
P  <.001 <.001 0.52 <.001 
 
Similarly, these worse outcomes are reflected in recent prospective 
intervention trials of primary PCI for STEMI conducted in the modern era of 
drug-eluting stents and newer drugs with lower rates of bleeding 
complications. [93]. Although it is clear that outcomes for PCI and CABG are 
worse in the presence of CKD, few studies have estimated or compared the 
alternative of optimal medical management alone. Herzog et al showed that 
thrombolysis therapy for STEMI was associated with 28%  relative-risk 
reduction in all-cause mortality at 2 years [94]. Hemmelgarn et al used risk-
adjusted models to estimate that compared to medical therapy, 
revascularisation by CABG reduced mortality by a similar degree to the non-
CKD population, although crude survival was much lower [95]. PCI showed a 
benefit in CKD but not ESRD (Table 2-5).  
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Table 2-5 Unadjusted and Adjusted Survival Rates at 8 Years for CABG and PCI 
Versus No Revascularization by Category of Kidney Function[95] 
 
The most definitive observational study to address which strategy to use in 
the absence of trial data was published recently. Chang et al abstracted data 
on 21,981 ESRD patients who underwent CABG or PCI for multivessel CAD 
between 1997 and 2009 [96]. As well as illustrating the remarkable stability in 
survival rates over time (Figure 2-12), unadjusted analyses showed no 
differences in 5 year survival of 25% [96]. However using cox-proportional 
hazards regression as well as a propensity-score matched cohort revealed 
13% lower risk of death and 12% lower risk of death or non-fatal MI for 
CABG compared to PCI. 
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Figure 2-12 Survival rates at 1, 2, and 5 years after initial multivessel coronary 
revascularization for 21,981 patients on maintenance dialysis in the USRDS by index 
year [96]. 
 
 
2.1.7.2. Recent insights from non-CKD population studies 
There is an abundance of data from non-CKD studies which have clarified 
indications and benefits of coronary interventions. PCI is recognized to 
reduce symptoms but not mortality in patients with stable angina. The best 
recent example of this is the COURAGE trial of 2300 patients demonstrating 
no benefit of PCI over optimal medical therapy in CAD [97]. This validated 
uncertainty over whether preventative PCI alters outcomes and clarified that 
the current first line approach to patients with stable angina is optimal 
medical management. With the caveats outlined and in the absence of 
evidence, it underlines uncertainty in the CKD population if stenting 
‘significant’ coronary stenosis will improve outcomes. There had also been 
uncertainty whether PCI with drug-eluting stents and optimal drug therapy 
was preferable to CABG in multivessel CAD, particularly in high risk patients, 
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because of lower procedural risks associated with PCI. The FREDOM trial 
randomly allocated 1900 patients with diabetes and multivessel CAD to 
CABG or PCI. Patients were followed for an average of 5 years. The primary 
outcome of all-cause mortality, nonfatal MI or nonfatal stroke, occurred more 
frequently in those who underwent PCI vs. CABG (27% vs. 19%, p=0.005) 
[98]. Stroke, however, occurred more frequently in the CABG group (5.2% vs. 
2.4%) [98]. Thus, there appears to be a clear benefit of CABG in diabetics 
with multivessel CAD, reflecting the outcome of the afore mentioned recent 
observational data in the ESRD population[96]. Finally, recent data have 
added to the abundance of existing data refuting the view that coronary 
angiography should be considered the gold standard for defining CAD. It has 
long been known that visual or computer based-estimation of coronary 
stenosis at angiography is a poor guide to functional significance[99]. 
Confounding factors include vessel tortuosity, overlap of structures, and the 
effects of lumen shape. The lumen is viewed in a single dimension, and 
many large constituents of atherosclerotic plaque are radiolucent. 
Interobserver variability of estimated luminal stenosis is as high as 50% and 
reported correlations of lumen size by angiography versus coronary 
ultrasound are as low as r=0.3 after PCI [100]. Coronary ultrasound and 
serial angiography studies have demonstrated that the majority of acute MIs 
occur in atherosclerotic plaques with <50% stenosis that would not be 
considered severe [101, 102].  A recent 60 patient study supports that this 
pattern is unchanged in CKD [103]. The FAME (Fractional Flow Reserve 
versus Angiography for Multivessel Evaluation) trial demonstrated that in 
patients with multivessel CAD, restricting PCI with drug-eluting stents to 
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functionally significant stenosis, significantly reduced death or MI at 2 years, 
compared with the conventional practice of PCI to all stenoses >70% [104]. 
In essence, measuring functional reserve directs the cardiologist as to 
whether the lesion should have PCI. Patients without functionally significant 
stenoses do not need PCI, even if the lesions appear severe by angiography.  
 
As I will outline in detail in a later section, it is well recognized that pre-
existing LVH, autonomic dysfunction and arterial stiffness are highly 
prevalent in CKD and they act to reduce coronary flow reserve, such that 
coronary artery stenosis is not required to produce significant myocardial 
ischaemia [105]. Thus, the chances of successfully determining whether 
elective PCI of asymptomatic coronary stenosis will improve outcomes in 
CKD are likely to be even further reduced.  
In summary, in the setting of acute coronary syndromes or symptomatic 
CAD, the available data clearly suggests that CKD patients still derive 
significantly improved outcomes from CABG or PCI compared with medical 
management although those outcomes are worse than the general 
population. The difficulties arise in detection and management of silent and 
asymptomatic CAD. This is likely to be common in CKD and ESRD and 
outcomes from known interventions are worse. Conversely, angiographically 
significant CAD is not essential to produce ischaemia. Whilst it seems 
rational to aggressively screen patients for asymptomatic CAD, data from the 
non-CKD population suggest uncertain benefits of coronary intervention over 
optimal medical therapy, particularly without measuring fractional flow 
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reserve. The benefits and harms of such interventions in CKD or ESRD 
cannot be assumed to be the same.  
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2.2. Cardiac imaging in CKD 
 
 
Figure 2-13 The ischaemic cascade 
 
 
2.2.1. The ischaemic cascade  
When coronary artery flow is impaired this leads to an imbalance of oxygen 
supply and demand, reduced perfusion, metabolic disturbance, regional 
ventricular dysfunction and electrophysiological change occur in succession. 
This sequence of events is termed the ischemic cascade. Another way of 
perceiving this process is that complex changes occur at a microscopic level 
and cascade to changes detectable at a macroscopic level. In the traditional 
 41 
 
‘bench-to-beside’ approach to research, animal models, basic science and 
molecular biology are used to elucidate a pathway of a disease at a 
microscopic level. By resolving this microscopic defect this might translate to 
alter the course of a disease at a macroscopic level. Similarly at a 
macroscopic level one can aim to relieve symptoms of myocardial ischaemia  
by opening up a ‘tight’ 90% stenosis by angioplasty of a coronary artery to 
improve microscopic perfusion. Both of these approaches may succeed but 
often fail to impact on patient-centred outcomes because they might over-
simplify the complexity of biological systems. To use a mathematical analogy 
they treat the macroscopic as classical Euclidean geometry, where shapes 
have regular edges with integral dimensions which can be reduced by 
axiomatic formulae to an integer of its smallest essential unit. Thus one, two 
and three integral dimensions describe a line, area and volume respectively. 
Despite huge success, Euclidean geometry failed to mathematically describe 
or model much of the complexity that scientists observed in the world. In the 
1960s, the mathematician Benoît Mandelbrot used the adjective ‘‘fractal” to 
indicate objects whose complex geometry can only be characterised by a 
fractional rather than integral dimension. A fractal is an irregular object 
composed of self-similar subunits. It was only with the rediscovery and 
elucidation of fractal geometry and other non-linear dynamics that scientists 
were better able to model and predict biology [106]. Like fractals, many 
patterns in biology display detail of microscopic self-similarity superimposed 
on seemingly random macroscopic variation.  
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Figure 2-14 Ice crystal formation on a leaf displays a self-similar geometry which can 
only be mathematically described using non-linear fractal dimensions. Many complex 
biological processes and patterns may be better described using fractal geometry. 
 
This complexity cannot be predicted using conventional models which rely on 
predominantly linear statistical modelling and leads to paradoxical findings. 
Medicine is littered with surrogate markers of disease that have failed, 
sometimes with the unintended consequences of misguided interventions. 
Opening a 90% stenosis may not improve perfusion because of the damage 
the process entails, the complexity of flow dynamics and the fact that the 
majority of blood is delivered in vessels much smaller than those visible 
[107]. Cardiac imaging is undergoing a paradigm shift from purely anatomical 
imaging of anatomy to augmentation by imaging inherent aspects of function. 
These should perform better as surrogate markers by being more closely tied 
to disease and hold promise for effecting change in clinical outcomes, the 
highest standard for a biomarker. An approach based on structural and 
functional imaging may help in explaining the complexity and the paradoxes 
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of multiple failed interventional trials to reduce cardiovascular disease In HD 
patients. It may identify those groups who benefited from an interventional 
trial but were not identified by the choice of surrogate and composite 
endpoints. It may also better identify those who require a different approach 
and produce more focused interventions which focus on treatment 
environment, timing, mode of delivery and recovery, as much as the 
treatment itself. In this thesis I will use two main imaging techniques to 
characterise cardiac abnormalities in HD patients, cardiovascular magnetic 
resonance and echocardiography.  
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2.2.2. Two-dimensional transthoracic echocardiography 
 
Cardiac assessment by conventional two-dimensional (2D) transthoracic 
echocardiography (2DE) is non-invasive, inexpensive to perform, and 
generates detailed information about gross cardiac anatomy, objective 
quantification of LVM and the geometry of LV hypertrophy, along with 
measures of function during systole and diastole. The predictive power of the 
most commonly used measures of cardiac geometry is underappreciated. 
Prospective studies have shown left ventricular hypertrophy (LVH) in most 
(70-80%) patients with end stage renal failure and this confers a poor 
prognosis [108]. LVM indexed to weight or body surface area (LVMI) confers 
difficulties in the CKD population with over- or under-estimation of LVMI due 
to the inherent variations in fluid volume status, body composition and 
nutritional status. A cohort study of 254 dialysis patients (demonstrated that 
death and cardiovascular outcomes are better predicted by indexing LVM to 
height in ESRD patients [109].  
 
The most widely used method for quantifying systolic dysfunction remains LV 
ejection fraction, derived from one dimensional linear M-mode diameter 
measurements at end-systole and end-diastole. However M-mode 
measurements use the Devereux formula to determine LVEF based on a 
regression model derived from a healthy population. The model performs 
poorly in populations with asymmetric LV hypertrophy such as those with 
hypertension or CKD [110]. Major international guidelines now recommend 
that LVEF be calculated using a bi-plane or tri-plane area length method, that 
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requires acquisition of 2 and 4 or 2, 3 and 4-chamber image loops capturing 
end-diastole and systole [111]. Newer software allowing this to be quickly 
calculated at the time of image acquisition should increase penetration to 
clinical practice but it is already regarded as standard for clinical research. 
Various other parameters of systolic dysfunction have been proposed based 
on fractional shortening (FS) across the entire myocardial wall. These also 
perform poorly in those with asymmetric LVH such as concentric LVH 
(present in over one-third of HD patients), due to differential contractility 
within the endocardium and epicardium. Standard FS has been superseded 
by mid-wall FS, which increases homogeneity [112]. Zoccali et al 
demonstrated that midwall FS was more sensitive than LVEF for the 
identification of asymptomatic dysfunction in HD patients [113]. In the same 
study, both midwall FS and LVEF had equal prognostic ability for 
cardiovascular events and death.  This study also confirmed that in ESRD 
the enhanced risk associated with both LVH and systolic dysfunction were 
additive [113, 114].  
 
2.2.2.1. Left atrial volume 
Measures of left atrial (LA) size are useful surrogate markers for left 
ventricular diastolic dysfunction, and predict cardiovascular events in the 
non-CKD population [115-117]. A recent cohort study of 249 ESRD patients 
demonstrated that height-indexed left atrial volume (LAVI) displays predictive 
power for all-cause mortality over and above that of indexed LV mass and 
ejection fraction [118]. Furthermore, change in LAVI over one to two years 
predicts future cardiovascular events independently of LVM and baseline LA 
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dimensions [119, 120]. Barbareto et al have recently shown in 172 
haemodialysis patients that LAVI independently predicts intradialytic 
hypotension [121]. Chan et al studied a mixed cohort of 200 CKD patients 
with around half using HD.  LA diameter independently predicted long term 
cardiovascular mortality and was incremental to stress single photon 
emission computed tomography (SPECT) [122].  
 
2.2.2.2. Limitations of 2D Echocardiography 
Notably, echocardiographic measures based on ventricular dimensions are 
sensitive to the degree of cardiac filling, which is important in dialysis 
patients where pre-load and after-load change as a function of fluid status. 
LVM measurements are particularly problematic as they rely on geometric 
assumptions. LVM calculated by post-dialysis echocardiography may be 
26g/m2 lower than pre-dialysis because of load dependency. This 
discrepancy is not seen when utilising cardiac magnetic resonance imaging 
[123]. Accurate measurements require excellent image quality and good 
acoustic windows which can be limited in many patients, particularly if obese. 
Other disadvantages of conventional echocardiography include a greater 
reliance on subjective interpretation and higher inter-observer variability for 
LVEF compared to alternative methods [124].  
 
2.2.3. Three-dimensional transthoracic echocardiography 
 
Early approaches to 3D echocardiography (3DE) were based on the principle 
that a 3D data set could be reconstructed from a series of 2D images. This 
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method required time consuming acquisition of data as well as off-line image 
reconstruction and analysis. Improved transducer technology allows faster 
image acquisition of the heart using ECG-gated images within 4 cardiac 
cycles, termed real-time 3D echo to distinguish it from the older technologies. 
From henceforth I shall refer to this as 3D echo (3DE) [125]. Semi-automated 
LV surface detection technology has reduced off-line processing times. The 
major advantage of 3DE compared to 2D methods is it makes no assumption 
of geometry making the accuracy and inter-observer variability comparable 
to cardiac magnetic resonance which is considered the reference standard 
[126-128]. The technology has some limitations. To reconstruct the 3D 
images requires a greater volume of data acquisition and better image 
registration than 2D echo. This necessitates ECG-gating and multiple breath-
holds for the subject to minimise respiration artefact. The breath-hold 
requirement can be problematic in patients with dyspnoea and arrhythmias 
and in this respect it is similar to CMR. However, a reduced resolution 
dataset that still outperforms the 2D technique in many respects can be 
captured in a single cardiac cycle. The transducer has a limited acquisition 
angle which may not be large enough to view the LV if it severely dilated. 
Finally equipment is more expensive, less available and less technical staff 
are trained to use it. This is particularly relevant for multi-centre research and 
clinical practice where penetrance is poor. Despite these limitations 3DE is 
emerging as a promising tool, particularly suited to a CKD population with a 
high prevalence of abnormal ventricular morphology [129]. As yet there are 
few studies in this setting [130].  
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2.2.4. Stress echocardiography 
 
Preoperative screening for coronary artery disease (CAD) is recommended 
in renal transplant candidates who are at high risk. Nuclear imaging 
modalities using thallium tracers have conflicting results for the accuracy of 
detecting (CAD) or predicting future cardiovascular events in the setting of 
CKD [131-138]. Study comparisons are confounded by significant 
heterogeneity with cardiac imaging after both exercise and pharmacologic 
induced stress or a combination of both. Exercise-dependent techniques are 
limited by poor exercise capability [139, 140], as well as the loss of specificity 
due to LVH seen in the majority of dialysis patients [141-143]. Therefore 
patients with CKD are often only considered suitable for pharmacological 
stress. Conventional 2D dobutamine stress echo (DSE) measures indices of 
global and regional ventricular dysfunction, and relies on high quality imaging 
and interpretation by experienced operators. Dobutamine increases heart 
rate and contractility via sympathetic stimulation, causing both transmural 
flow redistribution by arteriolar dilatation, and increased oxygen consumption 
[144].  The propensity for patients with ESRD to develop significant 
arrhythmias [145] may be a relative contraindication to adrenergic stress 
testing. Dobutamine-related side effects have been variously reported in 
about 10% of renal transplant candidates [146, 147].  In contrast, 
dipyridamole causes transmural flow redistribution by inhibition of adenosine 
breakdown, leading to arteriolar vasodilatation, subendocardial steal, and 
ischaemia caused by altering coronary haemodynamics in the presence of 
critical coronary stenosis. 
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DSE is sensitive and specific for coronary artery risk screening in renal 
transplant candidates. Herzog et al  studied 50 such patients with both DSE 
and coronary angiography showing sensitivity of 75% and specificity of 71% 
for a significant coronary stenosis [147]. Sharma et al have reported a study 
of 125 renal transplant candidates comparing screening techniques for 
severe coronary artery disease. DSE was an independent predictor of severe 
coronary artery disease (CAD), displaying excellent sensitivity of 88% and 
specificity of 94% for significant CAD [148]. About half of these patients were 
on dialysis, and made up two-thirds of those found to have severe CAD. 
Patients with severe CAD had significantly larger LV diameter, and more 
impaired systolic and diastolic function than those without. Resting ECG was 
also found to be independently predictive of CAD in this study, although 
significantly less sensitive (77%) and specific (58%). As expected, patients 
with diabetes had significantly higher prevalence of severe CAD compared to 
non-diabetics (44 vs 20%). This raises the possibility of investigating non-
diabetic transplant candidates with DSE and resting ECG for risk 
stratification prior to exposure to the risks of coronary angiography.  
However, De Lima et al studied DSE in 126 transplant candidates and 
showed lower sensitivity of just 44% with specificity 87% to detect CAD on 
coronary angiography [149]. Doubts about applicability of stress 
echocardiography in patients with more severe CKD has led to renal disease 
currently not being categorised in the most recent ‘Appropriateness Criteria 
for Stress Echocardiography’ recommendations [150]. 
A recent observational follow-up study in more than 2000 patients across the 
spectrum of renal impairment demonstrated that positive DSE for ischaemia 
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was an independent predictor of both death and hard cardiac events over a 
mean follow-up period of 8 years at all stages of CKD  [151]. Moderate renal 
impairment and normal baseline DSE conferred the poorest prognosis, with 
20% suffering cardiac death or myocardial infarction over 3 years. New wall 
motion abnormalities also independently predicted survival, although the 
predictive power of both models was strengthened when index of renal 
function was added. There have been few direct comparisons of 
dipyridamole stress echocardiography (DpSE) with DSE in a non-CKD 
patient group. Comparison in high-risk populations with hypertension or 
suspected CAD showed conflicting results of prognostic ability [144, 152, 
153].  An Italian study aimed to compare DpSE to DSE mainly for adverse 
effects reporting a slightly lower incidence for dipyridamole [154]. A caveat to 
many of these studies is that heterogeneity in selection for DSE leads to 
variable pre-test probability and hence negative predictive value of the test. 
For example Fragasso et al studied a population that had positive exercise 
test before DSE which would significantly increase the pre-test probability 
compared to the other studies of transplant candidates which were less 
selected [144]. Amongst non-nephrologists CKD is increasingly recognised 
as an independent risk factor for CV events and it is sobering that the 
majority of these screening studies have not reported renal excretory 
function as it alters the pre-test probability [152]. A 2003 meta-analysis 
confirms the overall prognostic value of stress echocardiography for 
assessment of CAD in renal transplant candidates [138].  3DE is emerging 
as a useful tool in the non-CKD population with the potential to enhance 
current non-invasive assessment of myocardial perfusion. 2D methods 
 51 
 
require the acquisition of multiple views of the heart at peak stress but a 3D 
dataset can be obtained in a few seconds with the ability to reconstruct 
infinite views for analysis off-line. 3DE however does not yet have the image 
resolution of 2D equipment and often requires contrast enhancement. 
Hence, early published comparisons show similar accuracy of 3D to 2D 
stress methods to detect CAD in the non-CKD population [155, 156]. In 
summary, the data on the utility of stress cardiac imaging to screen for CAD 
in CKD patients have wide heterogeneity and conflicting results.  
 
2.2.5. Myocardial Strain Imaging 
Strain is a dimensionless measure of deformation or the relative 
displacement between two particles caused by an applied force. The 
terminology of strain was first developed in engineering and physics. 
Lagrangian strain often denoted as İL, represents the fractional or 
percentage change from the unstressed dimension:   
İL = (LíL0)/L = ¨L/L0  
Where L0 and L are the unstressed and stressed lengths respectively. 
Therefore strain is usually described as a percentage, decimal or fraction.   
Mirsky and Palmley were the first to describe strain applied to the 
myocardium, where L0 is substituted by end-diastolic length, as the myocytes 
are never truly under zero stress [157]. Many consider that in biology, 
Eulerian strain denoted İe is a better representation of deformation:  
İe= L/L0 
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where L0 is the instantaneous length, that is, the length at the time before, 
rather than length at time zero. Hence Eulerian strain does not assume zero 
stress.  Lagrangian and Eulerian strain have been shown to be 
mathematically related. Lagrangian strain is the most commonly reported 
value. Myocardial strains can be positive (lengthening or expansion) or 
negative (shortening or compression).  Strain rate is the temporal derivative 
of strain and is a measure of the rate of deformation, with units of 1/s. As 
strain measures displacement per unit length, then strain rate is also 
equivalent to change in velocity per unit length. Thus strain, strain rate, 
displacement (motion) and velocity are both distinct and related. Measuring 
one of these quantities can be used to derive all four.  
Figure 2-15 Relationships of strain and strain rate to velocity and displacement. 
Figure redrawn with kind permission from Asbjørn Støylen 
 
Objects can deform in 3 dimensions. As a further complication there is also 
displacement in surfaces relative to each other. Therefore strain has three 
normal and six-shear components (Figure 2-16). In a Cartesian co-ordinate 
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system the components are x, y and z. For simplicity, in the heart, the 3 
principle coordinates are used relative to the tissue; longitudinal, 
circumferential and radial (transmural) as depicted in Figure 2-17.  
Figure 2-16 Deformation of a 3D object is described by three normal and six shear 
strain components. One normal component (a) and three shear components ࣅyx (b), 
ࣅzx (c) and ࣅxy (d)] are illustrated[158]  
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Figure 2-17 Graphic representation of the principal myocardial deformations: 
longitudinal (A), radial and circumferential (B), and torsion (C). The direction of 
deformation in systole is shown as solid lines and that in diastole is shown as dashed 
lines. LONG indicates longitudinal; RAD, radial; and CIRC, circumferential. [159] 
 
Longitudinal shortening can easily be demonstrated in long axis cardiac 
imaging. Radial thickening is equivalent to wall thickening, but as the 
myocardium is almost incompressible it can be shown that much of the wall 
thickening is a consequence of longitudinal shortening to conserve volume. 
The value of measuring strain compared to displacement is in being able to 
distinguish active from passive displacement. An ischemic basal segment 
may still show normal motion as it is tethered to healthy tissue but will not 
show deformation. It has been proven that the human eye is not capable of 
appreciating such subtle changes in deformation [160]. Thus strain and strain 
rate changes may be more sensitive markers of myocardial function [161, 
162] Visual or semi-automated tracking of the endocardial border provide 
estimates of cardiac volume, which are used to derive ejection fraction, a 
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quantitative indicator of global ventricular function. This reflects the sum 
contribution of several regions and does not provide information on regional 
function. Visual assessment of regional function is subjective and prone to 
error [163]. The heart has complex deformation which is incapable of being 
described in a single vector of strain [164]. Much of this complex deformation 
stems from the orientation of the myocardial fibres (Figure 2-18).  
Figure 2-18 Myocardial fibre orientation of the left ventricle from the epicardial to 
endocardial layer. Left to right epicardial oblique fibres represent a right handed helix, 
whilst oblique fibres towards the endocardium approximate a left handed helix. Figure 
adapted from source [165]   
 
The obliquely orientated fibres form a left and right-handed helical 
arrangement. This lends the heart a twisting motion which as a strain is 
represented by the circumferential-longitudinal shear strain. From the base 
the rotation is clockwise and from the apex counter-clockwise. The twisting 
motion is an essential part of myocardial function.  
Figure 2-19 Schematic representation of rotational motion of the heart during the 
cardiac cycle during early (A) and mid-systole (B) and viewed from the apex during 
mid-systole (C). Torsion versus time plot of a healthy adult man at rest (D) with 
counterclockwise rotation arbitrarily defined as positive and time normalised to 
percentage duration of systole During early systole (A), both apex (green) and base 
(red) rotate counterclockwise (blue arrows) whereas later in systole (B), the apex 
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rotates counterclockwise and the base rotates clockwise (yellow arrow) creating the 
wringing or torsional motion. Torsion (orange) is derived by subtracting the basal 
rotation from the apical rotation (D).  Caption adapted from Burns et al [166] 
 
Before the invention of cardiac magnetic resonance tagging study of cardiac 
motion was restricted to animal or ex-vivo studies using sonomicrometry, 
implantation of acoustic markers. Advances in cardiac imaging now allow this 
to be done using several techniques based on cardiac ultrasound and 
cardiac magnetic resonance. The most commonly used are cardiac magnetic 
resonance tissue tagging, Tissue Doppler Imaging (TDI) and two-dimensional 
(2D) speckle tracking echocardiography (STE). Ultrasound based techniques 
are more widely available.  
2.2.6. Tissue Doppler Imaging 
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Standard Doppler echocardiography imaging uses the Doppler principle 
which mathematically relates frequency shifts in reflected waves to velocity. 
Tissue Doppler Imaging (TDI) evolved from standard Doppler imaging by 
optimising the frequency filter settings of ultrasound to image low-velocity, 
high-intensity myocardial tissue signal rather than high-velocity, low-intensity 
signal from blood [167]. TDI is well validated in detecting systolic and 
diastolic function and regional components of cardiac function such as 
longitudinal or radial contraction. TDI has been validated against 
sonomicrometry in whole hearts and tagged CMR [168, 169]. Recent work 
has focused on longitudinal velocities proving TDI capable of detecting 
subclinical LV dysfunction. Mogelvang et al has shown that in a community 
cohort with normal LVEF, TDI detected diastolic dysfunction is an 
independent predictor of mortality and had incremental prognostic value to 
conventional echocardiography and biomarkers (Figure 2-20).  
Figure 2-20 KaplanMeier survival curves by tertiles of the eas index. The eas index 
includes combined information on systolic and diastolic performance by TDI. Shown 
are age- and sex-adjusted eas tertiles [170] 
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Hayashi et al found that TDI was able to detect systolic and diastolic 
dysfunction in CKD patients with or without left ventricular hypertrophy [171].  
In particular those with LVH had reduced isovolumetric contraction, with 
reduced peak systolic and early diastolic filling velocities. Galetta et al 
studied twenty HD patients without overt cardiac disease demonstrated 
reduced peak systolic and early diastolic velocities, with reduced early to late 
diastolic velocity (Em/Am) ratio post dialysis compared to pre-dialysis. 
Interestingly, these reductions in systolic and diastolic function negatively 
correlated with ultrafiltration rate and interdialytic weight gain [172].  Yu et al 
recently reviewed TDI studies summarising the paramters that had shown 
prognostic value in studies of heart failure, coronary artery disease and 
hypertension. Mitral annular or basal segmental (Sm) systolic and early 
diastolic (Ea or Em) velocities were shown to predict mortality or 
cardiovascular event [173]. Studies have variously demonstrated early mitral 
annulus velocity, peak systolic and peak late diastolic velocities to be 
relatively independent of pre-load in HD [174-176]. The search for pre-load 
independent echocardiographic measures of cardiac function has led to 
extensive study of the effect of TDI derived parameters in haemodialysis 
[172, 174-186]. TDI shares the limitation of all Doppler techniques in being 
angle dependent.  
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Figure 2-21 The importance of angle dependency in producing inaccurate velocities 
by Doppler-based imaging. A jet of known velocity (2.0 m/s) emerges from the aortic 
valve in systole. Moving 60 degrees from parallel only allows a peak velocity of 1.0 
m/s to be recorded. The most accurate velocities are recorded when the transducer is 
parallel to flow 
 
The vector of motion parallel to the ultrasound beam is measured so 
accuracy relies on an experienced operator to ensure the probe is aligned.  
This is best achieved in long axis images with higher intra and inter-observer 
variability of values obtained in the short-axis.  TDI also interrogates motion 
at a single point in the myocardium with reference to the transducer. Thus it 
is prone to inaccuracies caused by translational motion and tethering effects.  
 
2.2.7. Tissue Velocity Imaging 
Whereas TDI measures velocity of myocardial tissue relative to the 
transducer and remains prone to tethering effects, Tissue Velocity Imaging 
(TVI) uses TDI at adjacent loci in tissue to measure velocity gradients by 
regression to generate a Eulerian strain rate curve. The strain rate curve can 
then be integrated to produce a strain curve. TVI gives accurate 
quantification of LV filling pressures, myocardial contraction and relaxation. 
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Systolic myocardial velocities and strain rate quantify systolic function whilst 
diastolic function is measured with diastolic velocities and isovolumetric 
relaxation time [168, 187, 188]. Strain rate imaging by TVI has proven 
capable of detecting locally reduced contractility in small discrete infarcts 
induced by alcohol septal ablation in ten patients with septal hypertrophy 
who had normal global function by invasive haemodynamic monitoring [189]. 
Of particular relevance to the study of dialysis patients, TVI can detect acute 
changes in LV function [188], and measurements are considered less load 
dependent than conventional Doppler echocardiography [181]. A study of 13 
stable HD patients, without any overt cardiovascular disease, found pre-
dialysis peak systolic, early diastolic and late diastolic myocardial velocities 
were reduced in comparison to age- and sex-matched controls, indicative of 
systolic and diastolic dysfunction; systolic function improved based on TVI 
parameters post-dialysis. However, the majority of HD patients had no 
systolic or diastolic dysfunction detectable by conventional 2D echo, and no 
difference was discernible between pre-and post-dialysis measures [181]. In 
non-CKD settings TVI has shown changes in strain precede regional wall-
motion or tissue velocity abnormalities under vasodilator stress and can 
differentiate stunned from ischaemic myocardium [190, 191].  
 
2.2.7.1. Limitations of TDI and TVI 
As with TDI, TVI is angle dependent. The angle dependency can be 
minimised by narrowing the sector width of image acquisition but this 
compromises spatial coverage and resolution. The velocity-regression 
technique used to derive strain rate from velocity is exquisitely sensitive to 
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noise. Altering the temporal resolution to optimise spatial resolution may lead 
to over or under-estimation of velocities [159]. Also use of the Doppler effect 
to derive strain rate restricts measurement to one dimension at any one time. 
Measuring radial strains in short-axis images is extremely limited by the 
transducer angle, which particularly impairs the reliability of data in the 
anteroseptal and posterior segments [192]. Even measuring longitudinal 
strains in long axis images requires care because the myocardium has a 
curved septum and lateral walls, the same true tissue velocity will produce 
differential derived velocities that become greater over a larger sampling 
distance. Hence care is required to place the sampling volumes. This 
becomes particularly problematic at the apex. The complexity in deriving the 
measures, the requirement to acquire the TVI image loops separately to the 
standard B-mode ultrasound loops and the time required for largely off-line 
analysis reduces the clinical utility of the technique. Distinguishing true 
pathology from image artefact requires a high skill level [159]. Indeed, 
published validations of the techniques tend to be from centres with 
advanced echocardiographic expertise and clinical studies yield lower 
correlations between ultrasound derived strain and cardiac magnetic 
resonance tagging than those reported in experimental studies (r values of 
0.4-0.5) [192]. This means TDI and TVI are often confined to clinical 
research studies and have not penetrated into routine clinical practice. 
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Figure 2-22 Impact of angulation on strain rate imaging by TVI. Interrogation parallel 
with the wall (mid-septum, shown in blue) identifies long-axis shortening, and at right 
angles to the wall (apex, shown in red) identifies short-axis thickening. However, an 
intermediate angle (apical septum, shown in yellow) causes underestimation. A 
mixture of vectors at 45% produces a net absence of recordable strain. Scan planes 
are shown as continuous lines, longitudinal and radial contraction vectors as broken 
lines. Figure and caption from [193] 
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2.2.8. Speckle Tracking Echocardiography  
There was a clear need for the development of a Doppler-independent 
echocardiographic technique for strain and strain rate measurement.  Ideally 
this would be independent of the angle to the transducer, less sensitive to 
signal noise, able to measure strain in two dimensions and not require 
additional image acquisition. 2D Speckle Tracking Echocardiography (STE) 
was first described in 2004 [194]. STE estimates motions by tracking of 
speckles in the image. The speckles are the result of interference generated 
when sound waves scatter in tissue. This phenomenon appears when sound 
waves are reflected by sub-millimetre structures smaller than the wavelength 
of ultrasound.  The resulting interference between waves either destroy or 
summate their amplitudes (destructive or constructive interference).  
Figure 2-23 Schematic of constructive and destructive interference which is the source of 
the unique speckle pattern in biological tissues imaged by ultrasound. Left, in a regular 
pattern from just two wave sources and right from multiple scattered sources, 
approximating the situation in biological tissue. Figures adapted from two sources 
courtesy of Poon Siew Cheng and Asbjorn Stoylen [195] 
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This results in a pattern of bright and dark pixels in a B-mode ultrasound 
image. When applied to the myocardium, the tissue structures causing 
interference are stationary within the tissue and randomly distributed. This 
produces a speckle pattern that is a stable, unique ‘fingerprint’ of that region 
that moves with the tissue.  The speckle pattern can be tracked using an 
optical flow method or block-matching algorithm based on finding the 
smallest sum of absolute differences [196, 197]. The vector (distance and 
direction) is derived and can be easily combined with time data to determine 
velocity and strain. Most commercially available software track several 
regions of interest around 5mm x 5mm and average the vectors to determine 
average strain, for a sector of the heart using a 16 or 17 segment model. 
STE has many advantages over Doppler-based methods. Because the end-
diastolic length is known, STE inherently measures Lagrangian strain and 
can derive Eulerian strain. Motion is determined independent of the angle to 
the ultrasound transducer. Strain is determined as a 2D vector, better 
approximating true motion for curved regions of myocardium such as at the 
apex. It can be determined from standard B-mode ultrasound images and 
does not require additional acquisitions, thus shortening examination time. 
Junior echocardiographers are more able to acquire images of sufficient 
quality as it less noise sensitive than Doppler-based strain methods. Strain 
determination is semi-automated by software, theoretically reducing inter-
observer variability. Longitudinal strain can be determined from lateral motion 
on parasternal long-axis image in addition to longitudinal motion in a long-
axis image. Similarly radial strains can be calculated from long-axis as well 
as short-axis images and should be equivalent. The ability to deal with 
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curved ROIs mean that it is particularly suited to assessing torsion, rotation, 
radial and circumferential strains unlike Doppler-based methods which are 
essentially restricted to long axis images or specific segments in the short-
axis. STE has been validated against sonomicrometry and tagged CMR 
[198]. In summary, the many advantages of strain by STE over strain by 
Doppler, have led to a more rapid uptake of this technique in research and 
clinical practice.  
 
Figure 2-24 Two-dimensional (2D) strain is based on comparison of the image texture 
(i.e., pattern of individual speckle elements) from frame to frame. The distortion of this 
pattern permits assessment of strain in the axis of movement rather than the axis of 
the ultrasound transducer[193]  
 
 
2.2.8.1. Limitations of STE 
Frame-rate sensitivity  
There are careful considerations to be aware of when acquiring images for 
analysis by speckle tracking software.  Lateral resolution of ultrasound is 
inherently lower than its vertical resolution and decreases with depth. This 
means that over short distances (or times) the tracking is better than over 
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larger distances or times, making STE sensitive to the temporal resolution of 
the image. Low frame rates lead to poor tracking in all directions as too much 
motion has occurred for the algorithm to reasonably estimate. Too high a 
frame rate indirectly affects tracking by increasing noise and lowering the 
lateral resolution of ultrasound resulting in poor lateral tracking relative to 
vertical. Most published data have shown that the optimal frame rate lies 
between 40-80 frames/second [193, 199]. This is a much lower frame rate 
than using Doppler-based methods (>100) and may miss transient and 
important events in the cardiac cycle such as isovolumetric phases.  
Out-of-plane motion 
As the myocardium is deforming in 3 dimensions the unique speckle pattern 
will be degraded by true out-of image plane motion. 3-dimensional STE has 
recently been developed which may overcome this problem. 
Image quality  
Most STE studies show a proportion of segments that cannot be analysed 
due to image quality. In healthy subjects this is about 6% but rises to 15% in 
studies of disease. Marwick et el showed in a reference range of 250 healthy 
volunteers that excellent image tracking quality was achieved in only 79% 
and that there were systematic variations[200]. Tracking was best in the 
septum and inferior wall and worst in the anterolateral walls, especially at the 
apex (Figure 2-25).  
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Figure 2-25 Relationship between tracking quality (TQ) (mean and SD of TQ score, y 
axis), wall (color coded, see legend), and segment location (x axis) . The TQ scores 
are best (closest to 1) in the mid-wall and worst (averages >1.5) in the anterior and 
posterolateral walls. This regional variation emphasizes the role of image quality 
(especially edge detection) on TQ [200]. 
. 
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2.2.8.2. Utility of Strain by STE 
Normal range, accuracy and precision 
Published reference range studies for strain values by STE in healthy 
volunteers are remarkably consistent with strain by other methodologies such 
as Doppler-based strain and CMR tagging [200]. Peak longitudinal and 
circumferential strain ranges from -15% to -20%. Peak radial strain is in the 
30-40% range.  Values can be reported globally averaged across all 16 or 17 
segments of the LV, or segmentally. When reported at a segmental 
resolution there is significant heterogeneity in values, suggesting that 
segmental rather than global normal cut-off values could be preferable for 
clinical use [200]. Marwick et al determined interobserver reproducibility. The 
mean difference in segmental measurements was 0.24% percentage points, 
with 95% confidence intervals between í11.4% and +11.8%. Test–retest 
variability showed no systematic bias, and 95% confidence intervals were 
between í9.6% and +9.7%. This compares favourably with LVEF by 2D 
echocardiography which has  test–retest variability so that the smallest 
change of ejection fraction that is detectable with 95% confidence is 11% 
[201].  
 
Comparisons with Visual Regional Wall Motion Analysis  
Echocardiographic assessment of CAD currently relies on visually scored 
regional wall motion analysis. Guidelines recommend wall motion is scored 
into 5 categories, but this requires high image quality and a high level of skill 
and experience in interpretation [202]. However as with TDI, STE has proven 
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capable of quantifying ischaemia. This was initially proven in animal models 
[203]. Leitman et al showed in 30 patients with known regional LV 
dysfunction that there was a graded decrease in longitudinal peak-systolic 
strain between visually scored normal, hypokinetic and akinetic segments 
(peak systolic strain 13.4%±4.9 in normal, 10.5%±4.5 if hypokinetic, 
6.2%±3.6 if akinetic, P< 0.000001) [204].  Becker et al showed in 62 patients 
that radial and circumferential systolic strain and strain rate could identify 
Regional Wall Motion Abnormalities (RWMAs) well compared with RWMAs 
by CMR [205]. Liel-Cohen et al recently conducted a single centre study in 
105 patients, 90 admitted with chest pain and 15 with known dilated 
cardiomyopathy [206]. The ability of peak-longitudinal strain by STE was 
compared to the ability of 12 expert echocardiographers to visually determine 
RWMAs blinded to patient details. Automatic quantification using peak-
systolic longitudinal strain with pre-determined cut-offs performed as well as 
visual analysis by the echocardiographers, with a greater reliability and 
similar agreement to angiographic findings [206]. This demonstrates the 
potential to use 2D strain to assist less experienced echocardiographers in 
identifying regional dysfunction. It should be noted that for the latter study the 
visual technique does not directly assess the same component of cardiac 
motion [206]. Wall motion scoring is largely dependent upon radial 
displacement whereas the automated method was based on longitudinal 
deformation.   
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Figure 2-26 Longitudinal strain compares well to expert analysis of regional wall 
motion in 105 patients with known or suspected heart disease. Mean [SD] values for 
interobserver and intraobserver reliabilities (A and B, respectively) for binary 
classification of myocardial segments in normal versus abnormal, hypokinetic versus 
other, and akinetic versus other segments. An automatic scoring method (ASS) based 
on cut-offs determined by peak-systolic longitudinal strain by STE are compared to 
visual scoring (VSS) by 12 expert echocardiographers. Caption adapted from [206].  
  
  
Choi et al showed the utility of strain by STE extended to screening patients 
with suspected CAD. They studied 108 patients with suspected CAD and no 
resting RWMAs on conventional echo who underwent resting STE and 
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coronary angiography. They divided into tertiles of risk by severity of CAD at 
angiography. They then determined the peak-longitudinal systolic strain in 
each of those tertiles and used receiver operator characteristic curves to 
show that the groups were best separated by strain with sensitivity and 
specificity of 79%. The novelty of this study is that strain was able to risk 
stratify patients without stress testing even when resting wall motion and LV 
ejection fraction are normal [207]. Therefore, semi-automated determination 
of longitudinal strain by STE may be a more sensitive marker than wall 
motion abnormality for severe CAD [207]. 
 
2.2.9. Magnetic Resonance Imaging 
Magnetic resonance is an imaging technique that evolved from the field of 
nuclear magnetic resonance and so its origins can be traced back over 100 
years with major contributions from several people leading to the imaging 
technique it is today. Up until the 1970s nuclear magnetic resonance 
spectroscopy used magnetic fields to determine chemical composition. The 
signal was one dimensional and could not be localised in space. The shift 
from spectroscopy to imaging occurred in the 1970s when in a seminal 
Nature paper, Paul Lauterbur proposed a technique of interacting two 
magnetic fields to create a two-dimensional image in which the image 
resolution was unconstrained by the wavelength of the imaging field [208]. 
Unaware of Lauterbur’s work Sir Peter Mansfield independently 
demonstrated using varying interacting fields (gradients) to increase the 
resolution of the produced image [209, 210]. He also showed how ultra-fast 
gradient variation could rapidly encode an image [211]. These developments 
 72 
 
led to the modern equivalent of encoding an image by frequency and 
Lauterbur and Mansfield were jointly awarded the 2003 Nobel Prize for 
Physiology or Medicine. In 1975 Richard Ernst described the first use of Jean 
Fourier’s mathematical methods to decode information from the phase and 
frequency of the magnetic resonance signal. At present, the Fourier 
transform remains the basis of image reconstruction. 
 
2.2.9.1. Principles of Magnetic Resonance 
Complete confidence in the physics of magnetic resonance is not essential to 
use the technology but understanding the basic principles will help when 
trying to optimise image quality and applying more advanced techniques in a 
clinical research setting. An MRI system consists of a patient table sliding 
into a fixed magnetic field and several varying magnetic fields. The main field 
termed B0, is a large static superconducting electromagnet made by passing 
electricity through copper tubes supercooled by liquid helium. The B0 field is 
in the head-foot direction and is designed to have a completely uniform and 
homogenous field within its centre. This is usually a sphere of approximately 
50cm diameter and this determines the limits of the size of field of view that 
can be imaged at any one time without moving the patient on the table.  
Atomic nuclei possess the property of magnetic spin. This refers to a 
microscopically small rotating local magnetic field called the magnetic 
moment. MRI can be performed with any nuclei which possess the property 
of magnetic spin. These nuclei are MR active by virtue of an uneven number 
of protons and neutrons such as 31P, 23Na, 13C. In clinical practice the most 
commonly used nucleus for imaging is hydrogen (consisting of a single 
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proton). This is for two main reasons. Firstly, as the smallest of the MR active 
nuclei it has the highest spin allowing detection of a larger signal difference 
for the same strength of external field compared to other nuclei. Secondly, it 
is abundant in biological tissue as part of water and fat. These intrinsic 
microscopically small spins are very weak magnetic fields and are normally 
randomly oriented in the body. When a patient is introduced into the B0 field 
of the MR system, the proton spins in the patient have a net alignment of 
magnetization in the direction of B0. This net vector of magnetization M in the 
direction z is termed Mz. Both B0 and Mz are proportional to the strength of 
the field measured in units of Tesla. 
 
Figure 2-27- MR system components. a) Diagram showing the relative locations of the 
main magnet coils, x, y, and z gradient coils, integral rf transmitter body coil and rf 
receiver coils. b) Typical arrangement for a cylindrical bore MR system showing the 
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magnet bore and the reference coordinate axes with the static Bo field direction along 
the horizontal z axis  
 
To obtain a signal requires varying magnetic fields to be introduced to the 
fixed field B0. These fields can be switched on or off or varied in space on a 
gradient of field strength. They are called ‘gradients’ for short and delivered 
by gradient coils. If a pulse of radiofrequency (RF) waves with the same 
frequency as the resonant frequency of protons, are introduced perpendicular 
to B0 then the protons are excited and this excitation is termed resonance. A 
simple analogy is a guitar string. It has a note of a certain frequency, which 
can be made to resonate by introducing a tuning fork with the same harmonic 
frequency as the string. When the RF pulse stops the protons relax to their 
resting energy state and radiowaves are emitted and detected by the RF 
receive coil. The RF pulse tips the direction of the spin from the longitudinal 
Mz direction into the transverse or xy plane. The angle at which it is tipped is 
termed the flip angle and the resulting magnetisation is termed transverse 
magnetisation, Mxy. It is the transverse magnetisation that is measured by the 
receive coil. The received signal has a complex waveform which has no 
spatial information. To use another musical analogy several voices can be 
heard from a choir but the signal requires processing to determine location 
and the pitch of each individual voice. To localize the signal in space a 
gradient is applied in the head-foot direction at the same time as the RF 
pulse. This ensures only one part of the patient has protons which will be 
excited in the centre of the magnet (slice select gradient z). Without applying 
a simultaneous slice select gradient, protons from the whole patient would be 
excited and it would be impossible to spatially localize the origin of the signal. 
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Then a gradient varies frequency of spins along the y direction (frequency 
encoding). Finally a gradient varies phase of the spins along the x direction. 
The frequency and phase encoding steps are performed in between 
excitation and receiving the emitted signal. This only produces a single line in 
the data-space (termed k-space). The k-space is not a simple cartesian 
image. Rather, it is a complex image in which each line in k-space contains 
data from the whole imaging slice. The signal is sampled multiple times and 
the nature of the signal can be more clearly differentiated with each 
successive line of k-space. The most essential data is in the centre of k-
space with fine and edge detail in the outer k-space.  
Figure 2-28- K-space and the corresponding short-axis cardiac image that it produces. 
K-space is a complex image representing the raw image data which is Fourier 
transformed (FT) to produce a two-dimensional image.  
 
The sequence has to be repeated several times at the desired range of 
frequencies and phase encoding steps to form a recognizable image. How 
many times is determined by the spatial image resolution that is sought. 
Higher image resolution requires more image acquisition time. The final 
matrix of k-space is then Fourier transformed to produce the final image. 
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Fourier transform refers to Jean Fourier’s set of equations which reduce a 
complex waveform into a series of sines and cosines enabling description as 
the set of simple waveforms from which it was derived. 
Figure 2-29 A Fourier transform (FT) allows a complex waveform to be simplified into 
constituent waveforms described by a series of sines and cosines. K-space is Fourier 
transformed to reproduce the source image. Image adapted with permission of David 
Higgins[212]. 
 
 
CMR has particular challenges to reduce motion of the heart in the image. 
This is principally achieved by retrospective ECG-gating of the image and 
breath-holding to reduce respiratory motion. ECG-gating synchronises the 
RF pulse to occur after the R-wave of the ECG. The k-space acquisition is 
segmented into phases of cardiac cycle where each line in k-space is filled 
from multiple phases. The images are retrospectively phase-ordered to 
reconstruct a moving cinematographic (cine) image as in Figure 2-30. As 
such the cine is not a real-time representation of cardiac motion but 
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constructed from several R-R intervals into a single reconstructed cardiac 
cycle. How many lines are acquired per R-R interval is the number of k-lines 
per segment and determines the true temporal resolution of the resulting 
image and the breath-hold time. The number of k-lines required is 
determined by the spatial resolution and the size of the field of view. It can be 
seen that ultimately all images acquired are a trade-off between spatial and 
temporal resolution, signal-to-noise-ratio and breath-hold time (Figure 2-31). 
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Figure 2-30- Cine imaging using a segmented k-space acquisition with retrospective 
ECG-gating. Each line of k-space is acquired from multiple phases of the cardiac 
cycle, 5 in this example. With prospective gating the R-wave triggers the acquisition. 
There is a gap before the next R-wave to allow it to be detected. Retrospective gating, 
acquires data more efficiently and quickly by continuously recording phases and 
temporal position relative to the R-wave. The data is retrospectively sorted into phase 
order. Retrospective gating works well with a regular R-R interval but will incorrectly 
sort and produce a blurred cine if the R-R interval varies or if the MR system mistakes 
a T-wave for an R wave. 
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Figure 2-31- Trade-offs in CMR image acquisition. Although several pulse sequence 
parameters can be user-adjusted, they are all ultimately constrained by acquisition 
and thus breath-hold time. If patients cannot hold their breath adequately, trade-offs 
need to be accepted and optimised to achieve diagnostic quality.  
 
When a proton’s spins have been excited, it relaxes to its equilibrium energy 
state. The length of time over which this energy dissipation occurs are 
termed T1 and T2 relaxation times. They are essentially inherent properties 
of the tissue being imaged, varying according to relative water and fat 
content and the relative freedom of motion that protons have within these 
molecular structures. T1 is the time after excitation to recover longitudinal 
magnetisation in equilibrium. T2 relaxation time measures the transverse 
magnetisation decay. By designing the radiofrequency pulses in a particular 
way, the image can be weighted to highlight certain characteristics of tissues. 
 80 
 
The most commonly used weightings are T1 and T2 weighting. Images can 
also be T2* and proton-density weighted. The most common sequence used 
in cardiac imaging is steady-state free precession (SSFP). In terms of 
weighting SSFP has complex weighting being a mix of T1,T2 and proton-
density. 
 
2.2.10.  Cardiac Magnetic Resonance Tagging  
Analysis of left ventricular mass and volumes and ejection fraction are the 
current standard for assessment of global ventricular function and are 
powerful determinants of cardiovascular mortality. Despite this they are late 
markers of dysfunction. Assessment of regional deformation within the 
myocardium may have greater sensitivity and specificity for defining cardiac 
disease than inferring function from the motion of its boundaries. Strain 
analysis has been proven to detect early cardiac dysfunction prior to a 
decline in LVEF in non-uraemic settings [213-216]. Furthermore in 
heterogenous cardiomyopathy populations with both normal and reduced 
LVEF, strain was reduced in the subset of populations with normal LVEF and 
gave additional prognostic information beyond that provided by LVEF and LV 
mass [217, 218]. Quantifying regional myocardial motion or deformation was 
first done in animal studies using sonomicrometry, that is surgically implanted 
acoustic markers [219].  In 1988 Zerhouni et al described for the first time 
myocardial tissue tagging[220]. It was based upon altering the magnetization 
to produce visible markers on the myocardium that could be tracked in space 
and time. The basic principle required slice-selective sinusoidal RF pulses 
perpendicular to the imaging plane. This saturates the image to produce 
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areas of dark signal intensity. The sinusoidal nature of the pulse produces a 
series of lines in the imaging plane. If a second modulated RF pulse is 
repeated at 90 to the first pulse before image collection then a grid-tag 
pattern is placed on the heart. Because the magnetization is a property of the 
tissue the grid follows the shape of the myocardium through the cycle. This 
allowed visualization of deformation which might otherwise be difficult to 
visually appreciate. The technique was validated against sonomicrometry in 
animal and human studies and was termed Spatial Modulation of 
Magnetisation (SPAMM) [221, 222]. 
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Figure 2-32 SPAMM tagging. (A) SPAMM pulse sequence. The tagging consists of two 
non-selective 90° RF pulses separated by the tagging gradient (modulation) in the 
tagging direction, and followed by a crusher gradient to remove residual 
magnetization. The imaging part is a conventional cartesian k-space acquisition (RO = 
readout, PE = phase encoding, SS = slice selection). (B)This sequence creates parallel 
tag lines orthogonal to the x-axis. (C)  Example of a SPAMM grid-tagged image 
showing left ventricle (LV) and right ventricle (RV). Note that this grid pattern needs 
the application of a second tagging modulation (in the orthogonal direction) next to 
the first one before imaging takes place. Note also that the dark myocardium between 
the tag lines is not completely black due to longitudinal relaxation. Figure and caption 
adapted from [223] 
 
 
2.2.10.1. Tagging variants  
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Gradient-recalled echo imaging readout is the commonly used 
implementation of SPAMM tagging at 1.5T. However at this field strength the 
tag fades in mid-diastole and is not considered reliable to assess diastolic 
strain. There have been over 30 variants of tissue tagging since the first 
description and these have recently been reviewed [223, 224]. The rationale 
for improvements has been to enhance the utility of tagging by improving 
several characteristics of the tags including: 
i. Improved temporal and spatial resolution;  
ii. increased signal-to-noise ratio;  
iii. increased contrast-to-noise ratio;  
iv. shorter acquisition time; shorter analysis time  
v. to resolve the issue of through-plane motion in two dimensions.  
In 1993 Fischer et al introduced a complementary-SPAMM tagging technique 
(CSPAMM) [225]. Two consecutive scans are acquired with the same 
SPAMM tagging parameters except the polarity of one of the tagging RF 
pulses. This produces a positive tagging grid in one image then a negative 
tagging grid. Residual magnetization (which limits tagging contrast in 
subsequent phases) can be removed by subtracting the second from the first 
image. The subtraction can be done in such a way that the signal is 
summated (SNR increases 40%) and the noise is ‘cancelled’. Therefore at 
the same signal strength CSPAMM produces sharper tag lines, with less 
fading and greater access to diastolic phases. The disadvantage is in 
doubling scan-time compared to SPAMM with implications for the length of 
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breath-hold required. However, recent modifications to CSPAMM have 
overcome these problems to enable a tagged  image to be acquired in a 
single breathhold [226].   
Gradient-recalled echo imaging readout is the commonly used way of 
acquiring the imaging readout at 1.5T. More recent developments have been 
the use of echoplanar imaging (reducing scan time) and steady-state free 
precession techniques (improving image resolution and contrast) [227].  
Other developments have dealt with the issue of through-plane motion by 
tagging in 3 dimensions [228]. 
 
Finally, as tissue tags are saturated magnetization, then greater 
magnetization by scanning at higher field strengths will also improve SNR 
and reduce tag-fading by prolonging T1-relaxation time.  Comparison of 
tagging at 1.5T to 3T has shown it has superior diagnostic ability [229]. 
 
2.2.10.2. Tagging analysis 
Although tagging enabled easier visualization of regional wall motion, its real 
value lies in highly reproducible and quantitative determination of strain which 
requires post-processing of the tagged images. Various techniques were 
historically used including optical flow and active contour tracking methods. 
These were limited by requiring huge computing power for the era and 
typically might take 4 hours to analyse a single patient dataset. This confined 
tagging to the research setting for many years. Interest in tagging has 
increased since the development of commercially available software that 
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reduced this time to minutes. HARP analysis was originally developed by 
Nael Osman and is currently the most widely used method for analysis of 
tagged images [230]. HARP works by filtering the inverse Fourier transform 
of the first harmonic of the spectral peaks seen in the k-space (raw data 
space) of tagged CMR images to yield harmonic magnitude and phase 
images. Displacement can be calculated from changes in the phase images 
to determine Lagrangian or Eulerian strain. Strains can be determined locally 
and spatial resolution is limited to the resolution of the tag (typically 7mm). 
HARP analysis is now commercially available software (HARP 3.0 
Diagnosoft, Palo Alto, California) and has been used in several clinical 
studies. The accuracy of HARP has been validated in animal and human 
studies [231, 232].  
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2.3. MRI of organ perfusion in CKD  
 
2.3.1. Introduction  
Blood flow is crucial to ensure normal tissue metabolism. This concept has 
been confirmed in animal models in several organs, showing that interruption 
of blood flow leads to impaired oxygenation and metabolism, 
electrophysiological change, functional impairment and symptoms in quick 
succession. Appreciation of this continuum has led to the terms ‘ischaemic 
cascade’ or ‘ischaemic penumbra’(Figure 2-13) [233, 234]. Perfusion is a 
term used to describe the process of the delivery of blood to the 
microcirculation of the tissues and microcirculatory impairment marks the 
start of this cascade. The translation of experimental concepts into efficient 
treatments for organ ischaemia requires noninvasive methods by which 
regional blood flow, perfusion, oxygenation and metabolism can be 
repeatedly interrogated. This allows therapeutic interventions to be directed 
at the functional significance of disease rather than merely anatomical 
appearance.  An example of such utility is in coronary artery disease. Two -
year outcome data from the Fractional Flow Reserve Versus Angiography for 
Multivessel Evaluation (FAME) trial showed that using an invasive measure 
of functional reserve rather than degree of arteriographic stenosis to direct 
the use of drug-eluting stents significantly improved survival [104]. This 
paradoxical dissociation between the anatomical and functional severity of 
arterial stenoses is due to the complexity of flow dynamics [235]. This 
concept can be extended to other organ vascular beds and one can 
speculate that the lack of knowledge of blood flow or perfusion reserve might 
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be an explanation for the failure of angioplasty of renal artery stenoses to 
improve renal functional outcomes in the Angioplasty and Stent for Renal 
Arterial Lesions (ASTRAL ) trial [236]. 
 
Perfusion can be measured in animals using radio-labelled microspheres. In 
humans, quantification can be done by X-ray computed tomography at the 
expense of a high radiation burden and requirement for use of contrast 
media. Nuclear scintigraphy is nonquantitative, measuring relative rather 
than absolute perfusion. Positron emission tomography is quantitative but 
requires injection of a radioactive tracer and has low spatial and temporal 
resolution. The noninvasive nature of MRI, its high temporal and spatial 
resolution and the ability to alter signal characteristics to interrogate 
physiological change render it ideal to study perfusion. Perfusion 
measurement by MRI falls broadly into two types: those requiring exogenous 
contrast media and those that use endogenous tracers by magnetically 
labelling the blood. Contrast enhanced techniques typically use tracer 
kinetics of gadolinium chelates, nondiffusible tracers that remain in the 
vasculature. Delivery of an intravenous bolus of gadolinium shortens the 
relaxation time of tissue resulting in a large signal difference that can be 
captured by T1-weighted or T2*-weighted sequences. The nondiffusibility of 
gadolinium means that it measures local blood volume and using a kinetic 
model, perfusion can be estimated [237, 238]. This is a well validated 
technique of high spatial and temporal resolution in several organs. A recent 
landmark trial including 752 patients showed that it provides greater 
accuracy than nuclear scintigraphy for the detection of myocardial ischaemia 
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[239]. However, use of gadolinium is now restricted in chronic kidney disease 
(CKD) to prevent nephrogenic systemic fibrosis [240]. The clearance times of 
tracers also render these single-measurement techniques with no ability to 
repeat the acquisition in the same scan session. 
 
2.3.2. Blood oxygen level-dependent imaging 
 
Measuring tissue function without ionizing radiation, nephrotoxic iodinated 
contrast or gadolinium is particularly attractive to those managing patients 
with CKD. Blood oxygen level -dependent (BOLD) imaging uses 
haemoglobin as an endogenous contrast, exploiting the fact that the 
transition from diamagnetic oxyhaemoglobin to paramagnetic 
deoxyhaemoglobin increases microscopic magnetic field inhomogeneity 
causing more rapid spin dephasing, which decreases the T2*-relaxation time 
and reduces signal intensity in T2*-weighted sequences. Thus, signal 
intensity provides an index of tissue oxygenation. BOLD contrast is widely 
used in functional brain MRI and is the basis of detecting local changes in 
brain activity with task performance.  
In abdominal organs, A multiple gradient-recalled echo (GRE) sequence is 
most widely used to assess the BOLD signal. This is typically performed 
under a pharmacological or physiological challenge, such as renal-BOLD 
contrast following the administration of furosemide and to study water 
loading [241-243]. Renal-BOLD contrast can also detect the presence of 
renal hypoxia induced by renal artery stenosis, with an increase in R2* 
(R2*=1/T2*) in conjunction with a decrease in renal blood flow [244, 245]. 
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Thus it has shown promise in identifying those patients with renal artery 
stenosis who might benefit from renal angioplasty [245]. BOLD imaging has 
determined that the angiotensin-receptor blocker olmesartan causes a 
reduction in R2* indicating improved oxygenation in CKD [246], and has 
been shown to identify those kidneys with acute rejection from a measured 
decrease in medulla R2*[247]. However, in the largest human study of 
abdominal BOLD imaging, Michaely et al, have recently shown that renal-
BOLD contrast failed to discriminate between different stages of CKD among 
280 patients, questioning its ability to distinguish clinically meaningful 
differences from single measurements [248]. 
 
Some groups have developed novel BOLD schemes using a T2-prepared 
steady-State free precession (SSFP) signal readout, conferring inherently 
higher signal-to-noise ratio than GRE sequences with theoretically greater 
diagnostic accuracy. Arnold et al. studied 60 patients, assessing cardiac-
BOLD with T2-prepared SSFP against perfusion by gadolinium contrast-
enhanced MRI under adenosine stress [249]. BOLD contrast had an 
accuracy of 84%, sensitivity of 92% and a specificity of 72% for detecting 
significant coronary stenosis, compared with 91%, 92%, and 89% 
respectively for gadolinium contrast-enhanced MRI [249].  

It should however be emphasized that using BOLD imaging comes with the 
caveat that it is an indirect marker of oxygenation, resulting from the complex 
interplay of perfusion, haematocrit, blood volume, tissue microstructure and 
oxygen consumption. Further, a number of other factors can alter the T2*-
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weighted signal such as magnetic field homogeneity over the organ, vessel 
geometry and the MRI pulse sequence used. Comparison of myocardial 
BOLD imaging to perfusion measured by the gold-standard of positron 
emission tomography with radio-labelled  water, showed clear evidence of a 
dissociation of perfusion and oxygenation as measured by BOLD, with 
normal oxygenation in 40% of ischaemic segments under adenosine stress 
[250]. Ultimately, there is no way to convert the BOLD signal intensity alone 
to a quantitative measure of oxygenation; thus, challenges that modulate the 
BOLD signal are inherently more meaningful than single baseline 
measurements. BOLD imaging benefits from improved contrast-to-noise ratio 
at higher magnetic field strengths; however, inhomogeneity artefacts can 
become a greater problem [249]. 
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2.3.3. Arterial spin labelling 
 
Arterial spin labelling (ASL) is an MRI technique which provides a non-
invasive perfusion measurement. ASL uses the magnetic spins of freely 
diffusible water in blood as an endogenous tracer. It does so by labelling the 
magnetization of blood water, typically by inverting the blood water spins 
before they enter the tissue of interest. The labelled water then exchanges 
with tissue water, with the magnetization then decaying at a rate limited by 
the T1-relaxation time of the tissue water. By subtracting the difference of a 
labelled image from a control image with unlabelled blood water, a perfusion-
weighted image is obtained for which signal intensity is proportional to 
perfusion. Direct quantification of perfusion can be calculated from a kinetic 
model if knowledge of the tissue T1 relaxation time, blood-tissue partition co-
efficient and transit time of the blood water to tissue water is known[251]. 
Common to BOLD imaging, ASL is infinitely repeatable allowing applications 
that cannot be conceived using contrast media. However, as the signal 
change is small, ASL imaging relies on the acquisition of multiple label and 
control image pairs and averaging of the resulting perfusion-weighted 
images. ASL also has several additional features. The label is short-lived and 
decays with T1 relaxation time. Although this necessitates rapid image 
acquisition after labelling, it also ensures the signal is not affected by venous 
outflow and the kinetics are only related to arterial inflow. Gadolinium based 
flow measures are inherently volume dependent meaning that the signal 
depends on bolus timing and the water-tissue exchange slows the 
disappearance of the signal.  ASL is theoretically applicable to any organ 
 92 
 
with a well-defined arterial supply.  ASL was first used in the brain some 20 
years ago and the technique has developed to the extent that it is sufficiently 
robust for clinical use [252]. However, there is far less published data relating 
to its use in abdominal or thoracic organs (kidney, liver and heart). In the 
most advanced brain ASL schemes, the label can be modulated to yield a 
fast acquisition of perfusion mapped by individual feeding arteries (Figure 
2-33). If these advanced ASL schemes can be developed and applied in 
other organs, examples of utility might include the selective labelling of the 
left and right coronary arteries.  
Figure 2-33 Vessel-encoded ASL allowing three-vessel separation above the Circle of 
Willis. In the tagging plane shown on the right, the anterior cerebral artery (ACA) is 
confined to the midline and the corresponding territory is represented in the ASL 
maps as bright green. The territories supplies by the insula branches of the middle 
cerebral arteries (MCAs) are well tagged and are bright red and blue, but other smaller 
branches of the MCAs are not well tagged, leaving the ACA/MCA border unclear. Scan 
time: 6 min. Adapted with permission from [253] 
 
ASL can be broadly divided into two variants, continuous or pseudo-
continuous ASL and pulsed ASL. In continuous and pseudocontinuous ASL, 
the blood is continuously labelled until the magnetization reaches a steady 
state. Continuous ASL is limited by the requirement of long radiofrequency 
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pulses causing off-resonance artefacts, loss of the label as it travels to the 
imaging slice and high specific absorption rates of radiofrequency-induced 
heating. However, a recent pseudocontinuous ASL method has been 
introduced which uses a train of rapidly repeating low angle radiofrequency 
pulses to reduce such effects. In pulsed ASL, a single inversion 
radiofrequency pulse is used to provide a wide label in a slice of arterial 
blood and imaging is performed after a few seconds allowing the labelled 
blood to reach the tissue of interest. One of the most common 
implementations of ASL in body imaging is the flow-sensitive alternating 
inversion recovery (FAIR) pulsed ASL scheme, as depicted in Figure 2-34.  
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Figure 2-34 Principles of arterial spin labelling perfusion measurement by flow-
sensitive alternating inversion recovery. 
(A) Upper row: An image is collected with renal arterial blood water labelled by 
magnetic inversion (coronal, axial and sagittal views of a non-selective label slab 
shown outlined in white to label inflowing blood) which is subtracted from a control 
image (selective control slab shown outlined in black) to yield a perfusion-weighted 
image. (B) Lower row: The signal intensity difference between the control and label 
images generates a perfusion weighted image with signal intensity of ~ 14%. Using a 
kinetic model, this difference image can be converted to a map of absolute regional 
perfusion values. 
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The perfusion weighted signal can be quantified in units of ml/100g/min, 
when combined with measures of tissue relaxation time and label transit time 
(Figure 2-35).  
 
Figure 2-35 Estimation of renal perfusion generated by flow-sensitive alternating 
inversion recovery-arterial spin labelling using a (A) T1-relaxation time map; (B) 
arterial transit time map and (C) quantitative regional perfusion map in ml/min/100g of 
tissue. 
 
 
2.3.4. Developments of arterial spin labelling 
 
Cardiac gadolinium contrast-enhanced MRI conveys a signal difference of 
40–50% between normal and ischaemic tissue leading to images that are 
visually diagnostic at the time of acquisition. By comparison, ASL and BOLD 
images are both limited by low signal intensity differences in the order of 1–
4%. This is overcome in ASL by repeating the label-control acquisition to 
achieve an averaged signal, typically of the order of 40 averages in ASL of 
the brain. In the kidney, this requires multiple breathholds, and data has 
typically been acquired in a single 8–10mm slice following the labelling. 
However, recent advances in parallel imaging exploit multichannel coils to 
accelerate the time it takes to acquire an image [254]. Gardener and Francis 
performed the first study combining FAIR-ASL of the kidney with parallel 
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imaging and a fast imaging readout, allowing whole kidney ASL imaging 
[255]. ASL is a subtractive technique and is particularly sensitive to tissue 
motion. In the same study, Gardener and Francis examined strategies to 
reduce motion artefact, showing that using a respiratory navigator and 
postacquisition motion correction improved image quality [255]. 
 
2.3.5. Renal arterial spin labelling 
 
Glomerular filtration is dependent on renal perfusion. FAIR-ASL -measured 
perfusion of the kidney has been validated against radio-labelled 
microspheres in a swine model and para-aminohippurate clearance in 
humans [256, 257]. It has been shown to clearly differentiate between 
medullary and cortical perfusion and is capable of being competitive with 
contrast-enhanced magnetic resonance at 3T [258]. In a recent study 
including 25 patients, transplanted kidneys showed lower levels of perfusion 
compared to native kidneys at similar estimated glomerular filtration rate 
[259]. In a study of 34 hypertensive patients, ASL was used to determine that 
the renin inhibitor aliskiren causes a temporary increase in renal perfusion, 
which reversed despite sustained blood pressure reduction [260]. ASL has 
also recently demonstrated differential effects of 0.9% saline with balanced 
crystalloids on renal perfusion in 12 healthy volunteers [261]. A recent animal 
study used renal ASL to demonstrate that contrast-induced nephropathy is 
mediated at least in part by hypoperfusion [262]. Intravisit reproducibility has 
also been examined demonstrating excellent intraclass correlation [263, 
264]. 
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2.3.6. Cardiac arterial spin labelling 
Because of complex three-dimensional motion of the heart, the development 
of cardiac perfusion imaging using ASL has been challenging, requiring the 
use of cardiac triggering and breathholding or respiratory triggering. This 
increases the signal averaging requirements for cardiac ASL,  such that a 
large number of breathholds are required, which can make clinically useful 
ASL unfeasible without using motion registration techniques to allow free-
breathing acquisition. Thus far ASL measurements of myocardial perfusion 
are proven to be arterial inflow dependent, match the range of published 
literature values, and are capable of detecting changes with mild induced 
stress such as handgrip exercise [265]. Zun et al. recently showed that 
cardiac FAIR-ASL with adenosine stress was able to detect inducible 
ischaemia in patients with coronary artery disease [266].  The low signal-to-
noise ratio of cardiac ASL requires that the signal be averaged over many 
voxels for quantification. Zun et al. grouped perfusion data for a single short-
axis slice to achieve diagnostic accuracy [266], as depicted in Figure 2-36. 
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Figure 2-36 ASL Perfusion Reserve Maps and X-Ray Angiograms from 2 Patients. (A, 
B) Patient with total left anterior descending occlusion; (C, D) patient with total right 
coronary artery occlusion. Myocardial regions with lowered perfusion reserve were 
consistent with the territories of occluded vessels (arrows). LV left ventricle; RV right 
ventricle. Reproduced with permission from Zun et al [260]  
 
 
This technique is capable of detecting only large transmural deficits; is far 
from the currently achievable 1–3mm spatial resolution achievable with 
gadolinium and would miss subendocardial or diffuse ischaemia. To achieve 
this, whole heart coverage with acceptable spatial resolution, reduced motion 
artefacts and increase in signal-to-noise is required. Wang et al. have 
recently shown that such an approach is feasible using a free-breathing 
acquisition combined with parallel imaging, motion correction and noise 
suppression techniques [267]. Higher field strengths prolong the persistence 
of the label. This would additionally provide improved signal-to-noise ratio, 
allowing greater spatial and temporal resolution in the same acquisition time 
or the same spatial and temporal resolution in a shorter time. Another 
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specific issue to cardiac ASL is that labelling the blood using the commonly 
implemented pulsed ASL scheme to invert a slab will also label left atrial 
blood causing a large false signal change in the left ventricle which interferes 
with the true ASL signal at the endocardial border. This will require strategies 
such as spatially selective labelling of the left ventricular outflow tract. 
 
2.3.7. Translation of arterial spin labelling into clinical practice 
 
Table 2-6 ASL Variants 
One can speculate about the 
barriers of translation of ASL into 
clinical practice. One may be the 
sheer flexibility of the technique and 
its optimization by independent 
groups.  Currently, there are several 
variants of the methods used to: 
label the magnetization of inflowing 
blood, acquire the image, and 
reduce the effects of motion (such 
as breathholding, respiratory 
triggering or navigators), Table 2-6. Finally, there is a lack of large studies to 
validate or compare the variants in terms of sensitivity, specificity, 
reproducibility and change with disease state [268]. Table 2-7 suggests a 
developmental framework for ASL and BOLD imaging and against this 
 Method Sequence name 
Continuous 
ASL 
Asymmetric Original CASL 
DAI 
Symmetric SPDI 
Two coil Two coil method 
Pulsed ASL 
Asymmetric 
EPISTAR 
PICORE 
TILT 
Symmetric 
FAIR 
UNFAIR/EST 
FAIRER 
FAIRER 
Selective 
RPI 
PULSAR 
QUASAR 
QUIPSS 
QUIPSS I 
QUIPSS II 
Q2TIPS 
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benchmark, clinical use within the kidney and heart remains a few years 
away.  
 
Table 2-7 Framework of incremental steps required for development of noncontrast 
MRI to quantify perfusion in thoracic or abdominal organs (adapted with permission 
from Sado et al. [35] 
 
 
Preliminary observations support the use of ASL data as an outcome 
measure in clinical trials [269]. A recent landmark has been the introduction 
of commercially available BOLD and ASL sequences for use in the brain by 
MRI manufacturers, with a joint action towards the harmonization of ASL 
being recently established [268]. 
 
Each step is harder to fulfil. No current test in development achieves more than 5 of 
these 15 steps - 7 if abstracts are included—and many whole imaging modalities 
have never achieved the final step.  
1. Technical development and theoretical basis of test. 
2. Direct comparison (animal models and then human autopsy material). 
3. Detection of changes in established disease compared with normal subjects. 
4. Correlation with known markers of impaired perfusion (eg, diastolic function, left 
ventricular hypertrophy, reduced glomerular filtration). 
5. Correlation with known biomarkers of reduced perfusion (eg, cardiac troponins). 
6. Demonstration of the test in more than one clinical scenario. 
7. Demonstration of test sensitivity (early disease or with age). 
8. Demonstration of the ability to track change (with time, after treatment). 
9. Demonstration of predictive or prognostic value of the test. 
10. Standardisation of the test (reproducibility, different equipment, in non-research 
settings, quality control, limitations of test).  
11. Development of robust age/ethnic normal reference ranges 
12. Changes in biomarker remain tied to the disease after treatment. 
13. Demonstration of the test as a surrogate trial endpoint. 
14. Clinical use and regulatory approval of the test. 
15. Proof test use improves clinical outcome. 
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Accurate quantification of ASL perfusion also requires knowledge of the 
tissue T1 equilibrium magnetization, as well as transit time of the label. This 
is typically measured post-acquisition from additional images. Clinical utility 
will be increased by automating the post-processing steps (including T1-
measurement and kinetic modelling) to allow real-time ASL perfusion maps 
to guide clinical decisions and the first implementation of this has recently 
been described [270]. 
 
2.3.8. Conclusion 
 
ASL measures perfusion, whereas BOLD imaging provides a marker of 
tissue oxygenation and these techniques are, therefore, complementary 
rather than competing measures. ASL is inherently quantitative, whilst BOLD 
imaging is not. Thus, multiple measurements of BOLD contrast under 
physiological or pharmacological challenge are more meaningful than single 
measurements. In body imaging, ASL being a subtraction technique is prone 
to tissue motion, whereas BOLD imaging is additionally prone to 
inhomogeneity artefacts and both are relatively low signal techniques 
compared to contrast-enhanced MRI. However, their non-invasive and 
infinitely repeatable nature makes them attractive alternatives to using 
contrast media, particularly in the context of CKD. Given the importance of 
tissue hypoxia and ischaemia in disease processes, demand for the 
techniques is likely to be driven by clinical applications such as in CKD, 
where the greatest incentive to avoid the use of contrast media exists.  
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2.4. HD induced myocardial ischaemia 
 
2.4.1. Dialysis patients are primed to suffer myocardial ischaemia 
Patients with chronic kidney disease requiring either HD or PD are 
particularly susceptible to myocardial ischaemia. This is due to large vessel 
and microcirculatory changes resulting in reduced coronary flow reserve 
(CFR) [271, 272]. This results in reduced ability to increase blood flow to the 
myocardium during increased demand. This is partly a consequence of left 
ventricular hypertrophy (LVH), seen in 74% of patients on dialysis [108]. 
Increased peripheral artery stiffness also reduces the ischaemic threshold 
[273] whilst a high prevalence of vascular calcification in dialysis populations 
leads to increased arterial stiffness [274]. The two factors cause a propensity 
to reduced myocardial blood flow (MBF), and particularly sub-endocardial 
MBF. 
 
The baroreflex arc is responsible for short-term control of blood pressure 
(BP) [275]. Abnormalities of the baroreflex arc are well documented in 
chronic kidney disease (CKD) patients, in both pre-dialysis and dialysis-
dependent settings. HD patients characteristically exhibit defective blood 
pressure (BP) control in the face of ultrafiltration (UF) requirements, in part 
due to impaired baroreflex sensitivity (BRS). In patients with low BRS values 
this lack of effective vasoregulation results in a tight association over a 
dialysis session between change in relative blood volume (RBV) and change 
in cardiac output. In HD patients with intact BRS the fall in RBV has no 
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association at all with change in cardiac contractile performance. This lack of 
a fully intact baroreflex arc leaves cardiac performance excessively 
dependant on intravascular volume in patients where tissue flow/perfusion 
has become excessively dependant on pressure [276].  
2.4.2. Haemodialysis induced myocardial ischaemia 
In the setting of CAD without CKD, transient myocardial ischaemia may lead 
to left ventricular dysfunction that can persist for several hours after the 
return of normal perfusion but is eventually followed by functional recovery. 
This prolonged but reversible dysfunction is known as myocardial stunning 
[277]. Repetitive episodes of ischaemia are cumulative and eventually lead 
from myocardial stunning to hibernation to irreversible contractile dysfunction 
[278].  
It has long been suspected that myocardial ischaemia may also be 
precipitated by HD [279]. Reports of silent ST segment depression during HD 
were noted some twenty years ago [280]. Although this was noted in 15-40% 
of HD patients the evidence was inconclusive as the specificity of these 
changes to detect ischaemia is reduced in the presence of LVH. In addition, 
several studies confirmed the recognized phenomenon of elevated cardiac 
troponins in dialysis patients [281]. Short intermittent HD treatments exert 
significant haemodynamic effects, and 20-30% of treatments are additionally 
complicated by episodes of significant intradialytic hypotension (IDH) [282, 
283]. These studies provided indirect evidence that HD might induce 
myocardial ischaemia but lacked the techniques to provide definitive proof or 
elucidate the pathophysiology.  
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McIntyre et al utilised H2
15O positron emission tomography (PET) to measure 
myocardial blood flow (MBF) during HD. Significant CAD was excluded by 
angiography. There was a 30% mean reduction in MBF to levels at peak 
dialytic stress which recovered after dialysis consistent with the development 
of myocardial stunning [284]. The same study also confirmed that HD-
induced segmental left ventricular dysfunction measured by 2D 
echocardiography correlated with the matched reduction in segmental MBF 
seen with PET. These findings were confirmed in a study using 13N-NH3 PET 
[285]. 
Figure 2-37 Mean global myocardial blood flow (MBF) reduced significantly during 
dialysis from baseline with partial restoration in the recovery period 
 
HD is capable of inducing subclinical myocardial ischaemia, and this 
phenomenon is related to UF and haemodynamic instability. Burton et al 
studied a cohort of 70 prevalent HD patients. Myocardial stunning was 
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defined by the development and subsequent recovery of regional wall motion 
abnormalities (RWMAs) utilising serial intradialytic echocardiography [286]. 
Myocardial stunning occurred in around two thirds of patients. In multivariate 
analysis both intradialytic reduction in BP and UF volume independently 
determined the propensity to suffer HD induced cardiac injury. The only other 
associated factors of significance from this model were patient age and 
Troponin T level (pre-dialysis levels being around three times higher in 
affected patients). These four factors displaced all other standard 
biochemical, haematological, historical and dialysis treatment based 
variables.  12 month follow up of this group, revealed significant effects on 
cardiac structure, function and patient survival. Those patients who did not 
develop HD induced myocardial stunning experienced only one significant 
cardiac event, no change in segmental shortening fraction, no reduction in 
overall LV ejection fraction and 100% survival. This was in contrast to the 
group characterised by the development of myocardial stunning, where 28% 
of the patients had died. In those patients that survived to 12 months, 
shortening fraction had reduced by roughly half with an absolute reduction in 
LV ejection fraction (at rest and at peak during HD) by around 10% in 
conjunction with an attendant significant increase in troponin T. At 12 
months, intradialytic BP was significantly lower in patients who stunned c.f. 
their baseline assessment. This was in contrast to patients who did not 
exhibit dialysis induced myocardial stunning who had identical 
haemodynamic tolerability of HD at both ends of the study period [286, 287]. 
Given the underlying vulnerability of hibernating myocardium to increases in 
demand, coupled with decreased CFR in HD patients, it may be that this 
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adaptive process actually leads to further segmental injury by exacerbating 
intradialytic instability. This may be one of the reasons that prevalence of 
heart failure is so high, and survival so poor in HD patients that start to 
develop myocardial contractile dysfunction.  
 
Survival may also be determined by the incidence of intradialytic and post-
dialytic ventricular arrhythmias. Burton et al studied a cohort of 40 prevalent 
HD patients with 24 hour Holter recordings started just before a HD session. 
Patients also had baseline, intra- and post-dialytic echoardiography. The 
study showed a significantly higher frequency of ventricular arrhythmias in 
the 27 patients who demonstrated myocardial stunning and in all patients the 
arrhythmias occurred most frequently during HD [288]. 
 
To elucidate the relationship between UF volume or rate and myocardial 
stunning Jefferies et al performed an observational study in a cohort of stable 
patients across the spectrum of available quotidian HD regimes. Four patient 
groups were studied: Conventional in-centre HD 3 times per week (CHD3, 
n=12), short daily HD 5-6 times per week both in centre (CSD, n=12) and at 
home (HSD, n=12), and nocturnal home HD (HN, n=10). The groups were 
matched for age, dialysis vintage and baseline LV ejection fraction. UF 
volumes and intradialytic systolic BP reduction were both significantly lower 
in home-based frequent therapies. HD-induced myocardial stunning was 
ubiquitous in CHD3 patients. The proportion of patients exhibiting dialysis 
induced RWMAs reduced significantly with increasing dialysis intensity 
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(CHD3>CSD>HSD>HN). More frequent HD (HSD and HN) was associated 
with less RWMAs and lower high sensitivity C-reactive protein levels than 
CHD3. UF rate correlated strongly with the number of RWMAs [289]. This 
study demonstrated for the first time that more frequent HD regimes are 
associated with less myocardial stunning compared to conventional HD. It 
provides a mechanistic subtext to support the findings of large scale 
observational studies that associate higher UF volumes or rates with worse 
CV outcomes [26, 290] 
 
2.4.3. Role of epicardial CAD in HD-induced myocardial stunning 
There are convincing data that a combination of microcirculatory dysfunction, 
ischaemic potential of reduced peripheral arterial compliance, in addition to 
the other non-atheromatous consequences of the uraemic milieau, are 
capable of allowing dialysis induced injury to occur in the absence of 
conventional epicardial CAD.  Firstly, our initial study of MBF during HD was 
performed in patients who had first been subjected to coronary angiography. 
Despite the absence of any significant disease those patients still exhibited a 
myocardial ischaemic response to HD [284, 285]. Secondly, to acquire a 
patient group with uraemic cardiovascular disturbances, but in the absence of 
conventional cardiovascular risk factors, Hothi et al studied a cohort of 
paediatric HD patients. The dialysis treatments were characterised by 
particularly large UF requirements and significant relative dialysis induced 
hypotension. A high proportion of the children (11/12) exhibited evidence of 
acute dialysis induced myocardial stunning, with some biochemical evidence 
of cardiac injury [291]. 
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2.4.4. Modifications of HD that abrogate myocardial ischaemia 
 
A variety of therapeutic manoeuvres aimed at improving the haemodynamic 
tolerability of HD have been demonstrated to reduce dialysis induced 
myocardial ischaemia.  
2.4.4.1. Biofeedback controlled HD 
In the first of these studies Selby et al compared standard bicarbonate HD 
with a biofeedback technique that responded to significant declines in RBV 
by temporarily reducing UF rate and increasing dialysate conductivity. This 
was done within defined limits to ensure total fluid and sodium depuration 
was unaffected [292]. In a separate cohort Selby et al compared standard HD 
using a dialysate temperature of 37qC to a cooled dialysate of 35qC [293]. In 
both studies reduced RWMAs and improved mean shortening fraction were 
demonstrated. It may be that either the higher mean BP or the reduction in 
IDH was responsible for the reduction in the incidence of RWMAs, although it 
is also conceivable that the effects of both of these factors were synergistic, 
with IDH that occurs at a lower mean BP potentially having a greater 
detrimental effect on myocardial perfusion. In PET based study of intradialytic 
MBF, use of the biofeedback technique resulted in reduced instability only in 
the later part of HD and this was associated with a significantly better 
recovery of MBF post HD, supporting the contention that at least with this 
technique the beneficial effect on MBF was linked to maintenance of 
intradialytic BP [284].  
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2.4.4.2. Individualisation of dialysate sodium 
Larger inter-dialytic weight gain (IDWG) or larger ultrafiltration (UF) volumes 
are associated with increased mortality and myocardial stunning (Figure 
2-38). These might be removed by more intensified dialysis by treatment 
length or frequency and daily dialysis is associated with reduced HD induced 
myocardial stunning [294]. However access to intensified dialysis might be 
constrained by social and economic factors. Alternative strategies directed at 
minimising IDWG within the constraints of conventional thrice weekly in-
centre HD treatments of around four hours are essential to improve the 
tolerability of HD and the development of cardiac failure. 
  
Figure 2-38 Larger IDWG is associated with increased all-cause mortality both in 
registry studies (left Kalantar-Zadeh et al [26] and prospective studies (right, Movilli et 
al[290]). 
 
 
In HD patients without diabetes, larger IDWG is driven entirely by sodium 
intake. This is largely dietary sodium intake but due to a fixed osmolar set 
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point, use of one dialysate sodium concentration for a dialysis unit can lead 
to many patients receiving a net increase in total body sodium during dialysis, 
so-called ‘sodium loading’ [295, 296]. This will drive thirst and promote higher 
IDWG. There have been few attempts to optimise dialysate sodium [297, 
298].  We have previously studied use of a fixed two week stepwise reduction 
in dialysate sodium in this setting but the studies lacked detailed intra-dialytic 
haemodynamic assessment and the potential of these methods to abrogate 
myocardial stunning has not been investigated [299, 300].  These studies 
were further limited by their short duration, failing to capture effects of longer 
term sodium depuration from myocardium and the resistance vasculature 
[39, 301]. An important factor in study design is to exclude patients with type 
1 or 2 diabetes. HD patients with diabetes have thirst that is equally driven by 
hyperglycaemia and would require a separate study [43].  
 
2.4.4.3. Remote ischaemic pre-conditioning 
Another approach to reduce myocardial stunning may lie in protecting against 
ischaemia. Several studies have shown cardio-protective benefits of remote-
ischemic pre-conditioning but its potential to abrogate HD-induced 
myocardial stunning remains unexplored. Transient sub-lethal episodes of 
ischaemia (preconditioning stimulus) before a prolonged 
ischaemia/reperfusion injury, known as ischemic preconditioning (IPC), 
induce a state of protection against subsequent prolonged ischaemia. There 
are 2 phases of protection; the early phase, within minutes of the 
preconditioning stimulus for up to 4 hours and a ‘second window of 
protection’, 24 hours after the preconditioning stimulus, which lasts for up to 
 111 
 
72 hours. How this benefit is mediated has not been fully elucidated but 
involves induction of intracellular kinases and changes in mitochondrial 
function including activation of the mitochondrial KATP channel. The 
realisation that IPC protects tissues that are remote from those undergoing 
preconditioning (remote ischaemic preconditioning; RIPC) has led to its 
translation into the clinical setting in multiple studies[302]. RIPC is 
mechanistically similar to IPC inducing a similar degree of protection. The 
preconditioning signal is spread systemically by a mechanism that includes 
activation of the autonomic nervous system and unidentified humoral 
mediators. RIPC can be applied with a simple blood pressure (BP) cuff 
applied to a limb for 5 minutes or more at greater than systolic pressure. This 
has proven to be safe and tolerable in multiple human studies performed to 
date which have demonstrated cardio-protective benefits in a mixture of 
clinical and surrogate endpoints in settings including cardiac surgery and 
coronary angioplasty [303]. The studies are not universally positive, a recent 
study demonstrated no benefit on surrogate endpoints prior to cardiac 
surgery [304]. RIPC remains untested in the setting of conventional HD, a 
model of a repetitive ischaemic injury. There is some evidence suggesting 
patients with diabetes may have a suboptimal response to IPC [305, 306] 
hence it is rational to study this group using a pre-specified separation. 
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2.5. A randomised controlled trial of dialysate cooling 
The work presented in this thesis utilises data from the baseline study visit of 
a current randomised controlled trial of dialysate cooling to prevent left 
ventricular systolic dysfunction in HD patients. The main hypothesis of this 
trial is that patients having regular conventional HD will have a smaller 
decline in cardiac systolic function by using cooler dialysate.  
2.5.1. Trial background 
 
Maintenance HD patients represent an extreme phenotype of adverse 
cardiovascular risk and few interventions have proven efficacy in regressing 
cardiovascular morbidity. The HD procedure commonly induces cardiac 
ischaemia, characterised by reversible left ventricular regional wall motion 
abnormalities on echocardiography. Patients demonstrating such regional 
abnormalities have later development of cardiac systolic dysfunction and 
increased mortality [307, 308]. The Frequent Hemodialysis Network (FHN) 
trials showed regression of left ventricular mass and volumes [309, 310]. 
Resource availability and patient acceptance of more frequent schedules 
might be limited in some healthcare systems such that reducing circulatory 
stress within the constraints of conventional, thrice weekly treatments is of 
value [311]. Prior studies demonstrated that cooling the dialysate during HD 
reduces the number of episodes of intra-dialytic hypotension and the 
prevalence of de novo wall motion abnormalities [293, 312]. There are 
several postulated mechanisms by which cooler dialysate might improve 
haemodynamic stability, predominately mediated through maintenance of 
systemic vascular resistance. These include abrogation of thermoregulatory 
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peripheral vasodilation by reduced extracorporeal heat transfer or reduced 
nitric oxide release [307, 313].  However, prior studies were either not 
randomised, applied the intervention for less than one month or report 
changes in serum biomarkers as the primary outcome. Further, they studied 
prevalent patients being prone to survivor biases and were underpowered to 
detect outcomes validated to predict development of heart failure and 
mortality.  The aim of this study is to determine whether individualised cooler 
dialysate prevents the long-term development of cardiac systolic dysfunction 
and left ventricular hypertrophy in incident conventional HD patients. 
Individualised dialysate cooling to 0.5oC less than the patient’s core 
temperature is being tested as a pilot study suggested cardioprotective 
benefit with improved treatment toleration compared to that associated with a 
fixed temperature reduction strategy [314]. 
2.5.2. Study design and treatment regimen 
The trial is prospectively registered (ISRCTN00206012) and the protocol has 
previously been published [315]. Trial design is summarised in Figure 2-39. 
The trial is a multi-center, prospective, open-label, controlled, randomized 
interventional trial conducted in the dialysis units of four university teaching 
hospitals in the United Kingdom within a 40 mile radius. The study is 
performed in accordance with the Declaration of Helsinki. The protocol is 
approved by Nottingham Ethics Committee prior to study initiation and written 
informed consent is given by all trial participants. 
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Cool
(tympanic 
temp -
0.5°C)
Control
37°C
1:1 Randomisation to 
individualised cooling or 
control dialysate 
temperature
n = 72
Baseline
Multicentre randomised controlled trial of individualised dialysate cooling
Monitored Dialysis 
Investigations*
Cardiac and Brain MRI 
Cognitive assessment
Monitored Dialysis 
Investigations*
Cardiac and Brain MRI 
Cognitive assessment
Inclusion criteria:
On HD at least 3 times/week
Aged  16 years or over
Willing and able to give 
consent
Excluded:
1.Exposure to haemodialysis for >180 days
2.Contraindications for using MRI (eg. patients with 
pacemakers and metal implants, pregnancy or 
lactating) 
3.Inability to tolerate MRI due to claustrophobia
4.New York Heart Association grade IV heart failure
5.Mental incapacity to consent
12 months. Primary outcome 5% 
difference in LVEF by Cardiac MRI
* Monitored Dialysis Investigations comprise:
Non-invasive heart function and peripheral blood vessel  monitoring with Finometer and Vicorder, 
Echocardiography and blood tests 
Figure 2-39 Trial design for a randomised controlled trial of individualised dialysate
cooling 
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2.5.3. Participants 
Enrolment for the trial commenced in September 2009 and closed in January 
2012 with the final CMR exams scheduled in January 2013. Inclusion criteria 
are: 
1. Patients aged 16 years having HD treatment 3 times per week. 
2. Willing and able to provide consent. 
3. Exposure to haemodialysis for 180 days. 
Exclusion criteria are: 
1. Contraindications for Magnetic Resonance  
2. Inability to tolerate magnetic resonance due to claustrophobia 
3. New York Heart Association grade IV heart failure 
4. Pregnancy or lactating 
5. Mental incapacity to consent 
2.5.4. Randomisation and blinding 
Randomisation at 1:1 ratio is done in a single block by sealed envelopes 
generated by an independent statistician. The study is un-blinded as it is not 
pragmatic to enable appropriate dialysate temperature to be iteratively 
entered by different dialysis unit nursing staff and technicians. There is 
however blinding of treatment allocation for centralised analysis of cardiac 
imaging. 
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2.5.5. Dialysis Intervention 
The control group use a dialysate temperature of 37oC for 12 months. The 
intervention group use an individualised cooled dialysate temperature for 12 
months. The latter is set at 0.5oC less than the patient’s own temperature, 
determined from the mean of 6 prior treatment sessions with a tympanic 
thermometer, between a minimum of 35oC and a maximum of 36oC, ensuring 
a minimum temperature separation of 1oC between groups. Adherence to the 
allocated dialysate temperature is frequently checked by dialysis unit staff 
with protocol deviations recorded.  
2.5.6. Concurrent Treatments 
Patients in both trial arms have standard management with dry weight 
prescribed by the clinical team according to local protocol including three-
times weekly HD to achieve an equilibrated Kt/Vurea >1.1, a standardized 
Kt/Vurea of >2.0 and a treatment time 3.5 hours/session (70% of patients 
4 hours/session). HD treatments use low-flux polysulfone dialyzers, 1.8-2.0 
m2, (LOPS 18/20; Braun Medical Ltd, Sheffield, United Kingdom). Dialysate 
composition is sodium 136-138mmol/l; potassium 2mmol/l; calcium 
1.25mmol/l; magnesium 0.5mmol/l; bicarbonate 32-38mmol/l; glucose 
5.6mmol/l; and acetate 3mmol/l. Dialysate flow rate is 500 mL/min, blood 
pump speed 250-450 mL/min. Anticoagulation is by unfractionated heparin.  
2.5.7. Data collection 
CMR studies for LV volumes, mass and function are conducted on midweek 
non-dialysis days (avoiding the long break in dialysis after the weekend) at 
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two centers using identical 1.5T scanners (GE Signa HDxt, GE Healthcare, 
Milwaukee, US) with retrospective ECG gating and 8-channel phased array 
coil.  Steady-state free precession (SSFP) cine images are acquired in 2, 3 
and 4 chamber views to plan a stack of 8mm short-axis slices with a 2mm 
interslice gap covering the entire LV. Typical parameters are; field of view 
38cm, repetition time 3.2 ms, echo time 1.6 ms, matrix 224x224, spatial 
resolution <2mm, flip angle 60°, 1 signal average, 30 acquired phases per 
cardiac cycle achieving a heart-rate dependent temporal resolution of 20-
40ms. Radiofrequency tagging by a spatial modulation of magnetization 
(SPAMM) sequence with gradient recalled-echo readout is applied at basal, 
mid-ventricular and apical levels. Typical parameters are matched to the 
SSFP cine images except for slice thickness 10mm, matrix 224 x 160, flip 
angle 12° to achieve temporal resolution of 15-30ms. Brachial artery blood 
pressure is measured in the non-fistula arm immediately after CMR 
acquisition in a supine position after 10 minutes rest using an oscillometric 
device (Datex-Ohmeda, GE Healthcare, USA) and the mean of three 
readings is recorded. 
2.5.8. Data Analysis 
All CMR analysis is performed offline blinded to patient details. Volumes and 
mass are determined using cvi42 software, version 4.0.2 (Circle 
Cardiovascular Imaging, Calgary, Canada). Epicardial and endocardial LV 
contours including major papillary muscles and trabeculations are manually 
traced in end-diastolic and end-systolic frames using a signal-intensity 
thresholding tool. Left ventricular end-diastolic volume (LVEDV), LV end-
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systolic volume (LVESV) and LV ejection fraction (LVEF) are determined. 
Values are indexed to height and body surface area (BSA) using Mosteller’s 
method [316]. The volume is multiplied by the specific density of the 
myocardium (1.05 g/cm3) to determine end-diastolic LV Mass (LVM). 
2.5.9. Strain Analysis 
Mid-wall circumferential strain is measured in the short-axis tagged LV slices 
using validated and commercially available software (HARP 3.0, Diagnosoft, 
Palo Alto, California, USA) [231]. Epicardial and endocardial contours in the 
frame with optimal myocardial-blood contrast are manually drawn then 
automatically propagated to create a mesh in each frame. The anterior right 
ventricular septal insertion point is marked as a reference for segmental 
analyses. Contour tracking quality is checked and adjusted if required. The 
software derives lagrangian mid-wall circumferential strain for each time 
frame and exports to a spreadsheet. Data are regionally mapped to the AHA 
16 segment LV model, averaged per short-axis slice and summated across 
slice values to derive global peak systolic-strain (%), peak-systolic strain-rate 
(s-1) and peak diastolic strain rate(s-1).  
2.5.10. Statistical Analysis 
Descriptive statistics for continuous variables are summarized using 
mean±SD with independent T test for normal distributions or 
median(interquartile range) for non-normal distribution. Categorical variables 
are expressed as counts and percentage. Descriptive summaries of changes 
in treatment-related variables are provided for the constant cohort with non-
missing values at baseline and 12 months after randomization. The effects of 
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randomized treatment allocation to LVEF, LV volumes and mass are 
estimated by applying a linear mixed-effects model to baseline and 12-month 
values using a diagonal covariance matrix with covariate adjustment, 
including a time interaction for the baseline outcome measures, plus 
prespecified covariates age, sex and diabetes status. Because outcomes are 
assessed at a single follow-up time, this model produces essentially identical 
results to an analysis of covariance adjusted for the baseline value of the 
outcome and prespecified covariates. The effects of treatment allocation on 
regional strain and strain-rate are assessed using the American Heart 
Association 16 segment model of the left ventricle and a linear mixed-effects 
model with patients modelled as random intercepts and allowing for the 
within-subjects correlation of segments and adjusted for multiple covariates 
including age, sex, and baseline left ventricular mass. All analyses use a two-
sided significance at p <0.05. Analyses are performed according to an 
intention-to-treat principle using SPSS for Windows, v20.  
2.5.11. Primary Study Outcome  
The prespecified primary outcome is the change in resting LVEF by cardiac 
magnetic resonance (CMR) at 12 months compared to baseline between the 
intervention and control group.  
2.5.12. Secondary Study Outcomes 
The main secondary study outcomes are LV mass and LV volumes, adverse 
LV remodelling assessed by the LV mass/volume ratio and systolic and 
diastolic function assessed by global peak-systolic strain, global peak-systolic 
strain rate and global peak-diastolic strain rate.  
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2.5.13. Rationale for primary and secondary outcomes 
Previous observational study showed 13% reduction in LVEF by 
echocardiography over 12 months in patients with HD induced LV regional 
wall motion abnormalities [308]. Furthermore, reduced LVEF is a validated 
predictor of cardiovascular morbidity and mortality with a change greater than 
5% approaching the minimum clinically important difference [317]. CMR is 
the reference standard technique for precise determination of the primary 
outcome [318]. Strain is the ratio of the maximal change in myocardial length 
in systole to the original length and large non-CKD population studies show 
strain detects early cardiac dysfunction prior to a decline in LVEF [213]. 
Recent data have validated the ability of lower strain to predict all-cause 
mortality amongst HD patients with preserved LVEF[319].  
2.5.14. Sample size estimation 
Sample size estimations are performed by a statistician using commercially 
available software (Nquery Advisor v6) with data from a reference range 
study with similar CMR acquisition and analytic techniques [320]. Using a two 
sample t test and assuming a mean LVEF of 67% in the control arm and 
equal Standard Deviation in each group of 6% [320], we estimated 64 
participants would resolve a 5% between-group difference in LVEF from 
baseline to 12 months, with 90% power at 5%, 2-sided significance level. 
Allowing for study attrition and death of 10%, target recruitment is set at 72 
participants. 
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2.5.15. Monitoring for Adverse Events 
The number and proportion of participants who reported treatment-emergent 
adverse events are summarized for each treatment group.  
2.5.16. Trial completion 
Commencing in September 2009, trial recruitment of 73 patients was 
completed by January 2012. Follow-up will be completed in January 2013 
with results analysed and reported in mid-late 2013. Based on the final 
number recruited (73), the study has 90% power to detect a 5% difference in 
LVEF.  
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2.6. Background summary 
 
It is well recognised that HD patients suffer excess cardiac morbidity and 
mortality that cannot be fully explained by traditional atherosclerotic risk 
factors such as age, smoking, hypertension, hypercholesterolaemia and 
hyperglycaemia. There are paradoxical non-linear relationships of many of 
these risk factors to cardiovascular outcomes compared to the general 
population and a distinctly different pattern of causes of death. Non-
traditional risk factors, specific to CKD such as hypervolaemia, arterial 
stiffness and advanced glycation end-product deposition are increasingly 
recognised. A previously demonstrated non-traditional risk factor associated 
with worse outcomes is the presence of uraemic cardiomyopathy. This 
pattern of cardiac morphology and function has previously been defined as 
the presence of left ventricular abnormalities, including left ventricular 
hypertrophy, dilatation and left ventricular systolic dysfunction. 2D 
echocardiography relies on geometric assumptions to derive mass, volumes 
and global systolic function which frequently over or under-estimate 
abnormalities in HD patients. Cardiac magnetic resonance imaging provides 
direct measurements of mass and volume with greater precision, sufficient to 
resolve small differences in longitudinal studies and reduce the numbers 
required to show between-group differences in clinical trials. Furthermore, by 
using radiofrequency tagging, multi-directional determination of LV strains 
allow more sensitive regional and global measures of function without using 
gadolinium contrast. High spatial resolution magnetic resonance imaging can 
be extended into the aorta to directly measure aortic stiffness and the 
interaction with cardiac function. This may be superior to externally measured 
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aortic stiffness. HD itself is capable of exerting sufficient haemodynamic 
stress to cause repetitive cardiac ischaemic injury and may promulgate some 
of the excessive rates of cardiovascular morbidity and mortality. The cardiac 
tolerability to HD thus represents a HD-associated risk factor. Randomised 
trials of interventions directed at traditional risk factors have thus far not 
impacted on cardiovascular mortality and modifications to the process of HD 
may be the key to improving outcomes. The ischaemic cascade links 
reduced LV perfusion to reduced motion. Thus identifying HD induced 
ischemia previously relied on detecting regional radial LV wall motion 
abnormalities as a surrogate for ischemia by serial 2D echocardiography 
during dialysis which would be impractical by other modalities. 2D 
echocardiography can be enhanced by using serial studies tracking cardiac 
deformation similar to CMR tagging to generate multidimensional measures 
of regional and global strain in circumferential, radial and longitudinal 
directions as earlier markers of cardiac dysfunction.  Longitudinal strains 
should be particularly sensitive for subendocardial ischaemia detection due 
to myocardial fibre orientation and data in non-CKD populations show 
promise for detection of ischemia.  
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3. Aims  
For the first time the work in this thesis studies an incident HD population 
using multi-parametric strain-based imaging. This combines the accuracy of 
CMR resting cardiac and aortic function augmented with strain by tagging to 
longitudinal strain changes during HD by speckle-tracking echocardiography. 
The general aim of this thesis was to characterise the relationship of left 
ventricular function to HD using strain-based imaging. This might allow 
characterisation of HD-associated cardiomyopathy which may be distinct 
from the traditional definition of uraemic cardiomyopathy and may better 
define those patients who would benefit from modifications to the process of 
HD.  
 
3.1. Study I 
Study I aims to study resting cardiac abnormalities in an unselected incident 
HD population using strain by CMR tagging as a more sensitive marker of 
dysfunction compared to an age-matched non-CKD population. 
3.2. Study II 
Study II aims to investigate the contribution of uraemia to arterial stiffness by 
directly measuring aortic distensibility using cardiac magnetic resonance in 
incident HD patients compared to an age-matched non-CKD population.  
3.3. Study III 
The third study aims to detect dynamic changes in strain during HD by 
speckle tracking echocardiography and to determine nature and prevalence 
of HD-induced myocardial stunning to relevant biomarkers in a population 
new to HD.  
 126 
 
4. Materials and methods 
4.1. Subjects 
The patient flow and study design are summarised separately for HD patients 
and for non-CKD control participants in Figure 4-1 and Figure 4-2.  
4.1.1. Study I  
This study compared 54 HD patients to 28 age-matched non-CKD control 
participants. The original study population comprised of 65 HD patients who 
completed any part of the study but after withdrawals due to non-tolerance of 
CMR, 54 HD patients remained. Thirty non-CKD control subjects completed 
the study and two were excluded from the analysis upon expert advice due to 
incidental findings of valvular heart disease and probable unrecognized 
myocardial infarction. 
 
4.1.2. Study II  
This study compared 30 HD patients to 19 age and sex-matched controls. 
The study population was a subgroup of the participants in Study I. Aortic 
image acquisition was added to the protocol on expert advice after the study 
commenced and was consecutively available for 30 of the 54 HD patients. 
This required comparison to 19 of the 28 non-CKD control participants to 
achieve optimal age and sex-matching. 
 
4.1.3. Study III  
This study reports data on 60 patients. The original study population 
consisted of 65 HD patients. This included 52 of the 54 HD patients from 
Study I but also describes data for patients who did not tolerate or withdrew 
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consent for CMR studies but completed echocardiographic studies during 
HD. Five subjects were excluded from the analysis due to insufficient quality 
of the echocardiographic images.   
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Figure 4-1 HD patient flow described for all studies in the thesis 
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Figure 4-2 Participant flow for non-CKD control subjects described for studies in the
thesis 
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4.2. Ethical approval and eligibility criteria 
Ethics approval for the study was obtained from Nottingham Ethics 
Committee for all participating centres prior to participant enrolment. The 
studies were performed in accordance with the Research Governance 
Framework, International Conference on Harmonisation Good Clinical 
Practice Guideline and the 2000 Scotland Revision of the Declaration of 
Helsinki. All participants gave written informed consent. The studies 
compared incident HD patients to age and sex-matched volunteers without 
CKD. HD patients were recruited within 6 months of commencing in-centre 
HD at one of 4 UK research sites: Royal Derby Hospital; Stoke Royal 
Infirmary; Birmingham Heartlands Hospital  and Sheffield Teaching Hospitals 
as part of a randomised trial in dialysate cooling. All patients and non-CKD 
control volunteers were recruited by myself and Dr Eldehni.  Dr Eldehni and I 
also collected all the data in the study, which involved travelling to all four 
dialysis centres with the haemodynamic monitoring equipment to study 
patients on dialysis without changing their dialysis times.  Inclusion criteria 
were: (1) incident HD patients aged over 16 years; (2) within 180 days of 
commencing in-centre treatment 3 times per week and (3) Mental capacity to 
consent for the trial. Exclusion criteria were: (1) contraindications for 
magnetic resonance imaging; (2) inability to tolerate magnetic resonance 
imaging and (3) New York Heart Association Grade IV heart failure. 30 age 
and sex-matched healthy volunteers were recruited through a local clinical 
research healthy volunteer program. Inclusion criteria were:  (1) aged over 16 
years and (2) mental capacity to consent to the study. Exclusion criteria 
were: (1) contra-indications for magnetic resonance imaging and (2) history 
of kidney disease, ischaemic heart disease or cardiomyopathy. Two non-
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CKD control subjects completed the study but were excluded from the 
analysis due to incidental findings of valvular heart disease and probable 
unrecognized myocardial infarction.  
 
4.3. Cardiac Magnetic Resonance Imaging 
CMR studies for LV volumes, mass and function were scheduled on midweek 
non-dialysis days (avoiding the long break in dialysis after the weekend) at 
two centers using identical 1.5T scanners (GE Signa HDxt, GE Healthcare, 
Milwaukee, US) with retrospective ECG gating and 8-channel phased array 
coil.  Steady-state free precession (SSFP) cine images were acquired in 2, 3 
and 4 chamber views to plan a stack of 8mm short-axis slices with a 2mm 
interslice gap, covering the entire LV. Typical parameters were; field of view 
38cm, repetition time 3.2 ms, echo time 1.6 ms, matrix 224x224, spatial 
resolution <2mm, flip angle 60°, 1 signal average, 30 acquired phases per 
cardiac cycle achieving a heart-rate dependent temporal resolution of 20-
40ms. Radiofrequency tagging by a spatial modulation of magnetization 
(SPAMM) sequence with gradient recalled-echo readout was applied at 
basal, mid-ventricular and apical levels. Typical parameters were matched to 
the SSFP cine images except for slice thickness 10mm, matrix 224 x 160, flip 
angle 12° achieving temporal resolution 15-30ms. The LV contours were 
drawn manually excluding papillary muscles and trabeculations, and left 
ventricular end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), 
LV ejection fraction (LVEF) and end-diastolic LV Mass (LVM), mean end-
diastolic LV wall thickness (LVWT) were calculated.  The interventricular 
septum was included as part of the LV. The basal slice was included when at 
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least fifty percent of the blood volume was surrounded by myocardium. The 
apical slice was defined as the last slice showing intracavity blood pool. 
Values were indexed by body surface area using Mosteller’s method [316], 
denoted by the suffix ‘I,’ for example, LVMI.  LVM was also indexed to 
height1.7 which has been shown to be the best measure to detect left 
ventricular hypertrophy in taller and obese subjects [321]. LVWT was 
calculated by excluding the two most basal and two most apical slices before 
averaging to reduce the variability of between-subject comparison caused by 
the basal slice position. 
 
Figure 4-3 Slice positions for short axis cines were planned in end-systolic and 
checked on end-diastolic images to ensure consistency 
 
 
Brachial artery blood pressure was measured in the right arm for non-CKD 
controls and the non-fistula arm for HD patients immediately after CMR 
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acquisition in a supine position after 10 minutes rest using an oscillometric 
device (Datex-Ohmeda, GE Healthcare, USA) and the mean of three 
readings was recorded. 
[322].   
All CMR analysis was performed offline blinded to participant details. 
Volumes and mass were determined using cvi42 software, version 4.0.2 
(Circle Cardiovascular Imaging, Calgary, Canada).  
 
4.3.1. Tagging analysis 
Strains were measured using dedicated software (HARP 3.0, Diagnosoft, 
Palo Alto, California, USA) for each of the 3 short axis slices. Data were 
smoothed using a moving average of 3 points to reduce noise sensitivity and 
slices were averaged to give global or regional measures.  
 
4.4. Assessing cardiovascular performance during HD 
Detailed characterisation of cardiovascular performance will be assessed 
during HD at baseline and 12 months. This occurs during the patient’s usual 
HD session in their own centre using the same portable data collecting 
instruments across all centres.  
 
4.4.1. Regional LV functional assessment by 2D 
echocardiography 
 
2-dimensional echocardiography will be performed using commercially 
available equipment (1.5-4mhz probe, Vivid-I, GE Healthcare) by one of two 
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trained technicians in the left lateral position. Sector width, frequency and 
depth will be optimised to produce optimal border definition and a frame-rate 
of 50-80 per second. Standard apical 2 and 4-chamber image loops will be 
recorded pre-dialysis (rest) and 15 minutes before the end of dialysis 
(stress).  Image loops will be anonymised and analysed off-line in random 
order for regional deformation using dedicated software (EchoPac, GE 
Vingmed).   
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4.4.2. Finometer 
 
The finometer utilises a finger-clamp method to detect beat-to-beat changes 
in digital arterial diameter using an infrared photoplethysmograph.  A single 
brachial artery blood pressure measurement is made for calibration.  The 
time averaged data is subsequently downloaded to the PC based analysis 
program Beatscope™.  Pulse rate, blood pressure, stroke volume, cardiac 
output, total peripheral resistance and baroreflex sensitivity are derived. The 
finger-cuff will be placed on an appropriate finger (preferably the middle 
finger on the non-fistula arm) and on the upper arm of the same arm. For 
obtaining baseline values, monitoring is commenced 30 minutes before the 
start of dialysis. All Finometer data will be subsequently downloaded to a PC 
based analysis program (Beatscope™), allowing averaging of results over 
defined time periods and display of variables as percentage change from 
baseline.  The finometer has been well validated in several settings including 
critical care and haemodialysis [274, 323, 324]. 
Figure 4-4 The Finometer 
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4.4.3. NICOM 
 
Continuous non-invasive cardiac output monitoring will be recorded using a 
thoracic bioreactance monitor (NICOM™, Cheetah Medical). NICOM™ is 
based on the appreciation that changes in aortic blood volume induce small 
changes in the frequency of electrical signals propagating across the thorax. 
These small changes are highly correlated with blood flow and can thus be 
used to accurately and consistently report cardiac output.  The bioreactance 
system (NICOM™) consists of applying four pairs of adhesive electrodes to 
the patient - two on either side of the thorax (marginally below the ribs) and 
two pairs just below the shoulders (on either side of the mid-axial line) or on 
the upper back.  Each pair of electrodes delivers a low alternating current, 
sensed for its propagation characteristics along the thorax by the other 
electrode pairs.  This uses phase changes in alternating electrical current to 
derive cardiac output. The use of phase rather than amplitude, makes the 
exact location of the electrodes less important and also permits high-notched 
filtering of electrical interference typically encountered in hospital settings. 
This endows a greater precision and signal-to-noise ratio than impedance 
cardiography. This technique has been validated in healthy volunteers, 
intensive care settings and chronic heart failure [325-327]. A recent study 
found the monitor comparable to expert DSE to optimise cardiac 
resynchronisation therapy devices [328].  
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Figure 4-5 The NICOM, illustrating the data display and electrode placement 
 
 
4.4.4. Arterial stiffness by oscillometric PWV 
Arterial stiffness measured by pulse wave velocity is independently 
associated with increased risk of cardiovascular disease in HD patients [329]. 
Carotid-Femoral pulse wave velocity will be measured by an oscillometric  
device (Vicorder, Skidmore Medical Ltd, Bristol, UK) as previously described  
[330]. Briefly, a carotid pressure cuff is applied over the neck to detect the 
right carotid artery and a pressure cuff is placed around the proximal right 
upper thigh to detect the right femoral artery. The distance from the 
suprasternal notch to the middle of the thigh cuff was measured and entered 
into a PC running the Vicorder software. The cuffs are simultaneously inflated 
to a low pressure 40-60 mm Hg and signal from each cuff is analysed to 
derive arterial transit time. PWV is calculated by the software by dividing 
arterial transit time by measured distance. The mean of 2 measurements was 
recorded. 
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Figure 4-6 Oscillometric PWV using the Vicorder 
 
 
4.4.5. Body composition by bioimpedance 
 
Body composition and assessment of total body water will be done using 
segmental multifrequency bioimpedance (InBody BS20, Seoul, Korea). 
Bioelectrical impedance analysis (BIA) is based on the principle of detecting 
resistance to low-level electrical current flows through intracellular and 
extracellular fluid [331, 332]. The currents used are imperceptible to the 
subject. Fat-free mass contains the majority of total body water (TBW) and is 
a better conductor of electrical current than fat. Therefore BIA is essentially 
an index of TBW, from which fat-free mass is estimated. Segmental as 
opposed to whole body BIA is the preferred technique in patients with 
abnormal fluid states (eg. ascites, chronic kidney disease). It is most useful at 
tracking intra-patient variability in fluid status changes and is well validated in 
the setting of haemodialysis [333]. Body composition and assessment of 
TBW will be taken using a segmental multifrequency BIA analyzer (InBody 
S20, Biospace Co. Ltd., Seoul, Korea). Measurements will be performed 
using the standard tetrapolar technique, with electrodes placed on the 
dorsum of both wrists and anterior aspect of both ankles [334]. After cleaning 
the skin to ensure good contact, injection electrodes will be attached to the 
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wrists and ankles over the metacarpophalangeal and metatarsophalangeal 
joints, with the voltage detector electrodes at the line of the same joints. The 
analyzer will apply a safe and imperceptible current of 90-4000 µA at a 
frequency of 1-1000 kHz. The algorithms built into the software of the 
analyzer will measure resistance and reactance and calculate fat-free mass 
separately for each limb and the trunk at several frequencies. The 
extracellular fluid space will be expressed as a proportion of the estimated 
TBW. 
Figure 4-7 InBody S20 Bioimpedance analyser 
 
 
4.5. Study of non-CKD healthy volunteers  
As is conventional for magnetic resonance studies, healthy volunteer control 
data is often used to compare data in areas where normal ranges are not 
clearly established. The non-CKD volunteers underwent identical studies to 
the non-dialysis day assessment of HD patients comprising of CMR image 
acquisition, blood pressure and PWV measurement by Vicorder. 
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5. Study I Results: Circumferential Strain By Cardiac 
Magnetic Resonance Tagging In Patients New To 
Haemodialysis 
 
5.1. Abstract 
Introduction: HD patients with cardiac abnormalities are vulnerable to HD-
induced ischaemia and early identification allows strategies to improve 
outcomes. 2D-echocardiography uses geometric assumptions which 
overestimate abnormalities. Cardiac magnetic resonance (CMR) is the gold-
standard for analysis of cardiac morphology and strain analysis by tissue 
tagging detects early dysfunction in non-uraemic settings. Previous CMR 
studies of renal transplant candidates used prevalent, selected populations 
and did not investigate strain.  
Objectives: We aimed to study cardiac abnormalities in an unselected 
incident HD population using CMR augmented by strain as a more sensitive 
marker of dysfunction.  
Methods: 84 subjects were studied (54 HD, median vintage 170 days, 30 
age and sex-matched controls). Left ventricular (LV) mass and volumes were 
determined by planimetry. Global and segmental peak systolic 
circumferential strains (Ecc) were determined from strain curves. Discrete 
variables are expressed as counts (percentage) and continuous variables as 
mean ± Standard Deviation or median ± interquartile range (IQR) depending 
on normality. Comparisons were made by the independent T test or Mann-
Whitney test for continuous data and Chi-squared or Fisher’s exact test for 
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categorical data. Linear Regression analysis was applied to identify 
determinants of Ecc and repeated-measures analysis of variance was used 
to determine the heterogeneity of Ecc within subjects.   
Results: Median values±IQR are presented as HD vs Controls. Global LV 
function was reduced (LV Ejection Fraction 51.5%±11 vs 58.5%±5.4) with 
reduced strains (Ecc 15.9%±3.7 vs 19.5%±3.3), all p<0.001. LV mass was 
increased (63.4g/m2±24.4 vs 45.9g/m2±9.3, p<0.001) as was LV remodelling 
(LV mass/Volume ratio 0.76g/ml±0.22 vs 0.65±0.16g/ml, p=0.003) and LV 
dilatation (LV end-diastolic volume index 87.6±29.8ml/m2 vs 71.6±17.7ml/m2, 
p=0.03). Subgroup analysis of HD patients and controls with LVEF >50% 
(n=59) showed reduced strain persisted despite normal LVEF (Ecc 
17.5%±3.3 vs 19.9%±3.4 p=0.03). Using 2 Standard Deviations from the 
mean of the controls, sex-specific cut-offs were determined for abnormal 
morphology and function in HD patients. 48% (26/54) had abnormal 
morphology (increased LVH or dilatation) whilst 54% (29/54) had abnormal 
contractile function (reduced EF or strain) with overlap between categories. 
Only 19% (10/54) had no abnormalities (chi-squared, p<0.001).  
Conclusion: CMR tagging identified reduced circumferential strain in 
addition to abnormalities in LVEF and LV mass in the majority of incident HD 
patients. Strain was reduced in the subset of patients with normal LVEF. The 
independent determinants of strain were LVEF and LV Mass/Volume ratio. 
Strain shows promise in early identification.  
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5.2. Introduction 
It is well recognised that HD patients suffer excess cardiac morbidity and 
mortality and this is mainly due to cardiac failure and sudden cardiac death 
[13, 335].  HD patients are primed by abnormalities in cardiac and structure 
and function to be vulnerable to HD-induced ischaemia. These changes can 
occur in the absence of flow-limiting stenosis of the coronary arteries and can 
be explained by a high prevalence of decreased coronary flow reserve, 
impaired autonomic function, left ventricular hypertrophy (LVH) and arterial 
stiffness [336, 337]. Proof-of-concept studies by McIntyre et al showed the 
process of HD is capable of causing a stress sufficient to reduce myocardial 
blood flow by 30% [284]. These changes localised to areas of reversible 
regional wall motion abnormalities on 2D echocardiography. Patients 
demonstrating such dysfunction had a 30% mortality and mean 13% 
reduction in left ventricular ejection fraction (LVEF) by 1 year [286]. Whilst it 
is already recognised that LVH confers an adverse prognosis in HD patients 
[338], there is increasing evidence that LV remodelling of geometry 
(measured by the LV mass/volume ratio) determines prognosis [339]. 
Therefore early identification of cardiac abnormalities might allow strategies 
to improve outcomes. Conventional 2D-echocardiography is a convenient, 
inexpensive and widely available imaging modality for determining LV 
abnormalities. However it is under-recognized that test-retest variability of 2D 
echocardiography is high, so that the smallest change of LVEF and LV mass 
that is detectable with 95% confidence is 11% and 59g respectively [201, 
340]. Furthermore 2D echocardiography uses geometric assumptions which 
tend to overestimate LV mass in ESRD [110]. Cardiac magnetic resonance 
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(CMR) is the gold-standard for analysis of LV mass and volumes with low 
intra- and inter-observer variability of around 5% [318]. Strain analysis 
detects early cardiac dysfunction prior to a decline in LVEF in non-uraemic 
settings [213-216]. Furthermore in heterogenous cardiomyopathy populations 
with both normal and reduced LVEF, strain was reduced in the subset of 
populations with normal LVEF and gave additional prognostic information 
beyond that provided by LVEF and LV mass [217, 218]. CMR assessment of 
strain by tissue tagging has been validated against sonomicrometry and is 
considered the gold-standard modality for non-invasive assessment due to 
high reproducibility [224]. There have been few studies of strain in HD 
patients using 2D echocardiography with conflicting results [341-343]. 
Previous CMR studies of ESRD patients being assessed for renal transplant 
listing used prevalent, selected populations and did not investigate strain 
[87]. Therefore, we aimed to study cardiac abnormalities in an unselected 
incident HD population using CMR for accurate mass and volumes 
augmented with strain by tagging as a more sensitive marker of dysfunction. 
5.3. Materials and methods 
5.3.1. Subjects 
Ethical approval for the study was obtained from Nottingham Ethics 
Committee for all participating centres prior to study initiation and patient 
enrolment. The study was performed in accordance with International 
Conference on Harmonisation Good Clinical Practice Guideline and the 2000 
Scotland Revision of the Declaration of Helsinki. All participants provided 
written informed consent. Patient flow for the study is summarised in Figure 
4-1and Figure 4-2. We recruited 54 HD patients within 6 months of 
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commencing in-centre HD at one of 4 UK research sites as part of a 
randomised trial in dialysate cooling. Inclusion criteria were incident HD 
patients aged over 16 years; within 180 days of commencing in-centre 
treatment 3 times per week and mental capacity to consent for the trial.  
Exclusion criteria included: contra-indications for magnetic resonance 
imaging; inability to tolerate magnetic resonance imaging and New York 
Heart Association Grade IV heart failure. Thirty age and sex-matched healthy 
volunteers were recruited through a local clinical research healthy volunteer 
program. Inclusion criteria were aged over 16 years with capacity to consent 
to the study and.  Exclusion criteria were: contra-indications for magnetic 
resonance imaging; history of kidney disease, ischemic heart disease or 
cardiomyopathy. Two healthy volunteers completed the study but were 
excluded from the analysis due to incidental findings of valvular heart disease 
and probable unrecognized myocardial infarction. 
5.3.2. Data collection 
CMR studies occurred on non-dialysis days at two centres using identical 
1.5T scanners (GE Signa HDxt 1.5T, GE Healthcare, Milwaukee,US) with 
retrospective ECG gating and 8-channel phased array coil.  Steady-state free 
precession (SSFP) cine images were acquired in 2, 3 and 4 chamber views. 
A stack of 8mm short-axis slices with a 2mm interslice gap were obtained 
using cine imaging covering the entire LV from base to apex. Typical 
parameters were field of view 38cm, repetition time 3.2 ms, echo time 1.6 
ms, matrix 224x224, flip angle 60°, 1 signal average, 16 views per segment, 
30 reconstructed phases per cardiac cycle to achieve temporal resolution of 
20-40ms depending on heart rate. Three short-axis tagged cines were 
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acquired after planning in mid-systole from the 4 and 3-chamber cine at 
basal, mid-ventricular and apical levels. A spatial modulation of 
magnetization (SPAMM) sequence with retrospective ECG gating and 
gradient recalled-echo readout was obtained. Typical parameters were 
matched to the SSFP cine images except for slice thickness 10mm, matrix 
224 x 160, flip angle 12°,achieving temporal resolution 15-30ms.   
 
Arterial stiffness by pulse wave velocity (PWV) and blood pressure was 
measured in a supine position after 10 minutes rest.  
 
Brachial artery blood pressure was measured in the non-fistula arm in HD 
patients and the right arm in NCs using an oscillometric device (Datex-
Ohmeda, GE Healthcare, USA).The mean of three readings was recorded. 
Carotid-to-femoral  
 
PWV was measured using an oscillometric device (Vicorder, Skidmore 
Medical Ltd, Bristol, UK) as previously described [330]. Briefly, a carotid 
pressure cuff is applied over the neck to detect the right carotid artery and a 
pressure cuff is placed around the proximal right upper thigh to detect the 
right femoral artery. The distance from the suprasternal notch to the middle of 
the thigh cuff was measured and entered into a PC running the Vicorder 
software. The cuffs are simultaneously inflated to a low pressure (40-60 
mmHg) and signal from each cuff is analysed to derive arterial transit time. 
PWV is calculated by the software by dividing arterial transit time by 
measured distance. The mean of 2 measurements was recorded.  
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In HD patients only, blood samples for determination of high-sensitivity 
troponin-T and NT-proBNP were taken immediately after insertion of access 
needles on HD the day before the CMR study. Samples were sent to the 
laboratory immediately where they were centrifuged and analysed using the 
Elecsys 2010 system (Roche Diagnostics, Switzerland). ). The limits of 
detection of the troponin-T assay are 0.005ȝg/L, the 99th percentile 0.014 
ȝg/L and the 10% co-efficient of variation is 0.013 ȝg/L [344]. The limits of 
detection of the NT-proBNP assay are 0.6pmol/l and the interassay co-
efficient of variation is 3.9%.  
 
5.3.3. Data Analysis 
All CMR analysis was performed offline blinded to patient details. Volumes 
and mass were determined using cvi42 software, version 4.0.2 (Circle 
Cardiovascular Imaging, Calgary, Canada). The LV contours were drawn 
manually excluding papillary muscles and trabeculations, and left ventricular 
end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection 
fraction (LVEF) and end-diastolic LV Mass (LVM), mean end-diastolic LV wall 
thickness (LVWT) were calculated.  The interventricular septum was included 
as part of the LV. The basal slice was included when at least fifty percent of 
the blood volume was surrounded by myocardium. The apical slice was 
defined as the last slice showing intracavity blood pool. Values were indexed 
by body surface area (BSA) using Mosteller’s method [316], denoted by the 
suffix ‘I,’ for example, LVMI. LVWT was calculated by excluding the two most 
basal and two most apical slices before averaging to reduce variability. 
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5.3.4. Strain Analysis 
Peak-systolic mid-wall circumferential strain was measured for each of the 3 
short axis slices using dedicated software (HARP 3.0, Diagnosoft, Palo Alto, 
California, USA) which has been validated in animal and human studies [231, 
232]. After confirmation of appropriate k-space setup, epicardial and 
endocardial contours in the frame with optimal myocardial-blood contrast 
were drawn then automatically propagated by the software to create a mesh 
in each frame. The anterior right ventricular septal insertion point was 
manually marked to enable division of the ventricular slice into segments. 
Contours were checked for tracking and manually adjusted to ensure the 
mesh remained within the myocardium. The software subsequently 
calculated Lagrangian mid-wall circumferential strain for each frame from 
end-diastole to end-systole allowing export of the data to a spreadsheet. 
Data were smoothed using a moving average of 3 points to reduce noise 
sensitivity and the peak systolic-strain value was extracted (Error! 
Reference source not found.). Data was analysed for the AHA 16 segment 
LV model, averaged per short-axis slice and across all segments to give a 
global measure (Peak Ecc) expressed as a percentage.  
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Figure 5-1 Representative mid-ventricular circumferential strain curve from a single 
patient. Peak Ecc represents peak-systolic circumferential strain. 
 
5.3.5. Statistical Analysis 
Normality was assessed using the Kolmogorov-Smirnov test, histograms and 
normal Q-Q plot. Continuous data were expressed as mean (±standard 
deviation (SD)) if normally distributed and median (±interquartile range (IQR)) 
if not. Categorical data were expressed as counts and percentage. 
Unadjusted data were analysed using independent sample t-tests for 
normally distributed variables; Mann-Whitney U for non-parametric variables 
and Chi-Squared or Fisher’s exact test for categorical variables. Pearson’s 
test was used to assess univariate correlations with Peak Ecc for normally 
distributed variables and Spearman’s test if not. Variables with right-skewed 
distribution were log transformed for the correlations. Multivariable linear 
regression analysis, using the forward stepwise method, was used to identify 
independent determinants of Peak Ecc. A threshold of p<0.05 was used for a 
variable to enter the model which was built using a hierarchical approach that 
introduced one-by-one variables on the basis of biological plausibility 
determined by literature review and the strength of association in univariate 
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analyses. A scatter plot of regression residuals versus predicted values and 
Cook’s Distance plot were used for testing the assumptions of linear 
regression and identifying outliers. The adjusted R-squared value is reported 
as a measure of goodness-of-fit, with the regression coefficients (95% 
Confidence Intervals) and standardised coefficients. SPSS version 20.0 was 
used for all analyses and graphs.  All analyses were 2 sided, and significance 
was judged at p <0.05.  
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5.4. Results 
Table 5-1 Subject characteristics, CMR and Oscillometric findings. Continuous 
variables are mean±SD or median(IQR) depending on normality and comparisons use 
Independent t test or Mann-Whitney Test as appropriate. Categorical data are 
counts[percentage] and comparisons use Fishers exact test. Cut-offs for 
abnormalities by CMR: LVH; LVMI >77.7g/m2 males >56.g/m2 females, Low Peak Ecc 
<15.6%. LVEF <47% males, <53% females 
HD (n=54) Controls (28) 
( 290)
P val 
Age (years) 60 ±24 60±23 0.83 
Female  15[28] 14[46] 0.03 
BMI (kg/m2) 27±8 27±3 0.79 
BSA  (m2) 2.0±0.2 2.0±0.2 0.89 
Medical history    
HD vintage (days) 149 (150) - - 
Diabetes mellitus  15 [28] 2[7] 0.045* 
Ischaemic heart disease  13[24] 1[3] 0.029* 
Current/Ex-smoker 25[46] 8[29] 0.23 
Medication    
Treated hypertension 42[78] 2[7] <0.001 
RAAS antagonist 14[26] 1[3] 0.029* 
Beta blocker 19[35] 0[0] <0.001** 
Other antihypertensive 37[69] 2[7] <0.001 
Statin use 23[43] 4[14] 0.02* 
Laboratory results    
High-sensitivity troponin-T 32(58) - - 
NT-ProBNP (pg/ml) 177(476) - - 
CMR and oscillometric findings    
Peak Ecc (%) 15.9(3.7) 19.5(3.3) <0.001** 
          Basal Ecc (%) 14.8(4.9) 17.9 (4.9) <0.001** 
          Mid Ecc (%) 16.6(5.8) 19.1(5.5) 0.001** 
          Apical Ecc (%) 16.4(5.5) 19.4(4.6) 0.003** 
HR 72(19) 63(11) 0.014* 
SBP (mmHg) 141±28 141±26 0.89 
DBP (mmHg) 76(19) 82(14) 0.07 
PP (mmHg) 61(30) 59(20) 0.29 
PWV (m/s) 7.3(2.6) 8.9(2.5) 0.026* 
LVEDVI (ml/m2) 87.6(29.8) 71.6(17.7) 0.03* 
LVEF 51.5(11.0) 58.5(5.4) <0.001** 
CI (l/min/m2) 3.1(0.7) 2.7(0.5) 0.006** 
LVMI (g/m2) 63.4(24.4) 45.9(9.3) <0.001** 
LV Mass/Volume ratio (g/ml) 0.76(0.22) 0.65 (0.16) 0.003** 
Mean ED wall thickness (mm)  7.8(2.2) 6.5(1.0) <0.001** 
Abnormalities by CMR    
LVH  20 [37] 1[4] 0.02 
LV dilatation 15 [28] 0[0] <0.001 
Ecc  26 [48] 3[11] 0.03 
LVEF  19 [35] 1[4] <0.001 
Normal CMR 10[19] 21[75] <0.001 
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Subject characteristics and the main CMR and oscillometric findings are 
presented in Table 5-1 as HD vs NCs. The groups were well matched for 
age, BMI, BSA and smoking status but not sex. Most HD patients were 
treated for hypertension (78%) and 26% were treated with a renin 
angiotensin aldosterone system (RAAS) antagonist.  
Global function 
Global LV function was reduced in HD patients (LVEF 51.5%±11.0 vs 
58.5%±5.4). Peak Ecc was reduced in HD compared to NCs. (Peak Ecc 
15.9%±3.7 vs 19.5%±3.3, p<0.001).  
Mass 
All measures of LV mass were increased in HD patients, with greater 
hypertrophy, LV remodelling and wall thickness (p<0.05, Table 5-1). 
Regional function 
Ecc was significantly reduced in each short axis slice in HD patients 
compared to NCs (p<0.003, Table 5-1). Regional reductions in Ecc in HD 
extended to all 16 LV segments, being statistically significant in 9 (Table 5-2). 
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Table 5-2 Between-group comparisons of Peak Ecc using the AHA 16 segment model of the Left Ventricle. Ecc values are median % ±IQR 
P values are by Mann-Whitney test 
 
 
 
 
 
 
 
 
 
  
 
Basal Mid Apical 
Segment HD NC P val HD NC P val Segment HD NC P val 
Anterior 10.0±5.9 12.8±7.6 0.021* 14.6±7.0 15.8±6.3 0.076 Anterior 14.0±6.3 16.4±9.0 0.014* 
Antero-septal  7.9±6.5 11.2±6.9 0.011* 12.2±7.0 14.3±6.5 0.002** Septal 13.9±7.3 16.0±8.8 0.042* 
Infero-septal  7.8±7.9 12.1±9.3 0.105 12.6±8.4 14.3±6.8 0.087 Inferior 14.0±6.2 15.3±8.2 0.189 
Inferior 9.5±9.9 15.0±8.3 0.047* 14.0±9.0 18.9±5.6 0.008** Lateral 14.9±5.4 17.2±5.9 0.021* 
Postero-Lateral 13.7±5.6 17.3±8.4 0.007** 15.8±7.2 17.9±7.2 0.141    
Antero-Lateral 12.7±6.6 15.3±4.3 0.070 14.4±6.9 16.1±3.7 0.040*    
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Subgroup comparisons 
Strain was also significantly lower in HD patients with diabetes (Peak Ecc 
16.6±3.3 vs 14.1±4.0, p=0.027) but there was no relationship to age (r=-
0.1,p=0.37), sex ((HD, p=0.22, NC p=0.33) history of ischaemic heart 
disease (p=0.23) or smoking status (p=0.16).  
Using 2 Standard Deviations from the mean of the control group, sex-specific 
cut-offs were determined for abnormal morphology and function in HD 
patients. 48% (26/54) had abnormal morphology (increased LVH or 
dilatation) whilst 54% (29/54) had abnormal contractile function (reduced 
LVEF or strain) with overlap between categories (Table 5-1). 
Univariate and Multivariable analyses 
Strain showed significant univariate correlations to LVEF, troponin-T, 
measures of cardiac hypertrophy and PWV (Table 5-3). Multiple stepwise 
linear regression analysis showed that LVEF and LV mass/volume ratio were 
independent determinants of strain (R2=0.44, Table 5-4).  
Table 5-3 Significant Univariate Correlations to Peak Ecc. P values use Pearsons 
correlation for normally distribution or Spearman rank correlation for non-normally 
distributed data. *Troponin-T was only measured in HD patients. 
 Total Cohort 
(unadjusted) 
 r P-value 
LVEF 0.519 <0.001 
LVWT -0.389 <0.001 
Post HD High-sensitivity troponin-T* -0.376 0.017 
Pre HD High-sensitivity troponin-T* -0.354 0.015 
LV Mass/Volume ratio  -0.334 0.002 
LVMI -0.308 0.006 
PWV -0.209 0.04 
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Table 5-4 Independent Determinants of Ecc by Multiple Stepwise Linear Regression 
analysis B = un-standardised coefficient (95% confidence intervals), ȕ= standardized 
coefficient. Independent variables that did not enter the model were: LVWT, troponin-
T, LVMI and PWV 
 Total Cohort 
Adjusted R2= 0.44 
 B (95% CI) E p value 
LVEF (per 1%r) 1.41(1.25-1.52) 0.57 <0.001 
LV mass/vol ratio (per 1g/ml) 1.12(0.83-1.28) -0.36 <0.001 
 
Within-subjects analysis for heterogeneity of strain 
One way repeated-measures analysis of variance was conducted to 
determine the within-subject heterogeneity in strain between short-axis slices 
in each study group. Data were normally distributed after logarithmic 
transformation and the Greenhouse-Geisser correction was applied due to 
violation of sphericity. Mean Peak Ecc differed statistically significantly 
between the 16 LV segments in both HD and NCs (F statistic 16.62 (7.65, 
382.28), P <0.001). Post-hoc tests using the Bonferroni correction revealed 
that Ecc increased from the base to the apex in both HD and NCs. 
Finally, to determine if Peak Ecc could stratify HD patients with normal LVEF, 
we divided the HD patients into 2 groups by LVEF (group 2, LVEF50%, 
Group 3, LVEF<50%) and compared them to NCs (group 1, LVEF>50%). 
Ecc was significantly reduced in HD compared to NCs (p=0.03) despite non-
significant differences to NCs for LVEF (p=0.09) (Figure 5-2Error! 
Reference source not found.). 
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Figure 5-2 Boxplots of median±IQR for A) LVEF and B) Peak Ecc by study groups 
stratified by LVEF. Blue: normal controls with LVEF>50%; Green, HD patients with 
LVEF50%; Pink, HD patients with LVEF<50%. Ecc was able to stratify significant 
differences between all 3 groups whilst LVEF was not. 
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5.5. Discussion 
In this study we used CMR augmented by myocardial tissue tagging to 
characterise abnormalities in cardiac mass, volumes and circumferential 
strain in a population of unselected patients new to HD, compared to age-
matched controls. To our knowledge this is the first report of strain by CMR 
tagging in HD patients. The principle findings of the study are that unselected 
incident HD patients have significantly reduced circumferential strain and 
LVEF compared to age-matched controls. In those with normal LVEF, strain 
was still significantly reduced.  The reduced strain was seen at a global, slice 
and segmental level with an increase from the base to the apex.  Secondly, 
Ecc was significantly correlated to LVEF, troponin-T, measures of cardiac 
hypertrophy and arterial stiffness. It was also higher in patients with diabetes. 
LVEF and LV mass/volume ratio were independent determinants of strain but 
accounted for only 44% of observed biological variability.  Finally, only 19% 
of HD patients had a normal CMR. 
  
Our results support and augment previously published data in prevalent HD 
patients using CMR without strain as well as data reporting strain by other 
imaging modalities. Mark et al studied 134 patients with end-stage renal 
disease (ESRD) using gadolinium contrast-enhanced CMR as part of 
assessment for renal transplant listing [87].  The study was conducted prior 
to knowledge of the association of gadolinium with nephrogenic systemic 
fibrosis and did not investigate strain or relationships to troponin-T. Using cut-
offs derived from published reference range studies, they showed a 
prevalence of 72% for LVH, 11.2% for LV dilatation and 8.2% for reduced 
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LVEF. This compares to 37%, 28% and 35% respectively in the present 
study. Stewart et al used CMR to compare 44 prevalent HD patients to 11 
age-matched controls. They also did not determine strain. Their findings were 
concordant to our study demonstrating lower LVEF and greater LV mass in 
HD patients but with significantly different absolute values [345]. The 
differences between these prior studies and the present are likely to be 
explained by the different ESRD populations studied, different cut-offs used 
to determine abnormalities and different decisions with regards to manual 
contouring of the LV contours to determine the mass and volumes. Mark et al 
studied a mixed ESRD population using both HD and peritoneal dialysis who 
were candidates for renal transplantation and so would tend to have less co-
morbidity than an unselected population [87]. Also the population was 
prevalent with a median exposure to dialysis of 365±1308 compared to 
149±150 days in our study. Study of selected prevalent populations can lead 
to survivor bias [346]. Furthermore their study used cut-offs derived from 
published studies whereas we used cut-offs derived from our own control 
subjects. Finally we chose to exclude papillary muscles and trabeculations 
from the mass and include in the volume. This was because such an 
approach was shown in the largest CMR-based longitudinal study of 5093 
subjects to have higher test-retest reliability and lower inter-and intra-
observer variability [339]. This is particularly important as follow-up studies 
are planned but such an approach will lead to slightly lower LV mass and 
LVEF than alternative contouring methods [347]. There are few studies that 
reported normal ranges for circumferential strain by CMR tagging in healthy 
volunteers [348]. These report mean peak strains in the region of 16-19% 
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which is reassuringly in keeping with the values for the healthy volunteers in 
our study (19.5%±3.3). There are no previous studies that measured strain 
by CMR tagging in HD patients. A limited number of studies have reported 
data in HD patients on strain by Tissue Doppler or Speckle Tracking 
Echocardiography. Direct comparisons of our strain values to those studies 
carry the caveat that there is little data that directly compared strain values by 
CMR tagging to echocardiographic techniques [169, 349, 350]. Absolute 
differences of 1-3% have commonly been reported (relative difference 10-
20%), with r values of 0.5 in one study [194]. Gulel et al used Tissue Doppler 
echocardiography to determine strain in 31 HD patients matched to 23 
normal controls [351]. Importantly, patients with LVEF<50% were excluded 
and the length of exposure to HD was not reported. Peak strain was reduced 
in HD patients compared to controls to a similar extent as in the present 
study (15.0%±7.4 vs 18.8%±4.2, p=0.02). Tissue Doppler is limited due to 
dependency on angle of insonation, tethering artefacts and requiring 
advanced echocardiographic expertise to acquire and interpret. More 
recently, 2D speckle tracking echocardiography (STE) has emerged as a 
robust angle-independent method of estimating strain in a shorter time [194]. 
Yan et al compared 36 HD patients to 17 non-dialysis CKD patients and 18 
healthy controls [343]. They could not demonstrate statistically different 
strains in HD patients to CKD patients or controls. However, in keeping with 
our study, they did demonstrate increased strains from the LV base to apex.  
 
Another important finding in our study were the modest univariate 
correlations of strain to LVEF, measures of cardiac hypertrophy (LVMI and 
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LVWT); LV remodelling (LV mass/volume ratio) and arterial stiffness (PWV). 
Furthermore in HD patients there was a modest inverse correlation of strain 
to high sensitivity troponin-T(-0.354,P=0.015). The link to LVH is well 
established in HD patients. LVH is thought to be a maladaptive response that 
allows for normal LVEF despite abnormal pressure or volume load. This 
maladaptation is associated with increased risk of coronary events, heart 
failure, arrhythmia and stroke. In addition to traditional atherosclerotic risk 
factors, multiple factors are thought to be contributory in CKD including aortic 
stiffness, volume and pressure overload, hyperphosphataemia and 
neurohormonal activation [51]. Recent work has extended this picture with 
the implication of endogenous digitalis glycosides and fibroblast growth factor 
23, both known to have higher concentrations in ESRD [52, 53]. In particular, 
sodium has been shown to induce adrenal gland secretion of endogenous 
digitalis glycosides and in vitro studies have shown they directly induce 
myocyte hypertrophy, thus providing a novel mechanism linking high dietary 
salt intake and impaired sodium excretion to hypertension and LVH in HD 
patients [54].  LV geometric changes, termed remodelling, have mainly been 
investigated by echocardiography in relationship to cardiovascular events. 
Concentric remodelling is defined as the presence of LVH and a high ratio of 
LV wall thickness relative to LV diameter from 1 dimensional M-mode 
echocardiography [352].  The presence and type of ventricular remodelling 
has been noted to prognosticate cardiovascular risk beyond that by LVH in 
some but not all studies in the HD and general population [353]. Studies in 
HD using echocardiography must be cautiously interpreted with respect to 
the timing of the study because the definition is limited by volume changes 
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such that calculated mass changes by 26g/m2 over a HD treatment session 
[354]. As CMR determines mass and volumes without geometric 
assumptions, concentric remodelling is more simply determined by LV 
mass/volume ratio. The Multi-Ethnic Study of Atherosclerosis (MESA) used 
CMR in over 5000 healthy subjects followed for 5 years, showing LV 
mass/volume ratio was associated with a greater risk of cardiovascular 
events [355]. In our data HD patients had higher LV mass/vol ratio and this 
remained an independent determinant of strain after multiple regression.  
We also demonstrated a modest correlation of strain to troponin-T that was 
not independent of LV mass. This is concordant with recent data. Elevated 
troponin is frequently associated with LV hypertrophy in the HD population 
[356]. A recent study using strain by 2D echocardiography showed that 
longitudinal but not circumferential strain was reduced in asymptomatic HD 
patients with elevated cardiac troponin-T and preserved LVEF [357].  
 
We saw a lower strain in patients with diabetes. This is in keeping with some 
data supporting that reduced systolic and diastolic strains by tissue Doppler 
echocardiography are the earliest signs of diabetic cardiomyopathy in the 
absence of LVH, CKD or overt heart disease [358]. Impaired lipid metabolism 
causing reduced adenosine triphosphatase activity and consequent 
decreased contractility is a postulated mechanism. However data in this area 
are conflicting.  
5.6. Strengths and limitations  
This is a cross-sectional observational study so causal relationships cannot 
be proven. A limitation of this study is the wide heterogeneity of global 
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systolic function in the HD group limited our ability to explore the utility of 
strain to detect subclinical cardiomyopathy. However we were able to 
demonstrate reduced strain in the subgroup with normal LVEF. We have also 
not examined diastolic function as the SPAMM technique used for tissue 
tagging fades during the cardiac cycle and is known to produce less reliable 
strain data in the diastolic phase. Future studies using tagging techniques 
optimised for diastole or performed at higher magnetic fields would be useful. 
Furthermore we did not have a CKD or treated hypertension control group 
and thus cannot determine the extent of their relative contributions to the 
observed between group differences. 
 
The strengths of the study are the unselected population increases the 
generalisability of the findings. This study provides the first data on systolic 
strain by CMR, arterial stiffness and high sensitivity-troponin-T in incident HD 
revealing a greater degree of cardiac dysfunction in patients new to HD than 
previously recognized.  
 
5.7. Conclusion 
In summary, in an unselected cohort, CMR tagging identified reduced 
circumferential strain in addition to abnormalities in LVEF and LV mass in the 
majority of patients new to HD. Strain was reduced in the subset of patients 
with normal LVEF. The independent determinants of strain were LVEF and 
LV Mass/Volume ratio. Strain shows promise in aiding early identification of 
cardiac disease in HD patients. 
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6. Study II Results: Directly-measured Aortic Distensibility in 
Patients new to Haemodialysis  
 
6.1. Abstract 
Aim: To investigate the contribution of uraemia to arterial stiffness  
Methods: We used Cardiac Magnetic Resonance Imaging (CMR) to directly 
measure aortic distensibility (AD) in the ascending aorta of haemodialysis 
(HD, n=30) and age and sex-matched control (NC, n=19) subjects. These 
results were compared with concurrently measured left ventricular mass, 
volumes and strain by CMR and carotid-femoral pulse wave velocity (PWV) 
using an oscillometric device.  
Results: Univariate analysis across both groups showed significant inverse 
correlations of AD to age (r=í0.668, P<0.001), PWV (r=-0.407 p=0.005) and 
left ventricular mass(r=í0.34, p=0.016).  AD was positively correlated to 
ejection fraction (r=0.429, p=0.002) and peak-circumferential strain (r=0.327, 
p=0.023).  In HD patients, AD was also inversely correlated to high sensitivity 
troponin-T(r=í0.46, p=0.014). There were no significant relations to body 
mass index, body surface area or NT-Pro-BNP. AD was reduced in HD 
patients compared to NCs, despite similar blood pressure and PWV 
(2.0±1.8mmHgí1×10í3 vs 4.0±4.8mmHgí1×10í3, p<0.001). Multivariable 
regression analysis identified age, HD status and diabetes as the strongest 
independent determinants of lower AD (adjusted R2=0.65). PWV did not 
enter the final model.  
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Conclusion: In a cohort of incident HD patients, age and diabetes were 
independent determinants of AD. Long-term follow-up will investigate AD as 
an independent risk factor for adverse LV remodelling in HD patients.  
 
6.2. Introduction 
Measurement of blood pressure is the most frequently method used to 
assess peripheral vascular function but pressure is not the only component. 
The association of stiffening of arteries with age and disease was first 
described in Ebers papyrus in 1550 BC. As early as 150 years ago, 
physiologists developed sphygmographs to investigate characteristics of 
arterial pressure waves [359]. Today, there is strong evidence that central 
arterial stiffening is associated with adverse cardiovascular outcomes in the 
general populations and populations at high baseline cardiovascular risk 
[360, 361]. Patients with end-stage renal disease (ESRD) have a greatly 
increased risk of premature cardiovascular morbidity and mortality. Although 
there is clustering of traditional cardiovascular risk factors for atherosclerosis, 
the relationship of those risk factors to outcome is not always clear and can 
only partly explain the increased risk [16, 362]. Epidemiological and clinical 
studies have frequently shown that increased arterial stiffness, most 
commonly assessed by measurement of pulse wave velocity (PWV) or 
augmentation index, is independently associated with cardiovascular 
morbidity and mortality in HD patients [36]. Although these studies are 
robust, applanation tonometry as an indirect measure of central arterial 
stiffness has limitations. The length of arterial path has to be estimated and 
there are problems in patients with obesity [363, 364]. The studies also did 
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not determine the relationship of these measures to cardiac structure or 
function. 
Due to high spatial and temporal resolution, cardiovascular magnetic 
resonance imaging (CMR) is the gold standard for measuring left ventricular 
volumes and mass as it uses no geometric assumptions [318, 365]. CMR can 
be extended to cine imaging of the aorta allowing direct measurements of 
aortic distensibility (AD) and flow [366]. A previous study used CMR to 
determine AD in ESRD patients [367]. This study used a prevalent population 
using both haemodialysis (HD) and peritoneal dialysis, who were candidates 
for renal transplantation [367]. The study did not determine the relationship of 
AD to PWV, cardiac biomarkers or cardiac strain, an early marker of cardiac 
dysfunction [213]. We aimed to study AD in an incident HD population and 
relate to PWV, cardiac structure, cardiac function including strain and 
biomarkers. Furthermore we wished to compare the ability of AD to PWV to 
discriminate between study groups. 
 
6.3. Materials and methods 
6.3.1. Patients 
Ethical approval for the study was obtained from Nottingham Ethics 
Committee for all participating centres prior to study initiation and patient 
enrolment. The study was performed in accordance with International 
Conference on Harmonisation Good Clinical Practice Guideline and the 2000 
Scotland Revision of the Declaration of Helsinki. All participants provided 
written informed consent. HD patients were recruited within 6 months of 
commencing in-centre HD at one of 4 UK research sites as part of a 
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randomised trial in dialysate cooling. Inclusion criteria were incident HD 
patients aged over 16 years within 180 days of commencing in-centre 
treatment 3 times per week with capacity to consent for the trial and without 
contra-indications for magnetic resonance imaging.  Exclusion criteria 
included not meeting inclusion criteria, inability to tolerate magnetic 
resonance imaging and New York Heart Association Grade IV heart failure. 
19 age and sex-matched healthy volunteers were recruited through a local 
clinical research healthy volunteer program. Inclusion criteria were aged over 
16 years with capacity to consent to the study and without contra-indications 
for magnetic resonance imaging.  Exclusion criteria were history of kidney 
disease, ischemic heart disease or cardiomyopathy. 
6.3.2. Data collection 
6.3.2.1. CMR acquisition 
CMR studies occurred on non-dialysis days at two centres using the same 
model of 1.5T scanner (GE Signa HDxt 1.5T, GE Healthcare, Milwaukee,US) 
with retrospective ECG triggering and 8-channel phased array cardiac coil.  
Steady-state free precession (SSFP) cine images were acquired in 2, 3 and 4 
chamber views. A stack of 8mm short-axis slices with a 2mm interslice gap 
were obtained using cine imaging covering the entire left ventricle (LV) from 
base to apex. Typical parameters were FOV 38, matrix 224x224, TR 3.2ms, 
TE 1.6ms, FA 60, Phase FOV 80%, Nex 1, views per segment 16, 30 
reconstructed phases, temporal resolution 20-40ms depending on heart rate, 
spatial resolution 1.7mm x 1.7mm, ASSET disabled. Myocardial tissue 
tagging with a spatial modulation of magnetization (SPAMM) sequence with 
retrospective ECG gating and gradient recalled-echo readout was obtained. 
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Typical parameters were FOV 38, slice thickness 10mm, matrix 224 x 160, 
TR 3.2ms, TE 1.6ms, FA 12, Phase FOV 80%, Nex 1, ASSET disabled, 
views per segment 10, 30 phases/cardiac cycle, temporal resolution 15-30ms 
depending on heart rate, spatial resolution 1.7mm x 1.7mm. Three short-axis 
tagged images were planned in mid-systole from the 4 and 3-chamber cine at 
base, mid-ventricular and apical levels.  Three plane localizer images were 
obtained to identify the ascending and descending aorta through to the 
pulmonary artery bifurcation. SSFP cines were acquired in an oblique sagittal 
orientation to demonstrate the full length of the aorta. This was used to 
acquire a 5 mm thick axial cine planned at the level of the pulmonary artery 
bifurcation with FOV 28 and the remaining parameters identical to the short-
axis stack.  
 
6.3.2.2. Blood pressure  
PWV and blood pressure were measured in a supine position after 10 
minutes rest.  Brachial artery blood pressure was measured in the non-fistula 
arm in HD patients and the right arm in NCs using an oscillometric device 
(Datex-Ohmeda, GE Healthcare, USA).The mean of three readings was 
recorded.  
6.3.2.3. Aortic PWV by external device 
Carotid-to-femoral arterial PWV was measured using an oscillometric device 
(Vicorder, Skidmore Medical Ltd, Bristol, UK) as previously described [330]. 
Briefly, a carotid pressure cuff is applied over the neck to detect the right 
carotid artery and a pressure cuff is placed around the proximal right upper 
thigh to detect the right femoral artery. The distance from the suprasternal 
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notch to the middle of the thigh cuff was measured and entered into a PC 
running the Vicorder software. The cuffs were simultaneously inflated to a 
low pressure 40-60 mm Hg and signal from each cuff was analysed to derive 
arterial transit time. PWV was calculated by the software by dividing arterial 
transit time by measured distance. The mean of two measurements was 
recorded. In HD patients only, blood samples for determination of high-
sensitivity troponin-T and BNP were taken immediately after insertion of 
access needles on HD the day before the CMR study. Samples were sent to 
the laboratory immediately for centrifugation then analysis using the Elecsys 
2010 system (Roche Diagnostics, Switzerland). The limits of detection of the 
troponin-T assay were 0.005 ȝg/L, the 99th percentile 0.014 ȝg/L and the 
10% co-efficient of variation was 0.013 ȝg/L [344].  
 
6.3.3. Analysis 
6.3.3.1. CMR analysis 
All CMR analysis was performed offline blinded to patient details. Volumes 
and mass were determined using cvi42 software, version 4.0.2 (Circle 
Cardiovascular Imaging, Calgary, Canada). The LV contours were drawn 
manually excluding papillary muscles and trabeculations, and left ventricular 
end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection 
fraction (LVEF), end-diastolic LV Mass (LVM) and mean end-diastolic LV wall 
thickness (LVWT) were calculated.  The interventricular septum was included 
as part of the LV. The basal slice was included when at least fifty percent of 
the blood volume was surrounded by myocardium. The apical slice was 
defined as the last slice showing intracavity blood p
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by body surface area using Mosteller’s method [316], denoted by the suffix ‘I,’ 
for example, LVMI.  LVWT was calculated by excluding the two most basal 
and two most apical slices before averaging to reduce variability.  
6.3.3.2. AD analysis 
The scout images were used to plan a sagittal oblique view of the aortic arch 
and from this an axial cine and phase contrast acquisition at the middle of the 
pulmonary artery bifurcation to view both the ascending and proximal 
descending aorta (Figure 6-1). The aortic areas in all 30 phases of the axial 
aortic cines were traced using cvi42 software (Figure 6-1). The areas were 
exported into a spreadsheet and an area-time graph was drawn (Figure 6-2). 
AD was calculated using the Bramwell-Hill formula (Max area-Min area)/(Min 
area x delta P), where delta P is pulse pressure [368].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 Aortic image acquisition. A: Sagittal oblique view of the aortic
arch used to plan acquisition of axial cine and phase-contrast imaging. The
dotted line represents the middle of the pulmonary artery bifurcation and
the solid white line represents the path of the aortic pulse wave used to
determine PWV B: axial cine manually traced in 30 phases at the middle of
the pulmonary artery bifurcation used to determine aortic distensibility 
A B 
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Figure 6-2 Aortic area (red line, left y axis) and aortic blood flow (blue line, right y axis) 
against time in a typical study subject. Maximal flow occurs early in systole. 
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6.3.3.3. Aortic PWV by CMR 
Aortic arch PWV was derived from the axial phase-contrast images using 
through-plane velocity encoded flow vs time traces processed by a bespoke 
algorithm written in Javascript for Jim software (Jim version 6. Xinapse 
software, UK). It can be shown that the maximum correlation between the 
curves corresponds to the delay between the upslope of the ascending and 
descending aortic pulse waves. The cross-correlation approach has been 
shown to be superior to time-to-foot of the pulse wave methods for 
calculating the transit delay[369].  
Figure 6-3 Principles of PWV determination using cross-correlation of aortic flow vs 
time curves 
 
6.3.3.4. Tagging analysis  
Peak-systolic mid-wall circumferential strain (Ecc) was measured using 
dedicated software (HARP 3.0, Diagnosoft, Palo Alto, California, USA) for 
each of the 3 short axis slices. Data were smoothed using a moving average 
of 3 points to reduce noise sensitivity and slices were averaged to give a 
global measure (Peak Ecc). 
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Figure 6-4 Representative mid-ventricular circumferential strain curve from a single 
patient. Peak Ecc refers to peak-systolic strain. 
 
6.3.4. Statistical Analysis 
Normality was assessed using the Kolmogorov-Smirnov test, histograms and 
normal Q-Q plot. Continuous data were expressed as mean (±standard 
deviation (SD)) if normally distributed and median (±interquartile range (IQR)) 
if not. Categorical data were expressed as counts and percentage. 
Unadjusted data were analysed using independent sample t-tests for 
normally distributed variables; Mann-Whitney U for non-parametric variables 
and Chi-Squared or Fisher’s exact test for categorical variables. Pearson’s 
test was used to assess univariate correlations with AD for variables with 
normal distribution or Spearman’s test if the distribution was not normal. 
Variables with skewed distribution (exponential) were log transformed for the 
correlations. Multivariable linear regression analysis, using the forward 
stepwise method, was used to identify independent determinants of AD. 
p<0.05 was used for a variable to enter the model. The model was built using 
a hierarchical approach that introduced one-by-one variables on the basis of 
a literature review, biological plausibility, and the strength of association in 
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univariate analyses adjusted for age. Blood pressure was excluded from the 
analysis as it is not independent of AD. A scatter plot of regression residuals 
versus predicted values and Cook’s Distance plot were used for testing the 
assumptions of linear regression and identifying any outliers. The adjusted R-
squared value is reported as a measure of goodness-of-fit. The regression 
coefficients (95% Confidence Intervals) and standardised coefficients are 
presented from the final multivariable model. Receiver operator characteristic 
(ROC) curve analysis under the non-parametric assumption was used to 
compare the discriminatory ability of AD and PWV for the study groups. 
SPSS version 20.0 was used for all analyses.  All p values are based on two-
sided tests and <0.05 was considered statistically significant. Graphs were 
drawn in SPSS or GraphPad Prism version 6.01 for Windows (GraphPad 
Software, California, USA).  
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6.4. Results 
Baseline characteristics:  
Detailed characteristics of the study population are in Table 6-1 and CMR 
findings are summarized in Table 6-2. The control group was well matched 
for age, sex, blood pressure, body mass index and body surface area. AD 
was right-skewed in distribution and was log-transformed for correlations and 
regression analyses. 
 
Table 6-1 Participant characteristics. Continuous variables are mean±SD or 
median(IQR) depending on normality and use Independent t test or Mann-Whitney 
Test as appropriate. Categorical data are counts[percentage] and comparisons use 
Fishers exact test.  
HD NC P val 
(n=30) (n=19) 
Age (years) 55(27) 55 (26) 0.98 
Female 7 (23) 8 (42) 0.17 
HD vintage (days) 161(146) - - 
Diabetes 7 [23] 1 [5] 0.13 
IHD 6 [20] 0 [0] 0.07 
Treated hypertension 21 [70] 2 [11] <0.001 
Smoking status (never/current/ex/) 14/8/8 15/1/3 0.11 
PVD 4 [13] 0 [0] 0.15 
Statin use 12 [40] 1 [5] 0.01 
RAAS antagonist 5 [17] 1 [5] 0.39 
BSA (m
2
) 1.9 ±0.3 1.9 ±0.2 0.55 
Body Mass Index (kg/m
2
) 27.6 ±8.0 26.8 ±4.6 0.97 
Troponin-T (ȝg/L) 41 (56) - - 
BNP (pg/ml) 234 (531) - - 
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Table 6-2 CMR and oscillometric findings Values are mean±SD or median(IQR) 
depending on normality. P values use Independent t test or Mann-Whitney Test as 
appropriate. 
 HD NC P val 
AD (mmHg)-1x 10-3 2.0 (1.8) 4.1 (4.8) 0.001 
MR-PWV (m/s) 7.9 (3.5) 5.3(1.9) 0.014 
Ex-PWV (m/s) 8.4(3.0) 8.4(1.5) 1.0 
LVEF (%) 50.3 ±11.1 58.7 ±5.1 <0.001 
LVMI (g/m2) 64.1 (35.0) 45.8 (11.3) <0.001 
Peak Ecc (%) 15.5 ±4.2 19.8 ±4.6 0.001 
LVEDVI (ml/m2) 89.8 (40.2) 72.7 (12.7) 0.043 
CI (ml/m2) 3.4 (0.9) 2.7 (0.6) 0.07 
HR 73 (19) 64 (11) 0.08 
SBP (mmHg) 140 ±32 138 ±30 0.4 
DBP (mmHg) 77 (16) 83 (16) 0.44 
PP (mmHg) 57 (26) 51 (18) 0.12 
PWV (m/s) 7.9 (2.9) 8.8 (2.3) 0.2 
LVSVI (ml/m2) 38.8 (23.9) 41.5 (7.5) 0.58 
 
Figure 6-5 Spearmans rank correlation of Age to AD in the entire study cohort of 
Study II. AD was log-transformed prior to the correlation as it was right-skewed. It 
shows AD decreases with advancing age. 
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Table 6-3 Significant Univariate Correlations to AD. P values use Pearsons correlation 
for normally distribution or Spearman rank correlation for non-normally distributed 
data. *Troponin-T was only measured in HD patients. 
 Total Cohort 
(unadjusted) 
 
r P-value 
MR-PWV 
-0.72 <0.001 
Age (years) 
-0.67 <0.001 
Skin autofluorescence 
-0.57 0.013 
LVEF 0.43 0.002 
LV wall thickness -0.44 0.009 
External-PWV -0.41 0.005 
High-sensitivity troponin-T* -0.53 0.014 
LV Mass Index -0.34 0.016 
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Aortic distensibility 
Univariate correlations to AD are summarized in Table 6-3. AD was 
significantly inversely correlated to age, MR-PWV Ex-PWV and LVMI.  AD 
was positively correlated to global measures of cardiac systolic function 
including LVEF and Peak Ecc.  In HD patients, AD was also inversely 
correlated to high sensitivity troponin-T(r=í0.46, p=0.014). There were no 
significant relations to body mass index, body surface area or NT-Pro-BNP. 
Table 6-2 and Figure 6-6 shows AD was reduced in HD patients compared to 
NCs, despite similar age and blood pressure. AD was also significantly 
reduced in diabetic versus non-diabetic subjects (Figure 6-7). AD was 
reduced in males compared to females but this did not reach statistical 
significance (2.5±2.4 vs 3.1±3.5 mmHgí1×10í3, p=0.47). The ROC curve to 
discriminate between study groups showed that AD had a greater sensitivity 
and specificity to determine study groups than PWV (Figure 6-8). Forward 
stepwise multiple linear regression identified age, presence or absence of HD 
and presence or absence of diabetes as independent determinants of AD 
(Table 6-4).  
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Figure 6-6 Median and IQR of AD in HD patients vs controls (NCs). P values uses 
Mann-Whitney test. 
 
Figure 6-7 Median and IQR of AD in diabetic vs non-diabetic subjects. P values uses 
Mann-Whitney test. 
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Table 6-4 Independent Determinants of AD by multiple linear regression. B = un-
standardised coefficient (95% confidence intervals), ȕ = standardized coefficient. 
Independent variables that did not enter the model were: PWV, smoking status, 
history of IHD, log high sensitivity Troponin T, LVMI, LVEF, Peak Ecc and LV wall 
thickness. 
 Total Cohort 
Adjusted R2= 0.65 
 B (95% CI) E p value 
Age (per 1year) 0.99 (0.98-0.99) -0.62 <0.001 
HD (yes vs no) 1.29 (1.13-1.46) 0.34 <0.001 
Diabetes (yes vs no) 0.78 (0.65 to 0.92) -0.26 0.005 
 
  
Figure 6-8 Receiver Operator Characteristic curves to 
compare diagnostic accuracy of AD or PWV to discriminate 
between HD and NC study groups. This demonstrates AD has 
greater sensitivity and specificity than externally measured
PWV distinguishes between groups  
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Vicorder measured Pulse wave velocity 
PWV by Vicorder (Ex-PWV) was significantly correlated to age (r=0.52, 
p<0.001) systolic blood pressure(r=0.308, p<0.037), and pulse pressure 
(r=0.299, p=0.043). In contrast to AD there were no significant correlations to 
measures of LV function, LV mass or troponin T. 
 
6.4.1. Discussion 
 
This study showed that AD is higher in HD patients, after adjusting for age 
and diabetes status. Although unintended, the groups were well matched for 
BP further strengthening the independence of the findings. AD was also 
lower in diabetic versus non-diabetic subjects. In addition, AD had significant 
univariate correlations to high sensitivity troponin-T and multiple measures of 
LV function and mass that were not seen for PWV. This suggested that AD 
had a greater diagnostic accuracy than PWV to discriminate between groups 
and this was confirmed by the ROC analysis. Multivariable regression 
analysis identified age, HD status and diabetes as the strongest independent 
determinants of lower AD (adjusted R2=0.65). PWV did not enter the final 
model.  
 
The data are concordant with the findings of previous research but also 
contain novel findings. Zimmerli et al compared CMR determined AD and 
PWV in 35 prevalent ESRD patients to 24 controls and 24 patients with 
multivessel CAD [367] The study design was different to the present in that 
AD was calculated from volumes precluding comparison of absolute values. 
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Furthermore the 24 ESRD patients were subdivided into patients with or 
without CAD. Despite the design differences a number of comparisons can 
be drawn. We found a similarly strong correlation of AD to age that remained 
an independent determinant in the regression analysis. Intergroup 
comparisons were also similar to the present study, with a significantly lower 
AD and higher LV mass in ESRD vs controls and no significant difference in 
PWV. The strong relationship of age to AD is remarkably consistent across 
multiple methodologies and multiple disease groups [370-372]. The 
mechanisms proposed for reduced AD with age include disruption of the 
elastic component of the vessel wall, fibrosis and increase in collagen at the 
expense of medial vascular smooth muscle cells [373-375].  It may also be 
related to a deficiency of nitric oxide bioavailability and fatigue fracture of 
elastin fibres [376, 377]. This would partly explain the tendency for the age 
related increase in AD to occur mostly in the proximal aorta where elastin is 
most prominent. Such mechanisms are difficult to separate from the 
overlapping and additional changes known to be induced by CKD. Increased 
deposition of advance glycation end-products (AGEs) are known to increase 
collagen cross-linking and provide a direct mechanism of reduced AD [378]. 
AGE levels are markedly increased in HD patients and predictive of mortality 
[38]. McIntyre et al previously demonstrated that increased AGE levels occur 
in early stage CKD [379]. Other mechanisms to reduce AD which are more 
prevalent in HD patients include vascular calcification. This can be medial 
and intimal but is particularly medial in HD patients. In vitro studies show 
vascular smooth muscle cells undergo transformation to osteochondroblasts 
promoting calcification when cultured in phosphate at concentrations similar 
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to those seen in HD patients [380].  Another relationship seen in our study 
that is concordant with prior studies was reduced AD in subjects with 
diabetes. Van de Meer et al used CMR to determine AD was lower in 13 
patients with diabetes compared to 15 healthy subjects (4.5±2.2 vs. 
7.4±3.3mmHgí1×10í3 p<0.05) [381]. The multiple regression analysis of 
Zimmerli et al showed that the independent determinants of AD were age, 
presence or absence of ESRD and presence or absence of CAD [367]. In the 
present study, the determinants were age, presence or absence of ESRD 
(HD) and diabetes. Given that we examined an incident population which had 
been exposed to HD for a median 170 days, it is likely that the changes we 
saw in HD patients occurred at least in part, prior to commencing HD. 
Edwards et al compared CMR-determined AD in patients with CKD stage 3 
to normal controls [382]. They derived similar values to the present study 
(2.2±1.8 vs 4.1±1.3mmHgí1×10í3, p<0.01 in Edwards et al compared with 
2.0±1.8 vs 4.0±4.8mmHgí1×10í3, p<0.001 in the present study) [382]. 
However AD was not the focus of their study preventing further comparisons. 
 
The novel findings in our study include a relationship of AD to high sensitivity 
troponin-T and Peak Ecc. A direct mechanism linking AD to both raised 
troponin-T and increased LV mass is subendocardial perfusion due to 
increased afterload. Afterload is LV end-systolic wall stress. Increased aortic 
stiffness leads to increased afterload and reduces aortic pressure throughout 
diastole. Animal studies show this leads to an increased myocardial oxygen 
demand, hypertrophy and compromised coronary perfusion [383, 384]. Such 
a reduction in coronary flow reserve is well described in HD patients [337]. 
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McIntyre et al previously used intra-dialytic myocardial perfusion imaging by 
positron emission tomography with radio-labelled water during HD to 
demonstrate that the HD process itself exerted sufficient stress to precipitate 
myocardial ischaemia [385]. This raises the intriguing possibility that the 
combination of patients primed by aortic stiffness and repetitively stressed by 
HD might cause higher troponin-T levels. Such ischaemia would be 
independent of flow-limiting coronary artery disease in its absence and 
additive to coronary artery disease in its presence. The relationship of AD to 
HD-induced myocardial ischaemia will require further studies that separate 
the contributions of LV hypertrophy and coronary artery disease. 
 
6.4.2. Limitations 
This is a cross-sectional observational study so causal relationships cannot 
be proven. A limitation of this study is that invasive local assessment of aortic 
pulse pressure was not performed, which would have defined AD more 
accurately than the use of brachial pulse pressure. Furthermore we did not 
have a CKD or treated hypertension control group and thus cannot determine 
the extent of their relative contributions to the observed between group 
differences.  The strengths of the study are achieved matching for age, sex, 
body mass index and surface area and measured blood pressure used for 
the AD calculation.  To our knowledge we are the first to have shown 
associations of AD to raised troponin-T, LV mass and LV function by strain in 
HD patients. 
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6.4.3. Conclusions  
Our study documents for the first time the strong association of CMR-
determined AD to measures of LV systolic function and high sensitivity 
troponin-T. Age, diabetes and HD status were independent determinants of 
AD. Long-term follow-up will investigate AD as an independent risk factor for 
adverse LV remodelling in HD patients. 
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7. Study III Results: Haemodialysis-induced stunning 
detection using Strain by Speckle Tracking 
Echocardiography 
7.1. Abstract 
Introduction: Haemodialysis can induce recurrent myocardial ischemia 
(myocardial stunning) and early identification allows strategies to improve 
outcomes. This was previously assessed by lateral wall motion analysis of 
echocardiographic images in prevalent populations. Recently, myocardial 
tissue deformation using 2D strain by speckle tracking echocardiography 
(STE) has proven to be a powerful tool for detecting ischemia in the non-CKD 
setting but has not been applied to detect stunning during HD. Furthermore, 
the prevalence of HD-induced stunning in incident patients is not known.  
Objectives: The aims of the study were i) To detect HD-induced stunning 
using reversible abnormalities by STE ii) Study determinants of stunning with 
structural and functional biomarkers and iii) Determine prevalence of 
stunning in an incident HD population. 
Methods: 60 subjects were studied (median vintage 170 days). STE was 
performed immediately before HD (Pre) and 15 minutes before the end of HD 
(Peak).  Segmental and global peak-systolic longitudinal strain (GLS) and 
strain rate (GLSR) were determined using commercially available software. 
HD-induced stunning was defined as any reduction in GLSR at Peak-HD 
compared to Pre-HD. Aortic stiffness was measured by carotid-femoral pulse 
wave velocity and advanced glycation end-products were estimated by skin 
autofluorescence. The severity of intradialytic hypotension (IDH) was 
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determined by tertiles of frequency of 15% reduction from baseline using 
continuously recorded blood pressure data.  
Results: Data are presented as Median±IQR and Pre-HD vs Peak-HD. 70% 
(42/60) had reduced GLSR at Peak-HD and were defined as stunning. 
Stunning was associated with higher NT-proBNP values (323±839 vs 81±120 
pmol/ml, p<0.001) and greater troponin-T concentrations (46±51 vs 
14±35ng/ml, p=0.011).  In logistic regression analyses, NT-proBNP 
concentration was the only independent predictor of myocardial stunning 
(Odds ratio for 100pmol/l increase 1.766, 95% CI 1.099-2.839, p=0.019).and 
Troponin-T concentration was the only significant independent predictor of 
frequency of IDH (Odds ratio for 10µg/l increase 1.138, 95% CI 1.013-1.276, 
p=0.038). 
Conclusion: Strain-based imaging by speckle tracking echocardiography 
shows promise for detection of HD induced stunning. A decreased change in 
strain rate across HD was associated with higher BNP and troponin-T, 
arterial stiffness and hypervolemia by bioimpedance. Further studies are 
required to determine if a strain-based definition of HD-induced myocardial 
stunning can replace current methods.  
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7.2. Introduction 
HD patients represent an extreme phenotype of cardiovascular risk with a 
pattern of disease distinct from that in the general population [1, 2].  A high 
prevalence of impaired autonomic function, left ventricular hypertrophy (LVH) 
and arterial stiffness result in a decrease in coronary flow reserve enabling 
demand myocardial ischemia to occur without flow-limiting stenosis of the 
coronary arteries. We previously used perfusion imaging during HD to show 
the process of HD is capable of causing a stress sufficient to reduce 
myocardial blood flow by 30% in the majority of prevalent patients [284]. The 
ischemia was localised to areas of reversible left ventricular (LV) regional 
wall motion abnormalities on 2D echocardiography. Patients demonstrating 
such dysfunction had 30% mortality at 1 year [284]. These findings were 
confirmed by another group using LV wall-motion score index (WMSI) by 
expert observer [386].  These studies are robust and the motion indexes 
were predictive of higher mortality. However as the human vision has a 
relatively poor temporal resolution the WMSI requires a high-level of clinical 
expertise and remains subjective with high inter-observer variability [163]. In 
addition, such approaches cannot distinguish between active myocardial 
motion and that due to passive tethering of dysfunctional segments by 
adjacent healthy tissue, potentially reducing specificity [189].  
Assessment of regional deformation (strain) within the myocardium may have 
greater sensitivity and specificity than measuring function by the motion of its 
boundaries. Speckle Tracking Echocardiography (STE) estimates motion by 
tracking of speckles in a greyscale 2D ultrasound images. The speckles are 
the result of interference generated by microscopic intramyocardial structures 
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and represent tissue markers that can be tracked during the cardiac cycle 
with a block-matching algorithm.  Recently 2D myocardial strain imaging by 
STE has proven to be a powerful tool for detecting ischemia in the non-CKD 
setting [194]. Furthermore, prior studies of HD-induced stunning used 
prevalent populations and so the true incidence in patients new to HD is not 
known. 
Objectives: We aimed to detect HD-induced myocardial stunning using 
reversible abnormalities in longitudinal strain and strain rate by STE in an 
unselected population new to HD and study associations with cardiac 
biomarkers, arterial stiffness and haemodynamic changes. We hypothesised 
that we could identify stunning by two modes of response to the stress of HD: 
A normal stress response, with an increase in strain and strain rate or an 
abnormal stress response with a reduction.  
7.3. Materials and methods 
7.3.1. Patients 
Ethical approval for the study was obtained from Nottingham Ethics 
Committee for all participating centres prior to study initiation and patient 
enrolment. The study was performed in accordance with Good Clinical 
Practice Guideline and the Declaration of Helsinki. All participants provided 
written informed consent.. HD patients from 4 UK research sites were 
screened for enrolment and 73 consented to this study as part of a 
randomised trial in dialysate cooling (ISRCTN00206012). Patient flow is 
summarised in . Inclusion criteria were HD patients aged over 16 years within 
180 days of commencing in-centre treatment 3 times per week with capacity 
to consent for the trial and without contra-indications for magnetic resonance 
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imaging.  Exclusion criteria included not meeting inclusion criteria, inability to 
tolerate magnetic resonance imaging and New York Heart Association Grade 
IV heart failure. The data presented here is from screening data prior to the 
application of any intervention. 
Figure 7-1 Patient flow in the study 
 
7.3.2. HD Details 
Dialysis was performed using low-flux polysulfone dialyzers, either 1.8 m2 or 
2.0 m2, per individual patients’ usual prescriptions (LOPS 18/20; Braun 
Medical Ltd, Sheffield, United Kingdom). Dialysate composition was sodium 
136-138mmol/l; potassium 2mmol/l; calcium 1.25mmol/l; magnesium 
0.5mmol/l; bicarbonate 32-38mmol/l; glucose, 5.6mmol/l; and acetate 
3mmol/l. 40 of 65 patient treatments were of 4 hours duration with the 
remainder at 3.5 hours. Anticoagulation was by unfractionated heparin. The 
dialysate flow rate was 500 mL/min and dialysate temperature was set at 36-
37°C. For each session, net fluid removal was set on an individual basis 
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according to ideal dry weight. Blood pump speed varied between 250 and 
450 mL/min, depending on the patient’s vascular access.  
7.3.3. Echocardiography 
Conventional 2D grayscale echocardiography with second harmonic imaging 
was performed using commercially available equipment (1.5-4mhz probe, 
Vivid-I, GE Healthcare, Horten, Norway) by one of two trained technicians in 
the left lateral position. Sector width, frequency and depth were optimised to 
produce optimal border definition and a frame-rate of 50-80 per second. 
Loops of 3 consecutive cardiac cycles in standard apical 2 and 4-chamber 
views were recorded pre-dialysis (rest) and 15 minutes before the end of 
dialysis (stress). 
7.3.4. Strain Analyses 
Longitudinal strain was measured by STE in 12 segments (2 and 4 chamber 
views) of an 18-segment LV model. The regions of interest (ROIs) were 
manually adjusted to include the entire LV myocardium and exclude the 
pericardium. Segments with poor tracking were automatically identified by the 
software and excluded manually if necessary. Peak negative systolic strain, 
representing the maximum systolic longitudinal shortening before aortic valve 
closure was noted for each segment. Peak negative systolic longitudinal 
strain rate represents the slope of the strain curve. Values of all segments 
were averaged to obtain global longitudinal strain (GLS) and global 
longitudinal strain rate (GLSR). All echocardiographic and strain analyses 
were performed separately and blinded to other patient data in random order.  
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7.3.5. Intradialytic Hypotension 
Continuous systemic blood pressure was monitored during HD using digital 
infra-red plethysmography in the non-fistula arm. (Finometer, Finapres 
Medical Systems, Arnhem, The Netherlands). This utilises pulse-wave 
analysis to reconstruct a central aortic waveform by a validated transfer 
function allowing a beat-to-beat tracking of blood pressure throughout the 
treatment  [387]. The raw data was exported into mathematical analysis 
software (MATLAB R2012a, Mathworks Inc.)  and severity of intradialytic 
hypotension (IDH) was determined by tertiles of frequency using systolic 
blood pressure data with a bespoke algorithm which compared 5 minute 
averaged samples to a baseline reference of stable readings and defined an 
episode as 15% reduction. 
 
7.3.6. Body Composition by Bioimpedance  
Bioimpedance analysis (BIA) measurements of resistance and reactance 
were taken in the recumbent position after 5 min of rest using a 
multifrequency, multisegmental, BIA device (InBody S20; Biospace, Seoul, 
Korea). This device has previously been validated in HD patients [388]. Total 
body water (TBW) and extracellular water (ECW) were derived on the basis 
of the manufacturer's impedance algorithm, which sums estimates for each 
of the limbs and the trunk. ECW/TBW ratio as a marker of hypervolemia is 
reported.  
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7.3.7. Aortic Stiffness 
Aortic stiffness by carotid-to-femoral pulse wave velocity (PWV) was 
measured with the patient lying at 30 degrees after 5 minutes rest using an 
oscillometric device (Vicorder, Skidmore Medical Ltd, Bristol, UK) as 
previously described [330]. The mean of 2 measurements was recorded.  
 
7.3.8. Skin autofluorescence 
Advanced Glycation End product (AGE) deposition has been implicated as a 
risk factor for arterial stiffness. AGE deposition determined by skin 
autofluorescence (AF) reflects the systemic burden and has shown to be 
predictive of cardiovascular mortality [389]. AF was measured on the non-
fistula arm using an AGE Reader device (DiagnOptics, Groningen, 
Netherlands). The mean of three readings was recorded. Readings are 
known to be unreliable on dark skin and were not done in this event. Values 
are expressed in arbitrary units (AU) [379]. 
 
7.3.9. Haematological and Biochemical Variables 
Predialysis blood samples were drawn immediately after insertion of access 
needles and collected into lithium heparin and EDTA tubes. Haematological 
samples were immediately sent to the laboratory at each research site. 
Biochemical samples were centrifuged and frozen at -80°C before batch 
analysis in the laboratory of the lead site for determination of high-sensitivity 
troponin-T (hsTnT) and NT-proBNP (BNP) using a multichannel autoanalyser 
(Elecsys 2010 system, Roche Diagnostics, Switzerland). The limits of 
detection of the hsTnT assay are 0.005ȝg/L, the 99th percentile 0.014 ȝg/L 
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and the 10% co-efficient of variation is 0.013 ȝg/L [344]. The limits of 
detection of the NT-proBNP assay are 0.6pmol/l and the interassay co-
efficient of variation is 3.9%.  
7.3.10. Definitions 
HD-induced stunning was defined as any reduction in GLSR or GLS at Peak-
HD compared to Pre-HD. The rationale was that a normal response to a 
haemodynamic stress should be to improve contractility and GLSR is a less 
load-dependent marker of contractility than GLS [193, 390].   
7.3.11. Outcomes 
The primary variables of interest were changes in GLSR and GLS, frequency 
of IDH and Troponin-T.  
 
7.3.12. Statistical Analysis 
Normality was assessed using the Kolmogorov-Smirnov test, histograms and 
normal Q-Q plot. Continuous data were expressed as mean±standard 
deviation if normally distributed and median(interquartile range) if not. 
Categorical data were expressed as counts[percentage]. Comparisons 
between resting and stress STE at peak HD were made by the paired T test 
or Wilcoxon signed ranks test. Univariate correlations to changes in GLS and 
GLSR and biomarkers were analysed by Pearson’s or Spearman’s Rank 
correlation coefficient as appropriate. Variables with right-skewed distribution 
were logarithmically transformed for the correlations. Binary logistic 
regression analysis was applied to identify independent determinants of 
changes in GLS and GSLR. Univariate correlations then ordinal logistic 
regression were applied to identify determinants of the number of IDH 
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episodes.  A threshold of p<0.1 was used for a variable to enter regression 
models. Models used a hierarchical approach ranking variables by the 
strength of the univariate association as well as biological plausibility. Only 
one cardiac measurement was entered at a time to satisfy the requirements 
of collinearity. The adjusted R-squared value (Nagalkarke) is reported as a 
measure of goodness-of-fit. SPSS version 20.0 was used for all analyses. All 
analyses were 2 sided, and significance was judged at p <0.05.  
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7.4. Results 
 
Table 7-1 Patient characteristics Continuous variables are mean±SD or median(IQR) 
depending on normality and comparisons use Independent t test or Mann-Whitney 
Test as appropriate. Categorical data are counts[percentage] and comparisons use 
Fishers exact test. 
 Control Intervention P val 
Age (years) 60(24) 62(22) 0.57 
Female  8[36] 7[33] 0.84 
BMI (kg/m2) 28.8±6.0 28.2±6.0 0.70 
BSA  (m2) 1.9±0.2[] 1.9±0.2[] 0.90 
Medical history    
HD vintage (days) 165(168) 122(159) 0.47 
Tunnelled catheter 8[35] 3[14] 0.05 
Diabetes mellitus  6[27] 6[28] 1.0 
Ischaemic heart disease  2[9] 2[10] 1.0 
Current/Ex-smoker 7[37] 11[58] 0.3 
Peripheral vascular disease  2[9] 5[24] 0.2 
Primary renal disease    
Diabetes Mellitus 6[27] 6[28] 1.0 
Glomerulonephritis 4[18] 3[14] 0.9 
Interstitial nephritis 2[9] 2[10] 1.0 
Vasculitis 2[9] 1[5] 0.7 
Polycystic Kidney Disease 0[0] 1[5] 0.7 
Renovascular disease/malignant 
hypertension 
3[14] 3[14] 1.0 
Plasma cell dyscrasias 0[0] 2[10] 0.9 
Unknown/Others 5[23] 3[14] 0.6 
Medication    
Treated hypertension 17[74] 18[86] 0.5 
RAAS antagonist 5[22] 6[29] 0.7 
Beta blocker 8[35] 7[33] 1.0 
Statin use 10[44] 10[48] 1.0 
Phosphate binder    
            Calcium-based 9[39] 4[19] 0.2 
            Non-calcium 7[30] 5[23] 0.7 
Erythropoeisis Stimulating Agent 16[70] 15[71] 1.0 
Vitamin D analogue 13[57] 11[53] 1.0 
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Table 7-2 Laboratory results and clinical parameters. Values for continuous variables 
are given as mean±SD with independent T test if normally distributed or 
median(interquartile range) with Mann-Whitney test if non-normal. 
 
All 
(n=60) 
Stun 
Reduced 
GLSR 
(n=42) 
Non-Stun 
Preserved 
GLSR  
(n=18) 
P val 
Laboratory results     
High-sensitivity troponin-T (ng/ml) 37(56) 46(51) 14(35) 0.011 
NT-Pro-BNP (pmol/ml) 163(427) 323(839) 81(120) 0.001* 
Total Cholesterol 3.4±0.9 3.7±1.0 3.3±0.1 0.59 
HDL Cholesterol 1.0±0.3 1.1±0.4 1.0±0.0 0.70 
Total/HDL Ratio 3.4±0.6 3.4±0.6 3.3±0.2 0.73 
PTH 169(211) 186(225) 147(94) 0.55 
Calcium 2.33±0.14 2.34±0.15 2.33±0.10 0.91 
Albumin 36.0±3.4 35.7±3.6 36.5±3.7 0.51 
Phosphate 1.56±0.46 1.53±0.48 1.64±0.48 0.48 
CRP 4.0(8.0) 5.5(8.8) 4.0(12.5) 1.0 
Clinical parameters     
PWV (m/s) 7.3(2.7) 7.7(2.7) 6.8(2.3) 0.11 
Skin Autofluorescence (AU) 3.5±1.0 3.5±1.0 2.8±0.6 0.05 
Ultrafiltration volume (l) 1.9(0.9) 1.6(1.3) 2.0(0.7) 0.17 
Ultrafiltration volume/Post HD 25±16 25±13 25±7 0.99 
ECW/TBW by bioimpedance 0.40(0.02) 0.40(0.02) 0.39(0.02) 0.04 
Left ventricular mass indexed to BSA 67.5±18.1 70.2±18.3 62.0±12.4 0.09 
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Patient characteristics are presented in Table 7-1 with clinical parameters in 
Table 7-2 for the whole group and categorised by the contractile response at 
Peak-HD. It should be noted that GLS and GLSR are conventionally 
expressed as negative numbers with more negative strain or strain rate 
denoting improved contractile function.  
 
Prevalence of HD-induced stunning 
60% (42/60) had reduced GLSR at Peak-HD compared to Pre-HD. This 
group had greater NT-Pro BNP levels, greater Troponin-T concentrations, 
higher skin autofluorescence levels.  There was also greater usage of 
calcium based phosphate binders and erythropoeisis stimulating agents. 
There were trends towards higher PWV and higher LV mass.   
Pre-HD Resting Global Longitudinal Strain and Strain Rate 
Pre-HD GLS had positive correlations (denoting worse strain) to age, 
markers of ischemia, endotoxin, hypervolemia, central arterial stiffness 
(PWV) and advanced end-glycation product deposition (Skin AF). Pre-HD 
GLSR had similar correlations but had a weaker non-significant correlation to 
age and was more strongly tied to hypervolemia with positive correlations to 
NT-proBNP and LVEDV.  Both Pre-HD GLS and GLSR showed negative 
correlations (improved strain) to LVEF as denoted in Table 7-3. 
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Table 7-3 Significant Univariate Correlations to Pre-HD GLS and GLSR. P values use 
Spearman rank correlation. 
 Pre-HD GLS  Pre-HD GLSR  
 r P-value r P-value
Skin AF -0.604 0.002 0.608 0.002 
LVMI -0.206 ns 0.536 <0.001 
Pre-HD LVEF 0.485 0.001 -0.489 0.001 
Post-HD Endotoxin -0.324 0.036 0.419 0.006 
NT-ProBNP -0.139 ns 0.406 0.003 
LVEDV 0.158 ns 0.393 0.012 
Troponin-T -0.401 0.003 0.358 0.009 
PWV  -0.365 0.012 0.327 0.025 
ECW/TBW -0.399 0.007 0.310 0.04 
Age -0.299 0.03 0.124 ns 
 
Changes in Global Longitudinal Strain and Strain Rate 
GLSR decreased from pre- to peak HD in 70% (42/60) and increased in 30% 
(18/60). The group who decreased strain rate indicating impaired stress 
response and lack of contractile reserve were defined as demonstrating HD-
induced stunning. The group who increased strain rate would be 
characterized as a normal stress response demonstrating contractile reserve 
and were defined as not stunning. Stunning prevalence was not increased by   
age, diabetes, male sex, or history of ischaemic heart disease.  Stunning was 
correlated to markers of ischemia, hypervolemia or cardiac stress including 
hsTnT, ECW/TBW by bioimpedance and NT-proBNP. Stunning was also 
correlated to lower level of strain and strain rate at baseline (Table 7-5). The 
stunning group with negative ǻGLSR also had a decrease in GLS during HD 
that did not reach statistical significance (-16.2±3.8% to -14.5±2.1%, p=0.17). 
Conversely the positive ǻGLSR in the non-stunning group (improved strain 
rate) was accompanied by an increase in GLS that did not reach statistical 
significance. 
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Table 7-4 Changes in Strain, Strain rate and LVEF during HD P values use paired T 
test or Wilcoxon signed rank test as appropriate 
 Stun 
Reduced GLSR 
(n=42) 
Non-Stun 
Preserved GLSR  
(n=18) 
 
Pre-HD Peak-HD Pval Pre-HD Peak-HD Pval 
GLS (%) -16.2±3.8 -14.5±2.1 0.165 -14.0±4.4 -14.4±4.0 0.227 
GLSR (1/s) -1.27±0.25 -1.14±0.28 0.004 -1.06±0.3 -1.33±0.3 <0.001 
LVEF (%) 54.9±11.3 48.0±14.7 0.032 52.4±13.1 52.8±14.8 0.875 
SBP 139(24.0) 135(34) 0.02 131(23.5) 129(9.0) 0.14 
DBP 76(20) 79(19) 0.14 80(20) 71(21) 0.7 
 
Changes in ejection fraction 
In the stunning group there was a significant mean reduction in LVEF whilst 
LVEF was maintained in the non-stunning group (Table 7-4).  
 
Table 7-5 Significant Univariate Correlations to ǻGLSR. P values use Pearsons 
correlation coefficient for normally distributed variables or Spearman rank correlation 
for non-normally distributed variables. 
 r P-value 
NT-ProBNP -0.53 <0.001 
Troponin-T* -0.338 0.011 
ECW/TBW -0.305 0.042 
Pre-HD GLSR -0.317 0.021 
Pre-HD GLS -0.288 0.038 
 
Troponin-T 
hsTnT was highly correlated to several markers of cardiovascular stress or 
factors implicated in accelerated cardiovascular disease (Table 7-6). There 
was a strong correlation to hypervolemia as measured by ECW/TBW (r=0.71, 
p<0.001) as well as to NT-proBNP (r=0.53, p<0.001). Left ventricular 
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hypertrophy (LVMI r=0.464, p<0.001) and arterial stiffness by PWV (r=0.379, 
p=0.006). Skin AF, a measure of advanced glycation end-products implicated 
in causing arterial stiffness was also well correlated (r=0.502, p<0.008).  
Interestingly, hsTnt was not only significantly related to baseline strain and 
strain rate but also the change in strain during HD (Table 7-6).  Hence, 
hsTnT was higher in the stunning group (46±51 vs 14±35ng/ml, p=0.011, 
Figure 7-2 ).  
 
Table 7-6 Significant Univariate Correlations to Troponin-T. P values use Pearsons 
correlation for normally distributed variables or Spearman rank correlation for non-
normally distributed data. 
 r P-value 
ECW/TBW 0.714 <0.001 
NT-ProBNP 0.53 <0.001 
Skin AF 0.502 0.008 
LVEF -0.473 0.001 
LVMI 0.464 0.001 
Pre-HD GLS 0.401 0.003 
PWV 0.379 0.006 
Pre-HD GLSR 0.358 0.009 
Age 0.334 0.012 
 
Figure 7-2 Troponin-T between study groups where HD-induced stunning was defined 
as a reduction in global longitudinal strain rate (GLSR). Median±IQR shown. P values 
use Mann-Whitney test  
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NT-proBNP 
BNP was highly correlated to both baseline (GLSR) and HD-induced 
changes in strain rate (ǻGLSR) as seen in Table 7-7 . There were also good 
correlations to bioimpedance markers of hypervolemia and LVEDVI. BNP 
was also higher with lower LVEF or ǻGLS but the correlation did not reach 
statistical significance. BNP was significantly higher in the stunning group 
(324±751 vs 74±135 pmol/ml, p<0.001) as depicted in Figure 7-3. In binary 
logistic regression analysis BNP remained the only independent determinant 
of myocardial stunning (Nagelkerke adjusted R2=0.342, p<0.0001; Odds ratio 
for 100pmol/l increase 1.766, 95% CI 1.099-2.839, p=0.019). 
Table 7-7 Significant Univariate Correlations to NT-ProBNP. P values use Spearman 
rank correlation coefficient. 
 r P-value 
ECW/TBW 0.472 0.001 
LVEDVI 0.48 0.001 
Pre-HD GLSR 0.369 0.007 
ǻGLSR 0.48 <0.001 
 
Figure 7-3 Median±IQR of NT-proBNP between stunning and non-stunning groups 
defined by reductions in global longitudinal strain rate. P values use Mann-Whitney 
test 
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Intradialytic hypotension 
At least 1 episode of IDH was detected in 31% (18/58) of patients. The 
number of IDH episodes correlated with higher levels of hsTnT (r=0.487, 
p<0.005). IDH was categorised for severity by tertiles of the number of 
episodes; stage 1,   5; stage 2, 6-15; stage 3, >15. Ordinal regression 
analysis was performed to examine predictors of IDH. Factors assessed one-
by-one were age, sex, history of ischaemic heart disease, smoking status, 
diabetes status, ultrafiltration volume, body composition by bioimpedance, 
NT-proBNP and endotoxin. hsTnT concentration was the only significant 
predictor of stage of IDH (Nagelkerke adjusted R2=0.132, p=0.029; Odds 
ratio for 10µg/l increase 1.138, 95% CI 1.013-1.276, p=0.038).  
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Figure 7-4 Segmental strain curves for a typical patient Upper row are Pre-HD and Peak-HD longitudinal strain, lower row is pre-HDand peak-HD 
longitudinal strain rate. The 2 and 4 chamber views are divided into 6 segments to determine 12 segments of an 18 segment model of the left 
ventricle. In this example note that both the magnitude od the peak strain as well as the degree of LV dyssynchrony worsen at peak-HD compared 
to pre-HD. NOte laso that the peak strain rate is relatively unchaged in magnitude but worsens in the degree of dyssynchrony at peak-HD. In both 
curves the apical and mid-lateral walls (dark blue and pink lines) are particularly affected. 
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7.5. Discussion 
In this study we examined the ability of strain-based imaging using STE to 
detect HD-induced myocardial stunning and the associations of strain and 
strain rate changes during HD to cardiac biomarkers and haemodynamic 
changes associated with ischemia. We also wished to determine prevalence 
of HD-induced stunning in an incident population. The main findings of the 
study were:   
1) We were able to dichotomise patients by a strain-based response to HD, 
70% of patients decreased strain rate during HD and 30% increase strain 
rate during HD.  
2) The size of the response appeared to be well correlated with other 
markers of ventricular distress and hypervolemia, supporting a relation to 
contractile reserve. 
3) The response was also well correlated to known risk factors for myocardial 
ischemia.  
4) The proportion of patients with HD-induced stunning in this incident 
population was within the range of previously reported prevalent HD patients. 
 
This study supports and augments previous data on HD-induced stunning 
and also extends data on the utility of strain-based imaging in HD patients.  
 
Rationale for a strain-based definition of HD-induced myocardial ischemia 
The rationale that a strain-based definition is at least non-inferior to wall 
motion analysis for detection of HD-induced myocardial ischemia is well 
supported by recently published data in non-dialysis settings. In a cohort of 
30 patients with suspected IHD, Leitman et al demonstrated a graded 
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decrease in GLS between visually scored normal, hypokinetic and akinetic 
segments (GLS -13.4%±4.9 in normal, -10.5%±4.5 if hypokinetic, -6.2%±3.6 
if akinetic, P<0.000001) [204].  Becker et al showed in 62 patients that radial 
and circumferential systolic strain and strain rate by 2D echocardiography 
could identify RWMAs well compared with RWMAs by cardiac magnetic 
resonance [205]. Liel-Cohen et al recently conducted a single centre study in 
105 patients, 90 admitted with chest pain and 15 with known dilated 
cardiomyopathy [206]. The ability of an automated score determined using 
GLS by STE was compared to the ability of 12 expert echocardiographers to 
visually determine RWMAs blinded to patient details. Automatic quantification 
using GLS with pre-determined cut-offs performed as well as visual analysis 
by the echocardiographers, with a greater reliability and similar agreement to 
angiographic findings [206]. This demonstrated the potential to use 2D strain 
to assist less experienced echocardiographers in identifying regional 
dysfunction. Yu et al performed dobutamine stress echocardiography (DSE) 
in 34 patients with angiographically-proven multivessel CAD and compared 
to 42 non-CAD controls with preserved LVEF and previously negative DSE 
[391]. The control group had a relative increase of around 10% in GLS (-
17.6±3.1% to -19.4±3.2%) compared to less than 1% in the CAD group (-
15.28±2.4% to -15.41±3.5%, p<0.001). There was a 25% increase in peak 
strain rate under stress in controls (-0.95±0.19s-1 to -1.19±0.24s-1) compared 
to a 9% increase in CAD patients (-0.83s-1 to -0.91s-1, p<0.001). No 
significant changes were demonstrated for circumferential strains. 
Multivariate analysis showed that ǻGLSR (odds ratio (OR), 1.63; 95 % CI, 
1.12–2.82) was an independent predictor for the detection of multivessel 
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CAD [391]. This independence remained significant after adjustments for 
age, sex, heart rate, blood pressure, LVEF and WMSI.  By crude 
comparison, our study showed 11% decrease in strain rate and 12% 
decrease in strain amongst the stunning group with a 25% increase in strain 
rate and 3% increase in strain in the non-stunning group (). Strain by STE 
under dobutamine stress has also been used to differentiate subendocardial 
from transmural ischemia to determine viability and contractile reserve. Chan 
et al demonstrated reduced contractile reserve by strain rate with dobutamine 
infusion localised to segments with transmural scars by contrast-enhanced 
CMR, outperforming RWMA analysis [392]. Delgado et al used strain by STE 
to study 222 consecutive patients with IHD (including 99 with acute ST-
segment elevation MI,STEMI ) and 123 patients with ischaemic 
cardiomyopathy and 20 age-matched controls [393]. Average values for the 
entire group were 11.1±4.8% for GLS and 37±14% for LVEF. For the overall 
study population GLS was highly correlated to LVEF (r = 0.83; P <001) but 
the correlation was less strong in patients with STEMI or heart failure (r=0.42 
and r=0.62, both P<001). This compares to our correlation of GLS to LVEF 
(r=0.48, p=0.001). These data support that STE derived strain reflects 
different aspects of systolic left ventricular function, performing as well if not 
better than visual wall motion analysis. 
 
There are obviously significant differences between our study and these. The 
studies were not in the setting of HD, coronary artery status of subjects was 
known and there was pre-selection of candidates altering diagnostic 
accuracy. Therefore the data and derived cut-offs cannot be directly 
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translated in the HD setting. However it serves as proof-of-principle to 
emphasise that patients with myocardial ischemia have both lower baseline 
strain and strain rate as well as a blunted or absent increase in strain and 
strain rate when myocardial oxygen demand is increased. Indeed, there are 
case reports suggesting the magnitude of perfusion-imaging proven ischemia 
induced by the stress of HD is greater than that induced by pharmacological 
stress [85].  
 
Relations of strain to ischemia and hypervolemia in the present study 
There were strong correlations of both resting GLS and GLSR and ǻGLSR 
across dialysis to risk factors for and markers of ventricular distress and 
hypervolemia. Previous data supports that increased arterial stiffness lowers 
coronary flow reserve by causing pulse waves to arrive in diastole [105]. Data 
also supports that in addition to vascular calcification, several uraemic factors 
such as increase endogenous inhibitors of nitric oxide production and 
increased AGE deposition, promote arterial stiffness. To that end these data 
reflect the literature in showing a correlation of greater arterial stiffness by 
PWV (r=0.37) and higher AGE deposition by skin autofluorescence (r=0.6) to 
both lower baseline strain and strain rate () [213]. Breidthardt et al showed 
recently that Troponin-T reflected the presence and severity of HD-induced 
stunning [394]. We also demonstrated a good correlation to ǻGLSR and 
demonstrated a significant difference between patients with or without 
myocardial stunning using a newer high-sensitivity assay.  
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Prior data on strain-based changes in HD patients 
There have recently been a number of studies using STE in a HD setting 
[342, 395-397]. However they are mostly distinct from the present in that they 
have compared HD patients on inter-dialytic days to normal or CKD controls, 
broadly showing lower levels of baseline strain or strain rate in the HD 
patients. Of note these studies do reflect our data in showing correlations of 
lower strain to higher LV mass or arterial stiffness [396].  Few studies have 
performed strain-based imaging during HD. Hayashi et al used a Doppler 
based tissue velocity imaging before and after HD in 13 stable HD patients 
[181]. They showed increased peak systolic tissue velocities and strain rate 
after HD compared to before with no change in LVEF or shortening fractions. 
They concluded that systolic function improved during HD but diastolic 
function did not and explained their results in terms of load dependency or 
removal of uraemic factors enhancing contractility. Although methodologies 
are different their finding that strain rate increases reflects that seen in 25% 
(18/60) of patients in the present study. We propose that an increased strain 
rate across dialysis more likely reflects normal contractile reserve and not 
enhanced contractile function. The decreased strain rate seen in the majority 
of our patients supports that HD induces ischemia in those with limited 
contractile reserve and that factors such as increased arterial stiffness, 
higher left ventricular mass and hypervolemia are pre-disposing factors.   
 
Prevalence of HD-induced stunning 
We estimated that proportion of HD induced stunning was 60% which is 
within the range of the reported prevalence of 27-91% in prior studies of 
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prevalent HD populations [287, 311, 386, 398].  Assa et el recently reported 
HD induced stunning detected by WMSI in a population with median dialysis 
vintage of 21 months [386]. 105 patients completed the study. 27% of 
patients showed stunning during HD using a definition of an increase in wall 
motion score at any of three time points during and after HD compared to 
baseline in more than 2 of 16 LV segments. Stunning was higher in those 
with higher baseline WMSI and 1 year follow up showed a graded increase in 
mortality by the number of stunned segments. This is reflected in our study 
where lower resting GLS was associated with reduction in strain rate. In 
addition, we demonstrated significant univariate correlations to pre-dialysis 
Troponin T, BNP, PWV and hypervolemia. These biomarkers independently 
predict high mortality and development of heart failure. It is noteworthy that 
Assa et al also demonstrated that stunning was higher with higher LV mass. 
We demonstrated a trend towards stunning with higher LV mass and found 
that baseline strain rate was well correlated to LV mass (r=0.536, p<0.001). 
LV mass was also well correlated to Troponin-T supporting that myocyte-
capillary mismatch induced by LVH increases the risk of HD-induced 
ischemia as shown in experimental studies [399]. Burton et al reported 
prevalence of HD-induced stunning of 66% in 70 patients with median 
vintage of 45 months using a similar definition of increased LV radial wall 
motion score in more than 2 of 10 segments using semi-automated software 
[286]. The most pertinent difference between these prior studies is that our 
population was incident with a median vintage of 6 months. This may have a 
substantial effect as prevalent studies may lead to a survivor bias. The 
definition of stunning is also significantly different. We used mean change in 
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longitudinal deformation averaged over 12 segments as opposed to a 
segmental scoring index. The differences in definition, along with the different 
HD vintage and burden of co-morbidity may account for the reported 
differences.  
 
7.6. Strengths and Limitations  
 
There are a number of limitations to this study. Firstly, we did not know the 
coronary artery disease status of our population and cannot correlate HD 
induced strain abnormalities to angiographic findings. However we would 
propose that a reduction in strain or strain-rate in response to HD-induced 
stress suggests impaired contractile reserve which can occur in the presence 
or absence of functionally significant coronary artery stenoses. Future studies 
should address the proportion of contribution of coronary artery disease. 
Secondly, we used an arbitrary definition of HD-induced stunning which has 
not been validated by perfusion imaging. It is possible that the cut-offs will 
alter diagnostic accuracy for stunning and the data requires validation. 
Further it is a cross-sectional study and although we have inferred 
relationships, neither causality nor direction of cause can be determined. 
Finally we did not assess diastolic dysfunction. The lower frame rate of STE 
compared to Doppler-base imaging makes diastolic indices less reliable and 
there is a lack of consensus on the most robust diastolic indices. However 
diastolic indices are by their nature load-independent and may provide 
valuable insights into characterising the haemodynamic response to HD.  
The strengths of the study are in the comprehensive nature of the 
assessment being the first study to report HD-related echocardiographic 
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changes with independently measured biomarkers, arterial stiffness, skin 
autofluorescence and volume status by bioimpedance. We are the first to 
determine HD-induced stunning by strain rate or report STE data at two time 
points in incident HD patients. We are also the first to relate contractile 
reserve by strain rate change to be limited by arterial stiffness, higher LV 
mass and to be associated with higher BNP and troponin T.   
 
7.7. Conclusion 
In summary we were able to dichotomise patients by a strain-based response 
to HD, 70% (42/60) of patients decreased strain rate during HD and 30% 
(18/60) increased strain rate. A decreased change in strain rate across HD 
was associated with higher BNP, troponin-T, arterial stiffness and 
hypervolemia. Further studies are required to determine if a strain-based 
definition of HD-induced myocardial stunning can replace current methods. 
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8. Discussion  
8.1. Main findings 
 
In Study I we aimed to study cardiac abnormalities in an unselected incident 
HD population using strain by CMR tagging as a more sensitive marker of 
dysfunction. We identified reduced circumferential strain in addition to 
abnormalities in ejection fraction and mass in the majority of incident HD 
patients. Strain remained reduced in the subset of patients with normal 
ejection fraction. The independent determinants of strain were ejection 
fraction and left ventricular geometry.  
 
In Study II we aimed to investigate the contribution of uraemia to arterial 
stiffness by directly measuring aortic distensibility using cardiac magnetic 
resonance. There was a clear increase in directly-measured aortic stiffness 
between HD patients and age-matched controls despite similar blood 
pressure. Aortic stiffness increased with age and with greater degrees of 
ventricular hypertrophy, lower ejection fraction and lower circumferential 
strain. Aortic stiffness also was also inversely correlated to biomarkers of 
myocardial ischaemia. Age, dialysis status and diabetes were the 
independent determinants.  
 
In the final study we used strain by speckle tracking echocardiography to 
detect HD-induced myocardial ischemia in a population new to HD. 70% of 
patients decreased strain rate during HD whilst 30% had increased strain 
rate. A decreased strain rate across HD was associated with markers of 
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hypervolaemia, ischaemia, stiffness and ventricular stress, suggesting that 
ischemia was the cause of observed reductions in strain. Further studies are 
required to determine if a strain-based definition of HD-induced myocardial 
ischemia can replace current methods.  
 
8.2. Main limitations 
The study limitations were outlined in the chapters but the main overall 
limitation is the lack of a CKD-control group. As the HD population was 
relatively new to HD (median 6 months) many of the observed structural and 
functional abnormalities will have occurred in early or late stage CKD and an 
age-matched CKD control group might have allowed more insights into 
natural history. However it is planned to follow this cohort with CMR at 1 year 
as part of the dialysate cooling trial and this will allow greater insights without 
the problems of achieving adequate matching. Another limitation was the 
heterogeneity in the HD patients. For example ejection fraction ranged from 
20-80%. This sometimes limited the ability to see subclinical abnormalities. 
We performed subgroup analyses where possible to overcome this. It is an 
important principle to conduct studies which do not preselect the population 
but there are inherent problems.  Both the speckle tracking and CMR tagging 
analyses were limited by not examining diastole.  The CMR tagging 
technique used is prone to fading in diastole and this also led to noise in the 
strain curves. This reduces data resolution and the ability to determine 
between group differences. 
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8.3. Future work  
This thesis contributes to our understanding of haemodialysis-associated 
cardiomyopathy. The most pertinent future work is longitudinal follow-up of 
the present cohort to give a rare insight into the development of 
cardiomyopathy and whether cooler dialysate prevents the expected decline 
in left ventricular function. Future work should focus on novel interventions to 
reduce cardiovascular disease and studies with higher resolution to 
determine difference. 
A huge number of interventions remain untested. Many are being pursued by 
Prof McIntyre’s group and collaborators worldwide. An incomplete list would 
include remote-preconditioning to protect against HD-induced ischemia. Pre-
conditioning mimetics may be able to pharmacologically produce the same 
effect.  Interventional studies to lower dialysate sodium or improve glycaemic 
control to reduce hypervolaemia have commenced.  Arrhythmogenic risk due 
to ionic fluxes both during and between HD are a ‘black box’ that remains to 
be fully elucidated. 3D echocardiography and speckle-tracking allows 
bedside echocardiography without geometric assumptions. Less known are 
improvements in automated function imaging allowing on-line and more 
accurate measurements by echocardiography. Advances in harmonic 
imaging allow better image resolution, essential for strain-based studies. 
Most exciting are the developments in non-contrast magnetic resonance. 
MRI is truly capable of going beyond imaging anatomy to interrogate aspects 
of function. Most importantly for the setting of kidney disease, these 
techniques do not require contrast media. CMR tagging at higher fields or 
using novel sequences to allow better spatial and temporal resolution would 
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be of great benefit. Studies combining renal and cardiac arterial spin-labelling 
to determine the heart and kidney interaction are an obvious target. This 
could be extended to study the effects of several drugs on cardiac and renal 
perfusion, particularly renin-aldosterone-angiotensin-system antagonists. 
These drugs which have proven cardiac benefits but are underused in CKD 
and ESRD because of perceived risks to glomerular filtration, require detailed 
studies which would have wide clinical impact. CMR angiography is 
developing rapidly and will allow studies to unselectively determine coronary 
artery status and combine it with perfusion and oxygenation data from a 
single examination. There are cautions. Healthcare costs are rising and 
healthcare payers are wary of ‘test layering’. Patients rarely have one test. A 
developmental framework must be followed to show that newer but more 
expensive techniques have real utility and can be used to improve outcomes. 
Used judiciously, cardiac imaging remains one of the key tools we have to 
improve outcomes most quickly in our patients by enabling clinical trials to be 
conducted in fewer people with faster results and mechanisms elucidated. 
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9. Conclusion 
 
In summary the work presented in this thesis has identified abnormalities in 
cardiac structure, motion and deformation in haemodialysis patients using 
strain-based imaging. The remaining challenge is to evolve the interpretation 
of the results particularly with respect to time on dialysis that will allow better 
use of the data in the amelioration of cardiac disease in haemodialysis 
patients.  
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11. Appendices 
11.1. Abbreviations 
 
AD Aortic distensibility 
AGE Advanced Glycation End-Products 
BIA Bioelectrical impedance analysis 
BMI Body Mass Index 
BNP Brain Natriuretic Peptide 
BP Blood Pressure 
BSA Body Surface Area 
CABG coronary artery bypass graft 
CI Cardiac Index 
CKD Chronic Kidney Disease 
DBP Diastolic blood pressure 
ESRD End-stage renal disease 
GFR Glomerular filtration rate 
GLS Global longitudinal strain  
GLSR Global longitudinal strain rate 
HD haemodialysis 
HLA Horizontal long-axis (4 chamber view) 
IDH Intra-dialytic hypotension  
IHD Ischaemic Heart Disease 
LVEDVI Left ventricular end-diastolic volume index 
LVH Left ventricular hypertrophy 
LVMI Left ventricular mass index  
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LVSVI Left ventricular stroke volume index  
MI Acute myocardial infarction  
MRI magnetic resonance imaging 
NSTEMI Non-ST elevation myocardial infarction 
PD Peritoneal dialysis 
PP Pulse pressure 
PWV Pulse wave velocity 
RF Radiofrequency  
RRT Renal replacement therapy 
RWMA Regional Wall Motion Abnormality 
SBP Systolic blood pressure 
SPAMM Spatial modulation of magnetization 
SSFP  Steady-state free precesssion 
STE Speckle tracking echocardiography 
TBW Total body water 
TVI Tissue Velocity Imaging 
TDI Tissue Doppler Imaging 
VLA Vertical long-axis (2 chamber view) 
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11.3. Standard Operating Procedure (SOP) for Bioimpedance analysis 
with InBody S20 
 
SOP Number: SOP-
DHRD/2009/031-05 
 
Title:  Standard Operating Procedure (SOP) 
           for Bioimpedance analysis with InBody S20 
Effective 
Date: 
10/09/09 Revision 
Date: 
 
Supersedes: Nil 
Prepared by: Aghogho Odudu Date:  10/09/09 
Checked by:  Date: 10/09/09 
Approved 
by: 
Dr Chris McIntyre  Chief Investigator Date: 10/09/09 
 
Bioelectrical impedance analysis (BIA) is based on the principle of detecting 
resistance to low-level electrical current flows through intracellular and extracellular 
fluid. The analyzer will apply a safe current of 90-4000 µA at a frequency of 1-1000 
kHz for 3 minutes. The currents used are imperceptible to the subject but it is 
contraindicated if the patient has a pacemaker, or intracardiac defibrillator.  
The algorithms built into the software of the analyzer will measure resistance and 
reactance and calculate fat-free mass separately for each limb and the trunk at 
several frequencies. The extracellular fluid space will be expressed as a proportion 
of the estimated TBW. Measurements are taken at least 5 minutes pre-dialysis 
and at-least 5 minutes post-dialysis. 
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Equipment required 
x InBody S20 analyser 
x Electrodes 
x Biospace Electrolyte tissue 
x Power supply 
x Biospace printer 
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Instructions for the BIA analyser 
Safety  notes: 
a. InBody S20 should not be touched with wet hands, nor should it 
be used to measure a wet body. If water soaks into the 
equipment, it may cause an electrical shock or corrosions on 
equipment. 
b. This product should always be grounded. Always use a three-pole 
socket that has ground electrode. 
c. Do not operate this equipment if it has a damaged power cord or 
plug, if it is not working properly, or if it has been damaged. 
d. Do not immerse power cord in water or use the equipment near 
water. 
e. Do not touch signal parts for external communication such as the 
parallel port, a serial port, etc. and a human body at the same 
time. 
 
f. Connect O in the above picture- the equipotential terminal of 
InBody S20 to an equipotential line of the medical room. This 
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protects a patient against an undesirable current that may occur 
when several devices use the same power source. 
g. Individuals with any kind of contagious disease or any kind of 
injury to the palm or sole must not use or come in contact with 
this product. 
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Test procedure 
1. Plug the power cable to the mains. If battery is charged it will run without 
mains. See troubleshooting section for info on battery power display. 
2. Turn on at the back. There are 2 switches. The one nearest the floor is 
for the battery only. The power switch for the analyser itself is at the top. 
When main power and system switch are turned on, InBody S20 starts 
system boot up; this takes 10 minutes, so start before patient 
arrives or on arrival.  
  
3. When the system boots up, the startup window comes up, allowing you enter 
data. If patient is non-caucasian this must be changed in the set-up 
menu. Press ‘SET-UP’ button and choose from asian-african-hispanic-others 
and be sure to change back after taking post-HD values. Otherwise, the 
mistake will only be apparent after the analysis is completed on your next 
patient .   
4. Remove watches/metal/gold chains from the subject prior to measurement.  
5. Clean palms and soles with electrolyte tissue. 
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6. Attach electrodes (see ‘detailed notes on testing methodology’ below for 
position if you are unsure) 
7. Enter patient ID in the form study ID_visit no_pre/post eg AOBS001v1a for 
pre-HD and AOBS001v1b for post-HD measure. This is to ensure you don’t 
overwrite your pre-HD value with your post HD-value. Enter ID, Age, Height 
Weight, and Gender (Female is selected as a default.  Use male/female button 
on panel). Enter weight and height (cm) and weight (kg)to one decimal 
place 
8. Ensure measure time is set at 3 minutes. ‘Intervals’ refer to time between test and is 
60 mins by default but you will disattach electrodes during dialysis and save post-dialysis values 
as a new file so this is not relevant. 
9. After finishing the data entry, press the 'Enter' button and see the information 
window prompting the patient to get ready for a test.  
10. Check patient position and ask them to relax, maintain posture and avoid 
flexing muscles for 3 minutes then press ENTER again and testing will 
commence. Problems at this stage are usually due to inadequate 
electrode contacts. Use the electrolyte tissue/alcowipes. Check your 
contacts.  
11. When testing is complete this is displayed on screen. Results are automatically 
saved under patient ID. 
12. Check data. Look at the cole-cole plot at the bottom of the screen to make 
sure it is a good curve before taking the electrodes off.  Also look at the 
electrical data- ALL the limbs measurement should be in POSITIVE values but 
you can expect to have SMALLER and occasionally NEGATIVE values for the 
TRUNK segment.  If there is some suspicious data, repeat the measurement. 
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13. For post-HD values ensure you save under a new file, especially as you will 
now input the post-HD weight. 
14. The machine is then switched off at the back.  
Data transfer 
1. For download of data use USB lead or stick. The download is of the entire 
database of up to 7000 unique IDs. Results export as an unlabelled Excel 
spreadsheet. This can be ‘decoded’ with our labelled template ‘BIA template.xls’ 
on the secure drive S:/cooling study/data/BIA. We have written a macro to link 
this to our study database for ease of analysis. 
2. However it is imperative to print a results sheet after the test on the Inbody 
S20 specific results paper using the biospace printer. The printer cannot be used 
near the patient and can only be attached when the analyser is off. For this 
reason printout is best done after the whole study procedure is complete or even 
the next day. File the results sheet in the CRF. 
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Detailed notes on testing methodology for best results  
1. Data entry. After entering two digits for age and three digits for height, move 
on to the next text field. If you want to use the decimal digits for age and 
height, use the direction buttons (W) to return to previous fields and enter the 
values for decimal digits using the ‘point’ button to the left of ‘0’.  Use 
backspace key (Í) to delete incorrect 
data. It is impossible to re-enter data 
whilst analysis is in progress. In this 
case press ‘stop’. Re-enter data and start 
again. Press ENTER when data input is 
complete. 
2. Position. Lie subject as close to 
flat as possible, 30 degrees at the most, 
with arms and legs stretched out 
comfortably. Do not leave the arms by the 
side but form an angle of 15 degree 
between the arms and the side. Also ask subject to adduct lower limbs by the 
same angle. 
3. Electrodes To improve electrical contact, use the biospace branded electrolyte 
tissue to wet the palms and soles. Don’t excessively wet the skin and avoid 
wetting the leads as this might cause corrosion of the metal.  
4. Use the A type electrode position as illustrated. The leads are labelled for the 
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appropriate limb- eg RA=right arm. Black electrode is placed medial, red lateral 
in the anatomical position.   
 295 
 
5. Alternatively use tactile electrodes- this first requires you to change to tactile 
mode in set-up menu by pressing SET-UP button: 
 
a. Hand electrode. Affix tactile electrode onto the hand as illustrated below, so that 
metal part of the electrode touches the bottom (palmar surface) of fingers. Put 
red electrode (I) to the thumb and black 
electrode (V) to the middle finger. Check the 
mark on the electrode module and use the correct 
one (RA-Thumb: right thumb, RA-Middle: right 
middle finger, LA Thumb:left thumb, LA-Middle: 
left middle finger). 
 
 
b. Foot electrode 
Affix foot electrode onto 
the foot like the 
illustration, in such a way 
that marked side of the 
electrode touches the 
sole of the foot. Put red 
electrode (I) to the inner 
part of foot and black 
electrode (V) to the outer part. 
 
 
6. Other tips for accurate testing: 
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a. Enter the exact height and weight. This can be entered to one decimal place. 
b. Keep the room temperature between 20-25 deg C. Subject should warm up for 
20 minutes before a test in winter. 
c. Wait 2 hours post-meal before testing. 
d. Subject should pass water/open bowels before testing. 
e. Do not exercise or have a bath before a test. 
f. Lie on the back for 5 minutes before a test. 
g. Do not have a test while taking diuretic. 
h. Avoid having a test during menstruation. 
 
Troubleshooting 
 
Power indication lamps 
The lamp displays the battery conditions of InBody 
S20, as well as whether the main power and system 
power are ‘On’ or ‘Off’ status.  
M Mains- red is on and charging starts. 
N Charging indication lamp: shows the charged 
conditions of InBody S20.  
- When it blinks: it indicates that InBody S20 is at low voltage. In this case, the 
system power will go out automatically if not attached to mains.  
- Yellow light: signals that the battery is half charged. 
-Green light: signals that the battery is fully charged. 
 297 
 
O Green lamp lights on if system power is turned on. 
 
References 
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11.4. Standard Operating Procedure (SOP) for Finometer 
measurements 
 
SOP Number: SOP-
DHRD/2009/031-04 
 
Title:  Standard Operating Procedure (SOP) 
           for Finometer measurements 
 
Effective 
Date: 
10/09/09 Revision 
Date: 
 
Supersedes: Nil 
Prepared by: Aghogho Odudu Date:  10/09/09 
Checked by:  Date: 10/09/09 
Approved 
by: 
Dr Chris McIntyre  Chief Investigator Date: 10/09/09 
 
 
The improved Finapres apparatus, known as the Finometer, measures finger 
blood pressure noninvasively on a beat-to-beat basis and gives waveform 
 299 
 
measurements similar to intra-arterial recordings. The Finometer measures 
brachial pressure and corrects for finger pressure accordingly. It also corrects 
for the hydrostatic height of the finger with respect to the heart level.  Do take 
care not to damage the delicate finger cuffs which cost over £300 each to 
replace. 
Instructions for setting up the finometer 
2. Ensure switched on at the mains 
3. Press rocker switch at the back to On 
4. On the front panel, press finometer “research” button twice 
5. Press “mark” to confirm and go 
6. Insert gender, age, height and weight using direction arrows so that the 
7. correct values are highlighted in orange. 
8. Press “describe subject” to confirm changes 
9. Place BP cuff on arm as accurately as possible with arterial marker over brachial 
artery. 
10. Attach Finometer unit to wrist with the Velcro straps. 
 
11. The main components of the finger cuff are an inflatable air bladder, and a 
plethysmograph consisting of a light source (infrared light light-emitting diode) 
and a light detector (infrared photodiode). These appear as two circular dots on 
FinometerFront ?EndUnit 
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the inside of the cuff. The air bladder is connected to the front-end unit via an air 
hose and both components of the infrared plethysmograph via a cuff cable. The 
front-end unit is connected to the main unit and pump unit in the Finometer. 
Place appropriately sized finger cuff on middle finger ideally but any finger will 
do. Ensure the laser "spots" are parallel with each other, that the attachments 
emerge from the proximal end of the cuff and that the cuff is snug but not too 
tight. 
 
12. Attach connections from finger cuff to the front-end unit 
13. Press the two height sensors together and press mark to calibrate the 
14. sensors and ensure the "hite" is reading 0 or below 
15. Attach the rectangular sensor to the finger cuff and the round sensor to the arm 
BP cuff 
16. Warn the patient they will be aware of the finger cuff inflating and deflating 
17. Press “start” 
18. After approximately 2 minutes, perform a return-to-flow “RTF” calibration: 
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a. Move highlighted orange box across the screen to highlight the 
RTF box 
b. Using direction arrows highlight "ramp" in orange 
c. Press “RTF” button, arm BP cuff should inflate and you will be 
informed that the RTF calibration has been successful. This gives 
more accurate values of the Fimoneters outputs. 
19. Ask nurse/technician to insert the needles into AV fistula or attach lines to 
commence dialysis and press "mark" to mark the trace after a period of pre-
dialysis monitoring. You should also mark the trace at the start of the 225 min 
intra-dialytic and the 15 min post-dialytic echocardiography recording.  
20. Once you have finished recording, press stop. 
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Instructions for downloading the finometer outputs 
The Finometer traces are analysed through the Beatscope software, this can be 
installed on any laptop with admin rights. It is also installed on the laptop in the 
research office known as the "brick". 
1. Ensure the computer and Finometer are attached to the mains and switched on 
2. Open Beatscope software 
3. Select “finometer” with the mouse 
4. Select “download” 
5. Ensure correct directory for storage of the information has been selected in the 
left hand column. 
6. Highlight files in right hand column that you wish to download  
7. Click on “<” button to start downloading 
8. Once downloading has finished: 
9. Click on “x” in the top right corner to close the screen 
10. Click “yes” to confirm closing the download 
11. Close Beatscope 
12. Rename file in the format studyID_fino_visitnumber, eg AOBS006_fino_v1 
13.  Transfer file to Derby Hospitals NHS FT secure drive folder path:  
The Effects of Cooling The Dialysate on Systolic Dysfunction in Haemodialysis 
Patients/Data/Finometer Data 
References 
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11.5. Standard Operating Procedure (SOP) for Pulse Wave Velocity 
(PWV) Measurements using the Vicorder® 
 
SOP Number: SOP-
DHRD/2009/031-04 
 
Title:  Standard Operating Procedure (SOP) 
          for Pulse Wave Velocity (PWV) Measurements using 
the Vicorder® 
 
Effective Date: 10/09/09 Revision 
Date: 
 
Supersedes: Nil 
Prepared by: Aghogho Odudu Date:  10/09/09 
Checked by:  Date: 10/09/09 
Approved by: Dr Chris McIntyre  Chief Investigator Date: 10/09/09 
 
Aim: The purpose of this test is to determine a measurement of arterial stiffness by 
calculating Carotid-femoral pulse wave velocity (PWV). 
  
Equipment needed:  
x Vicorder 
x Neck cuff 
x Thigh cuff 
x Laptop with 2 USB ports or a USB hub 
x Red and Blue Inflation tubing 
x Measuring tape (preferably metal so as not to stretch over 
time) 
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x Vicorder software installed on a password protected NHS 
trust notebook computer 
Intialisation 
 
1. Plug in the 2 USB leads from the Vicorder into the laptop 
2. Turn on the laptop after the USB leads are plugged in. 
3. Open and minimise Vicorder software (version 3.2.3483.15471) 
4. From the Quick Launch window on the right of the screen select PWV with the 
mouse 
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Aortic pulse wave velocity measurement using the neckpad  
 
The Patient should be in a semi-prone position with the head and shoulders raised by 
approximately 30 degrees, this should prevent Venous contamination of the Arterial signal.  
30°  
 
 
 
The Neckpad is placed around the Patients neck with the pressure pad over the right Carotid 
area. 
 
 
…...and secured with the Velcro fixing, do not 
over-tighten. Remind the patient this will inflate so may be uncomfortable but to a very low 
pressure (less than 30mm Hg). 
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A cuff is placed around the Patients upper right thigh.  
Both Neckpad and thigh cuff are connected to the Vicorder (Red cuff- carotid (proximal), 
Blue cuff- femoral. 
 
 
 
 
1. Measure the distance between Supra-Sterna Notch and thigh cuff in centimetres and enter 
via the Calcs button (F8). 
2. Warn the subject about the inflation again, then inflate the cuffs, by pressing the space bar, 
adjust the displayed waveforms for amplitude if required (let run for at least 4 runs). 
3. Acquire several steady pulses of data and freeze. 
 
4. Pulse Wave Velocity and Transit Time are displayed (but not stored). 
 
5. Record the PWV onto the case report form.  
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6. Press Enter to save the data, you will be prompted for a filename and it will export as a 
comma separated file which can be uploaded into Microsoft acces, excel or SPSS. The 
filename should be saved in the format study ID_PWV_Visit No eg AOBS009_PWV_v1.csv 
7. After the study procedures are completed the file should then be transferred onto the Derby 
Hospitals NHSFT secure server in the appropriate vicorder data folder and removed from the 
operators laptop. 
 
 
Troubleshooting 
 
 
 
.  
Note : If the Jugular Vein is particularly active (example on the upper trace) make sure the 
Patient is at 30°, if so ask the Patient to take a deep breath, exhale and hold. Take the 
measurement during the held breath. 
 
References: 
 
Davis,B. Aortic Pulse Wave Velocity measurement using the Vicorder (January, 2008). 
Skidmore Medical Ltd, Bristol, UK. 
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11.6. Standard Operating Procedure (SOP) for Magnetic Resonance 
Imaging 
SOP Number: SOP-
DHRD/2009/031-07 
Title:  Standard Operating Procedure (SOP) for 
Magnetic Resonance Imaging 
Effective Date: 15/03/2011 Revision 
Date: 
 
Supersedes: Version 4, 1/02/2011 
Prepared by: Aghogho Odudu, Tarek Eldehni, 
Rachel Hall and Kathryn Appleyard, 
Gerry McCann 
Date:  15/03/11 
Checked by: Aghogho Odudu Date: 15/03/2011 
Approved by: Dr Chris McIntyre  Chief Investigator Date: 15/03/2011 
 
Aim: The purpose of this test is: 
(1) To record magnetic resonance images that allow geometric and strain 
measurements of the heart, using standard cine imaging and myocardial tagging 
(2) To allow assessment of ventricular-arterial coupling by measuring aortic 
distensibility and aortic-pulse wave velocity  
 
Prerequisites: 
Studies will occur on standardised post-midweek haemodialysis day at a single 
centre (Nuffield Hospital Derby) using a 1.5T scanner (GE Signa HDxt 1.5T, GE 
Healthcare, Milwaukee,US) 
Participant arrives: 
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MRI safety questionnaire (see appendix) is completed only by trained 
personnel. 
  
Cardiac geometric imaging protocol: 
1. Serial contiguous short axis cines will be piloted from vertical or 
horizontal long axis of the LV and RV, LVOT and RVOT. 
2. Using ECG-gated, FIESTA 2D CINE sequence; TR 45ms, TE 1.7 ms, 
-FA60°.  
3. Short axis images acquired at slice thickness 8mm, with no spacing 
from apex to base of LV (below level of mitral valve) using validated 
methodologies (Maceira 2006). 
4. Matrix 256 x 160, Smallest FOV possible , typically 320mm x 320mm, 
Nex 1. 
 
Myocardial tagging protocol: 
1. Using Prospective ECG-gated, FastCARD Gradient-Recalled Echo 
sequence  
2. Asset enabled 
3. 8-mm slice thickness.  
4. 3 tagged short-axis images parallel to the cine sequence, equally 
spaced from LV base (full disc in all phases) to mid-papillary level to 
apex (full blood pool visible in all phases), hence spacing between 
slices depends on length of LV, typically 6-12mm.  
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5. A grid-tag is applied with spatial SAT pulses throughout the FOV using 
a SPAMM technique. Tag separation of 7mm, TE 3.1 msec with matrix 
256x160, Nex 1, flip angle _ 12°.  
6. “Number of cardiac phases to reconstruct” se to 30.  
7. Maximum 10 views per segment. If HR >65 decrease to 6-8. If 
HR<55 consider increase to 12-14 to achieve breath-hold of 14 
secs or less 
8. 2 long axis-tag views in HLA (4 chamber view) and VLA (2 chamber 
view) 
Cine phase-contrast sequence  
1. Short breath-hold (<14 secs) FIESTA Cine sequence acquired in oblique 
sagittal plane to demonstrate the full length of the aorta.  
2. Axial Short breath-hold (<14 secs) FIESTA Cine to measure distensibility 
with the following parameters: 30° flip angle, 5-mm slice thickness, 
280x280-mm field of view (or smallest possible), 6.7 repetition time, 256 
x256 matrix. 
3. Phase contrast sequence (PCMRI) is set up FREE- BREATHING (4-6 
mins depending on RR) with the following parameters: 30° flip angle, 5-
mm slice thickness, 280x280-mm field of view, 6.7 repetition time, 256 
x256 matrix, 2 excitations, and through-plane velocity encoding 
starting at 200cm/s, with 1 view per segment and No of views to 
reconstruct 100. 
References 
Maceira et al. Normalized left ventricular systolic and diastolic function by steady 
state free precession cardiovascular magnetic resonance. J Cardiovasc Magn 
Reson 2006; 8: 417-426. 
